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2010, 70% in low-income or middle-income countries.4 During the preceding decade, 
the number of individuals with PAD increased by almost 30% in low-income or middle-
income countries, and by 13% in high income countries.4 
Intermittent claudication
Up to half of the symptomatic PAD patients will demonstrate typical symptoms of inter-
mittent claudication (IC, which means ‘to limp’).(3) IC is defined as muscle discomfort in 
the lower limb that is reproducibly elicited by exercise and relieved within a 10 minutes 
rest.(3) Patients with IC have sufficient blood flow at rest and therefore do not experience 
limb symptoms while standing, when seated or while resting in bed. Conversely, during 
exercise, obstruction of the arterial supply of the leg muscles limit a required increase 
in blood flow resulting in a mismatch of oxygen supply and muscle metabolic demand, 
leading to IC. This mismatch causes cramping or aching pain in the buttock, hip, thigh, 
calf or in rare occasions the foot, forcing the patient to pause. In rest, the oxygen debt can 
be redeemed and symptoms are relieved.
General Introduction
“I swear by Apollo, the healer, Asclepius, Hygieia, and Panacea, and I take to witness all 
the gods, all the goddesses, to keep according to my ability and my judgment, the following 
Oath and agreement…”
Each medical student likely remembers the very moment he or she took the Hippo-
cratic Oath. By doing so, the world embraced another certified physician. The oath can be 
broken down into twelve different precepts. One of the most essential ones is the promise 
of ‘abstaining from doing harm’. This portion was later reformulated by the English phy-
sician Thomas Sydenham (1624–1689, figure 2) into a popular aphorism ‘Primum non 
nocere’ (‘First do no harm’).(1) This approach originates from an era when physicians were 
paternalistic and abstained from shared decision making with their patients. This para-
digm derives from an era with very limited alternative treatment options and served well 
as a touchstone of medical ethical practice. Despite its restrictions, this original thought 
remains a potent reminder of the fact that each medical and pharmacological decision 
inherently carries a potential for harm. The implications of this maxim are still up-to-
date. Improved medical technologies are becoming of more importance in current health 
care and may offer physicians generous options, possibly without overseeing any future 
impact. A perfect example of the slippery slope between ‘primum non nocere’ and the 
growing set of treatment possibilities is the management of peripheral arterial disease.
Peripheral arterial disease
Peripheral arterial disease (PAD) commonly results from progressive narrowing or oc-
clusion of arteries feeding or residing in the lower extremities and is mostly due to athe-
rosclerosis(2). The atherosclerotic process of progressive narrowing and hardening of 
arteries can occur in each human artery.  However, it mainly affects coronary, cerebral 
and peripheral arteries, especially those in the lower extremities(3). The spectral mani-
festations of PAD range from ‘no symptoms’ to ‘tissue loss that may eventually require 
amputation of an affected limb’. 
Total disease prevalence based on objective testing was found to range from 3-10% 
in adults, increasing to 15-20% in persons over 70 years.3 PAD increases progressively 
with age, beginning after the age of 40. Globally, 202 million people were having PAD in 
Figure 1  Illustration of publication by Larsen and Lassen.
Lancet. 1966 Nov 19;2(7473):1093-6.
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The presence of IC is associated with serious health risks. A 19% 5-year mortality rate 
is found of which 70% is due to cardiovascular causes. Non-fatal cardiovascular events 
(e.g. myocardial infarction, stroke) in patients with IC are found in 29% of the population 
at 5 years of follow-up.(5) An overall strategy is well described in several international 
guidelines including the American College of Cardiology/American Heart Association 
(ACC/AHA), Trans-Atlantic Inter-Society Consensus on Management of Peripheral 
Arterial Disease (TASC II) and the national institute for health and care excellence 
(NICE).(3,6,7) 
Treatment of PAD should consist of a multicomponent therapy of cardiovascular risk 
reduction including lifestyle coaching and symptomatic treatment. The first two compo-
nents aim to prevent cardio- and neurovascular events (myocardial infarction, stroke) 
and related morbidity and mortality. The most important modifiable risk factors for athe-
rosclerosis are smoking, hypertension, diabetes mellitus, hyperlipidaemia and obesity.
(8) The third component is to improve the overall quality of life (QoL). This regimen is 
currently mainly focussed on increasing walking capacity that is realized with conserva-
tive treatment (daily exercise) or invasive techniques such as vascular surgery or percuta-
neous transluminal angioplasty (PTA). The latter is a method of mechanically widening 
of narrowed or obstructed arteries. An empty and collapsed balloon on a guide wire is 
passed percutaneously into the narrowed artery portion and then inflated to a fixed size. 
The balloon forces expansion of the atherosclerotic plaque, opening up the artery. The 
balloon is then deflated and withdrawn, allowing an improved flow. A stent may or may 
not be inserted to ensure the vessel’s patency.
Pharmacological therapy for IC has been subject of numerous studies. However, only 
beneficial effects of cilostazol and naftidrofuryl were described.(9,10) Interestingly, appro-
val of this type of medicine is limited to a few countries. Other therapies such as Gingko 
Biloba, vitamin E, chelation therapy, omega-3 fatty acids and oestrogen therapies were 
not effective.(3,11) Most pharmacologic treatment regimens for IC typically involve drugs 
that are used for cardiovascular risk reduction.
Conservative treatment for IC: Exercise therapy
In 1898 the German neurologist Wilhelm Erb was the first to describe success following 
exercise therapy in a patient with IC.(12) The first randomized clinical trial (RCT) was 
performed by Larsen and Lassen in 1966 (figure 1).(13) In this study, 7 patients treated 
with exercise therapy were compared with a control group of 7 patients who were given 
a placebo medical treatment using lactose tablets. In contrast to the control patients, the 
exercise group demonstrated a significant increase in maximum walking time.
Nowadays, exercise therapy for patients with IC is extensively studied.(14-17) Apart 
from a significantly improved maximum walking distance/time, exercise therapy also 
reduced levels of hypercholesterolemia, hypertension and diabetes mellitus.(16) Thereby 
reducing cardiovascular mortality and morbidity as collateral beneficial side effects.(18) 
The most commonly used exercise therapy prescription consisted of a single oral advice, 
usually without supervision or follow-up. However, patient adherence to orally adminis-
tered exercise advices is low. Comorbidity, confusion about (specific) advice, fear, lack of 
discipline and incomplete supervision are barriers precluding regular walking exercise.19 
The importance of supervision for IC treatment was gradually recognised over the past 
decades.
Supervised exercise therapy for IC
Supervised exercise therapy (SET) entails adequate coaching by a physical therapist or 
another exercise specialist (e.g. exercise physiologist, exercise therapist, specialised car-
diovascular nurse). SET aims to increase maximum walking distance (capacity), physical 
activity and Health-related Quality of Life (QoL). Effective programs employ treadmill 
walking of a sufficient intensity causing symptoms, although other modes of exercises 
were also studied.(20) Exercise sessions are typically conducted three times a week for a 
period of 3-12 months.(3,7) A 2006 Cochrane review compared SET with non-supervised 
exercise programmes in patients with IC.14 SET showed statistically significant and cli-
nically relevant differences in improvement of maximum walking distance compared to 
non-supervised exercise therapy regimens, with an overall effect size of 0.58 (95% confi-
dence interval 0.31 to 0.85) at three months. These results translate into an improvement 
of approximately 150 meters of maximum walking distance in favour of the supervised 
group.
Another systematic review compared supervised and unsupervised ET with PTA in 
patients with IC in an effort to obtain the best estimates of their relative effectiveness.21 
Eleven studies (reporting data on eight RCTs) met inclusion criteria. One trial included 
patients with isolated aortoiliac artery obstruction(22), three trials studied SET and PTA 
in femoropopliteal artery obstructions and five trials studied combined lesions. In sum-
mary, no obvious preferential strategy could be defined as both SET and PTA showed 
inconsistent results. Another large multicenter RCT in aortoiliac PAD randomly assigned 
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patients to receive optimal medical care (OMC), OMC plus SET, or OMC plus PTA. The 
authors concluded that SET resulted in superior treadmill walking performance compa-
red to PTA.(23) The most recent guideline therefore advocates a multimodal approach in-
cluding medication, lifestyle changes and symptomatic treatment, mentioning SET as the 
primary treatment option independent of the anatomical location of the compromising 
lesion.(7)
Few studies have focussed on the long-term (>12 months) effects of SET. Gardner et 
al. tried to determine whether improvements in physical function after 6 months of SET 
were sustained over a subsequent 12-months in older patients with IC.(24) They conclu-
ded that improvements in maximum walking distance and physical activity level, after 6 
months of exercise training, were sustained for an additional 12 months period using a 
less intense exercise maintenance program. Ratliff et al. reported a 3-year follow-up of 
212 patients with IC who initially were treated with SET with an exercise programme 
of two sessions a week for 10 weeks.(25) Their results showed that the maximum walking 
distance observed at 12 weeks was still present at three years. Based on this limited expe-
rience, it appears that SET may have long term benefits for patients with IC.
SET in hospital or community based setting?
An outpatient hospital setting is routinely offered in the majority of studies on SET. This 
approach may seem appropriate in trials but is associated with several limitations in daily 
clinical practise. First, the capacity of an exercise therapy program in an outpatient clinic 
is limited and possibly not sufficient to accommodate all patients with IC. Second, at-
tending a hospital 3 times a week leads to considerable transportation fees and is rather 
time-consuming. For this reason, implementation of a community-based SET program 
was instigated in the Netherlands.(26) The first results of a cohort study of patients treated 
with community-based SET resulted in a statistically significant improvement in maxi-
mum walking distance (as determined using a treadmill) after 3 and 6 months.(27) Others 
suggested initiating exercise programs in a home-based environment, thereby dimini-
shing the amount of labour-intensive supervision.(28,29) Two recent published trials and 
a meta-analysis revealed promising results regarding the effect of such an approach.(30-33) 
Although SET may seem superior compared to other conservative treatment regimens 
with respect to improvement in walking distances, no significant differences between 
home-based exercise and SET was found at six months of follow up.(31) 
Cost-effectiveness of SET
Several cost-effectiveness analyses in the treatment of IC have been performed.(34-39) 
Non-supervised exercise therapy was compared with supervised programs in both a mul-
ti-centered trial and in a Markov model.(34,39) For community-based SET, the incremental 
cost-effectiveness ratio for cost per QALY was estimated between £1,608 to €28,693. Both 
studies considered SET as cost-effective compared to ‘no exercise’. Others compared SET 
in a randomized cost-effectiveness analysis with endovascular revascularization 
(PTA).(35-38) There was no significant difference in effectiveness between endovascular 
revascularization compared to SET. Any gains following PTA appeared non-significant. 
Moreover, endovascular revascularization was more costly in relation to the generally 
accepted threshold of ‘willingness-to-pay’ (£11,777 to € 231,800 per QALY), a result that 
favors SET.(35,37) Others revealed that QALYs were lost when PTA alone was used as first-
line treatment in comparison with SET.(35)
Overall, SET seems to be the most cost-effective first-line treatment for IC.(35-38) If SET 
fails, it may subsequently be combined with endovascular revascularization, a sequence 
that is probably more cost-effective than PTA alone. 
Also ‘Primum non nocere’ in IC
The prevalence of IC is growing as a clinical problem due to the increasingly aged popu-
lation in developed countries. Recently, governments as well as nongovernmental organi-
zations and the private sector were called to assess the social and economic consequences 
of PAD and to explore the best strategies for optimum treatment and prevention of this 
disease.(4) Numerous studies and guidelines have issued clear recommendations for IC 
treatment. Ideally a ‘primum non nocere’ strategy, existing of an initial treatment with 
SET should be followed.(7,40) However, SET programs are largely underutilized in daily 
practice.(41-44) Some blame the lack of a sufficient number of supervised settings as well as 
the need for patients to travel to a SET facility.(30,36,40,41,45) Another complicating factor is a 
failing reimbursement policy issue for SET in most of the Western societies including the 
Netherlands.(30,40,41,44,46) Despite a claimed 100% Dutch SET availability, reimbursement 
issues stimulate physicians to direct patients towards a vascular intervention strategy.(44)
This reimbursement issue in IC treatment originates from a contradictory policy in 
the Dutch healthcare system. In the Netherlands, healthcare insurance companies have 
an obligation to accept everyone for a basic healthcare insurance. The Dutch govern-
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ment determines coverage of the standard 
insurance. In case of patients suffering from 
IC, the government decided not to cover the 
first 20 treatment sessions of a SET program. 
Therefore, these sessions have to be paid by 
the patient, either directly or through addi-
tional insurance. From the 21st session on-
wards all additional treatment sessions given 
in one year are covered by the basic health 
care insurance. Around 30-40% of the peo-
ple aged >50 years who are insured by CZ 
(one of the largest Dutch insurance compa-
nies) do not have an additional insurance 
package that covers 100% of those first 20 
physiotherapy sessions. Therefore, a proven 
effective, nationwide available SET program 
with supervision performed by trained phy-
siotherapists, aimed at improving cardiorespiratory health status as well as life style fac-
tors and medication compliance is not fully reimbursed in the Netherlands. 
On the other hand, a (minimally) invasive intervention, a possibly less effec-
tive(23,37,47-49), less durable(50-53), potentially harmful(52,54), and single leg focused treatment 
option is fully  reimbursed from the basic healthcare insurance. Most of these interventi-
ons are continuously advertised by marketing campaigns. Novel invasive techniques are 
thus promoted, frequently without solid level of evidence, by multi-billion dollar compa-
nies, whereas SET lacks sponsoring promotional activities.(36,40) 
Another factor contributing to SET under usage is a knowledge gap of physicians 
using outdated arguments for not offering SET to IC patients(40,55). As a consequence, 
exercise regimens often instituted in the form of a basic “go home and walk” advice or 
the non-“primum non nocere” interventional approach. Patients may also not enthusi-
astically embrace SET as some are in need, or at least think they are, of a ‘quick fix’ of 
their problem. Changed lifestyles such as reducing nicotine use, adopting a healthier diet 
and increasing exercise habits are not very popular. Current guideline recommendations 
are clear: “SET is advised as primary treatment option”. So the following question arises: 
“How to optimize the implementation of our current guidelines and research outcomes?”  In 
this thesis, a nationwide innovative strategy (a so-called ‘stepped care approach’) for the 
treatment of IC is introduced. 
Outline of thesis
Both the 2007 TransAtlantic Inter-Society Consensus (TASC II) and the 2012 NICE 
guideline are based on large meta-analyses. Both clearly advise SET as the first line treat-
ment in the symptomatic treatment of patients with IC.(3,7) 
In chapter two, an update of such an underlying systematic meta-analysis is provided. 
It focuses on the effectiveness of SET compared to non-supervised exercise as earlier 
studied by Bendermacher et al.(14) Although it is generally accepted that SET should be 
part of the initial treatment for each patient with IC, this therapeutic tool is seriously 
underused in clinical practice.(40,42,43) 
Since these guidelines recommend SET as primary treatment for IC(3,7), a calculation 
of treatment costs in patients with IC was made in chapter three to estimate potential 
nationwide annual savings if a stepped care model (SCM; primary SET treatment fol-
lowed by revascularization in case of SET failure) was followed. Data for this study were 
retrospectively obtained from a database of one of the largest health care providers in the 
Netherlands (CZ). 
Some physicians or physical therapists providing SET fear the onset of cardiovascular 
events that may possibly occur during exercise. Moreover, (outdated) physical therapists 
guidelines advocate cardiac screening prior to SET(56) although evidence to support such 
a strategy is lacking. In chapter four, a systematic meta-analysis analyzes the safety of 
SET as reflected by the onset of untoward (cardiovascular) events in patients suffering 
from IC. 
Monitoring of both quality and performance is necessary to study effectiveness of 
suggested treatment strategies. This is particularly true in case of a nationwide SCM im-
plementation. Structurally obtaining outcome indicators in combination with patient 
reported outcome measurements (PROMS) could be helpful in facilitating SCM imple-
mentation. eHealth and mHealth initiatives may play a major role in both abovementi-
oned goals and are outlined in chapter five in combination with future developments in 
the organization of a nationwide community based SET network. Innovative technolo-
gies may lead to new insights in the conservative treatment of IC.  These novel tools can 
be used to monitor the quality of provided care.
Figure 2 Thomas Sydenham
(10 September 1624 – 29 December 1689).
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In the second part of this thesis, the introduction of a possible new clinical outcome 
parameter is studied. A prospective case-control effort (chapter six) studies whether a 
bicycle test is a reliable alternative diagnostic tool compared to a standard treadmill test 
in patients possibly having IC.
A clear call was made for alternative tests to determine walking capacity over a pro-
longed period of time.(57,58) In chapter seven, the clinical applicability of various types of 
treadmill protocols is investigated. Moreover, despite the fact that IC patients have an 
increased risk for cardiovascular or cerebrovascular events(3), current PAD treatment is 
mainly focussed on the limitation in walking distance. However, an increased walking 
capacity does not automatically imply a change in a patients’ exercise behaviour. From a 
therapeutic as well as research standpoint, it may be more relevant to determine exercise 
behaviour or physical activity (PA) as outcome measure for treatment modalities of IC. 
Therefore, the validity of an activity monitor determining physical activity and ambu-
latory activities is investigated in a group of IC patients in chapter eight. Subsequently, 
outcome parameters obtained from this activity monitor are compared to healthy sub-
jects in a prospective case control study in chapter nine. Subsequently the effect of a 
3-month SET program on both physical activity and ambulatory activities is investigated 
in chapter ten. 
In chapter eleven, the main findings of this thesis are discussed. Methodological as-
pects of the different studies, implications for clinical practice, and implications for future 
research are described. Finally in chapter twelve a valorization document is provided in 
Dutch. 
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2 Abstract
Background
Although supervised exercise therapy is considered to be of significant benefit for 
people with leg pain (peripheral arterial disease (PAD)), implementing supervised 
exercise programs (SETs) in daily practice has limitations. This is an update of a 
review first published in 2006.
Objectives
The main objective of this review was to provide an accurate overview of studies eva-
luating the effects of supervised versus non-supervised exercise therapy on maximal 
walking time or distance on a treadmill for people with intermittent claudication.
Search methods
For this update, the Cochrane Peripheral Vascular Diseases Group Trials Search 
Co-ordinator searched the Specialised Register (last searched September 2012) and 
CENTRAL (2012, Issue 9). In addition, we handsearched the reference lists of rele-
vant articles for additional trials. No restriction was applied to language of publica-
tion.
Selection criteria
Randomized clinical trials comparing supervised exercise programs with non-su-
pervised exercise programs (defined as walking advice or a structural home-based 
exercise program) for people with intermittent claudication. Studies with control 
groups, which did not receive exercise or walking advice or received usual care 
(maintained normal physical activity), were excluded.
Data collection and analysis
Two review authors (HJPF and BLWB) independently selected trials and extracted 
data. Three review authors (HJPF, BLWB, and GJL) assessed trial quality, and this 
was confirmed by two other review authors (MHP and JAWT). For all continuous 
outcomes, we extracted the number of participants, the mean differences, and the 
standard deviation. The 36-Item Short Form Health Survey (SF-36) outcomes were 
extracted to assess quality of life. Effect sizes were calculated as the difference in 
treatment normalized with the standard deviation (standardized mean difference) 
using a fixed-effect model.
Main results
A total of 14 studies involving a total of 1002 male and female participants with PAD 
were included in this review. Follow-up ranged from six weeks to 12 months. In 
general, supervised exercise regimens consisted of three exercise sessions per week. 
All trials used a treadmill walking test as one of the outcome measures. The overall 
quality of the included trials was moderate to good, although some trials were small 
with respect to the number of participants, ranging from 20 to 304.
Supervised exercise therapy (SET) showed statistically significant improvement 
in maximal treadmill walking distance compared with non-supervised exercise 
therapy regimens, with an overall effect size of 0.69 (95% confidence interval (CI) 
0.51 to 0.86) and 0.48 (95% CI 0.32 to 0.64) at three and six months, respectively. 
This translates to an increase in walking distance of approximately 180 meters that 
favored the supervised group. SET was still beneficial for maximal and pain-free 
walking distances at 12 months, but it did not have a significant effect on quality of 
life parameters.
Authors’ conclusions
SET has statistically significant benefit on treadmill walking distance (maximal and 
pain-free) compared with non-supervised regimens. However, the clinical relevance 
of this has not been demonstrated definitively; additional studies are required that 
focus on quality of life or other disease-specific functional outcomes, such as wal-
king behavior, patient satisfaction, costs, and long-term follow-up. Professionals in 
the vascular field should make SET available for all patients with intermittent clau-
dication.
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2 Plain language summary
Some people experience a type of leg pain in the calf of one or both legs that occurs 
during walking and is relieved only by rest. This is called intermittent claudication (IC), 
and it is the main symptom of peripheral arterial disease (PAD). PAD is characterized 
by reduced flow of blood in the leg due to hardening of the arteries, or blood vessels. 
Exercise is considered to provide significant benefit for people with this type of leg pain. 
People need to walk at least three times a week by themselves, or they can participate in 
a formal, supervised exercise program that involves walking on a treadmill. This review 
found that people in a supervised program improved their walking ability to a greater ex-
tent than those following an unsupervised walking program. After three months, people 
who followed the supervised treadmill program could walk 180 meters farther than those 
who did unsupervised exercise. Before participating in the program, they had walked 
around 300 meters, with a pain-free distance of 200 meters, so this improvement is likely 
to help with independence. These conclusions are drawn from the findings of 14 trials 
in which participants with PAD had been assigned to either supervised or unsupervised 
exercise. Altogether, 1002 participants with a mean age of 67 years were included. The 
overall quality of the included trials was moderate to good, although each had enrolled 
only a small number of participants. The trials lasted from six weeks to twelve months. 
Keeping to an exercise program is important because it leads to decreased leg pain and 
the likelihood of improving general physical condition, but it is not yet clear if it also 
improves quality of life.
Background
Description of the condition
Intermittent claudication (IC) is a symptom of peripheral arterial disease (PAD) and is 
defined as leg pain in the muscles of the lower extremities that occurs with exercise and 
is relieved by rest. PAD increases progressively with age, in particular after the age of 40. 
The relationship between PAD prevalence and age was illustrated by data from the 1999-
2000 National Health and Nutrition Examination Survey (NHANES), an ongoing cross-
sectional survey of the civilian, non-institutionalized population of the United States. The 
prevalence of PAD, defined as an ankle-brachial index (ABI; the ratio of blood pressure 
in the lower legs to blood pressure in the arms) < 0.90 in either leg, was 0.9% between the 
ages of 40 and 49, 2.5% between the ages of 50 and 59, 4.7% between the ages of 60 and 
69, and 14.5% in those 70 years of age and older (Selvin 2004). These numbers indicate 
that PAD affects more than 5 million adults in the United States. International guidelines 
reveal 27 million affected individuals in North America and Europe (Norgren 2007).
Description of the intervention
The primary and most effective treatment for people with IC is exercise therapy (Stewart 
2002), which was first suggested by Erb (Erb 1898). In 1966 the first randomized control-
led trial (RCT) of exercise therapy in participants with PAD demonstrated an obvious 
improvement in treadmill walking ability (Larsen 1966). In a Cochrane systematic re-
view of randomized clinical trials, Leng et al (Leng 2000) and later the updated version 
by Watson et al (Watson 2008) described an overall improvement in maximal walking 
time: mean difference (MD) 5.12 minutes (95% confidence interval (CI) 4.51 to 5.72) 
with an overall improvement in walking ability of approximately 50% to 200% associated 
with exercise therapy compared with no exercise therapy. However, the exercise programs 
included in this meta-analysis vary widely, ranging from physician recommended unsu-
pervised walking in the community to a formal supervised exercise program involving 
walking on a treadmill.
How the intervention might work
Exercise training provides significant symptomatic benefit for patients with claudication; 
however, the exact mechanisms for this improvement remain unclear (Beckitt 2012). The 
mechanisms of response to exercise training have been reviewed previously and include 
improvement in walking efficiency, induction of vascular angiogenesis, inflammatory ac-
tivation, increased exercise pain tolerance, endothelial and mitochondrial dysfunction, 
and metabolic adaptations within skeletal muscle (Gustafsson 2001; Hamburg 2011; Nor-
gren 2007; Stewart 2008; Zwierska 2005). Further benefits of exercise therapy are seen in 
the reduction of cardiovascular risk factors such as hypercholesterolemia, hypertension, 
and diabetes mellitus. Exercise is therefore implemented in secondary prevention thera-
pies in patients with coronary artery disease (Smith 2011). Given its clear benefits, the 
importance of exercise therapy is highlighted in contemporary international guidelines 
(Hirsch 2006; Norgren 2007). In daily practice, lack of specific individual guidance and 
the absence of uniform supervision appear to be important barriers to the initiation and 
continuation of exercise therapy (Bartelink 2004).
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2 Why it is important to do this reviewBefore the release of the original version of this review in 2006, the prescription of exer-
cise therapy consisted mostly of “go home and walk” advice by the general practitioner, 
sometimes accompanied by a brochure. After this review was published, more studies 
compared supervised exercise therapy with non-supervised exercise therapy. Although 
supervised exercise therapy proved effective in the treatment of PAD by increasing maxi-
mal or pain-free walking time or distance, exercise programs are not designed to change 
day-to-day walking behavior (Crowther 2008; McDermott 2009). Moreover, limitations 
continue to hinder implementation of supervised exercise programs in daily practice. 
Some describe the lack of a supervised setting to which patients can be referred to or a 
lack of knowledge among referring healthcare professionals; in other studies participants 
are not willing to persist with an exercise program to maintain the benefit (Fokkenrood 
2012; Lauret 2012a; Makris 2012; Norgren 2007; Stewart 2008). Therefore debate conti-
nues about whether exercise should be offered under supervision. With disregard for all 
financial and organizational aspects, we believe it is important to provide an accurate sys-
tematic review of the effects of supervised exercise therapy in relation to non-supervised 
exercise on walking distance and quality of life.
Objectives
The main objective of this review was to provide an accurate overview of studies eva-
luating the effects of supervised versus non-supervised exercise therapy on maximal wal-
king time or distance on a treadmill for people with intermittent claudication.
Methods
Criteria for considering studies for this review
Types of studies
Parallel-group RCTs comparing supervised exercise programs with non-supervised exer-
cise programs, in participants with PAD, were included. Trials were included irrespective 
of whether an intention-to-treat analysis was carried out.
Types of participants
Adults (18 years and older) with intermittent claudication (Fontaine II/Rutherford 1 to 
3) (Fontaine 1954; Rutherford 1997) due to atherosclerotic disease, diagnosed by ques-
tionnaire or clinically, who were considered for conservative treatment, were included. 
Studies of participants with asymptomatic lower limb atherosclerosis identified by testing 
were excluded.
Types of interventions
Supervised exercise programs
A supervised exercise program needed to consist of more than six consecutive weeks 
of training, with more than 50% of the exercise time spent on walking or training the 
lower limbs. Inclusion of trials was not limited by frequency or intensity of the exercise 
program.
Non-supervised exercise programs
Non-supervised exercise programs were defined as those in which control group mem-
bers were advised to walk (with or without a predefined exercise scheme or logbook) or 
were treated according to a structural home-based exercise program (walk advice with 
regular contact and exercise support from medically trained personnel). Studies with 
control groups, which did not receive exercise or walking advice or which received usual 
care (maintained normal physical activity), were excluded.
Types of outcome measures
Primary outcomes
The primary outcome measure was the effect on maximal treadmill walking distance or 
time. Outcomes had to be available at baseline.
Secondary outcomes
The following secondary outcome measures were also considered:
• Pain-free treadmill walking distance, or time;
• Mortality;
• Adherence to exercise program; and
• Quality of life.
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2 Search methods for identification of studiesNo restriction on language of publication was applied.
Electronic searches
For this update, the Cochrane Peripheral Vascular Diseases Group Trials Search Coor-
dinator (TSC) searched the Specialized Register (last searched September 2012) and 
the Cochrane Central Register of Controlled Trials (CENTRAL) 2012, Issue 9, part of 
The Cochrane Library (www.thecochranelibrary.com). See Appendix 1 for details of the 
search strategy used to search CENTRAL. 
The Specialized Register is maintained by the TSC and is constructed from weekly 
electronic searches of MEDLINE, EMBASE, CINAHL, and AMED, and through hand 
searching of relevant journals. The full list of the databases, journals, and conference pro-
ceedings which have been searched, as well as the search strategies used, are described 
in the Specialized Register section of the Cochrane Peripheral Vascular Diseases Group 
module in The Cochrane Library (www.thecochranelibrary.com).
Searching other resources
A hand search of references lists of relevant studies was carried out.
Data collection and analysis
Selection of studies
Two review authors (HJPF and BLWB) independently selected trials for this review, 
whereas two other review authors (JAWT and MHP) confirmed the suitability of selected 
trials for inclusion in the review. Disagreements regarding inclusion/exclusion of selected 
trials were resolved by discussion.
Data extraction and management
Two review authors (HJPF and BLWB) independently extracted data using a standard 
data collection form. Data were entered into Review Manager (RevMan 2011). When 
necessary, additional information was sought for included trials. For all continuous out-
comes (ie, walking distance or walking time, adherence to exercise program, quality of 
life), we extracted the number of participants and the mean difference between treatment 
groups per follow up period with accompanying standard deviation for each treatment 
group, if available. We also recorded other details of the included trials, for example, the 
study set- ting, the statistical power, and the number of dropouts in each group. We con-
tacted authors for missing information regarding their methods.
Trials that compared three or more different therapy programs - supervised and non-
supervised therapy programs - with other kinds of programs, were included. From these 
trials, only participants treated by supervised or non-supervised exercise therapy were 
taken into account.
Assessment of risk of bias in included studies
Three review authors (HJPF, BLWB, and GJL) assessed and one review author (MHP) 
confirmed the methodological quality of the trials, primarily for adequacy of allocation 
concealment and follow-up. In trials that compared exercise programs with walking dis-
tance as the primary outcome, blinding of staff and participants is not possible and was 
therefore not considered.
We graded study quality in a table of risk of bias on the basis of a checklist of design 
components. This checklist comprised random sequence generation, allocation conceal-
ment, incomplete outcome data, and selective reporting. We achieved consensus by in-
formal discussion. We summarized the adequacy of each category as “low”, “unclear”, or 
“high” risk according to the criteria provided in the Cochrane Handbook for Systematic 
Reviews of Interventions (Higgins 2011).
Measures of treatment effect
We standardized reported data on walking time and distance to effect sizes to enable the 
calculation of an overall standardized mean difference (SMD). If standard errors (SEs) 
had been reported (and authors did not reply to our request to send unpublished data), 
we converted these to standard deviations. We used a fixed-effect model to obtain sum-
mary statistics for all types of outcome measures. When significant heterogeneity was 
found (P < 0.05), we calculated overall efficacy using random-effects models.
Unit of analysis issues
Only RCTs with follow-up of at least six weeks’ duration were included in this review.
Dealing with missing data
We contacted the study authors to request any missing information. For each trial, we 
extracted the number of participants originally allocated to each treatment arm from the 
data, and we performed an intention-to-treat analysis.
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2 Assessment of heterogeneityWe used both a Chi2 test and an I2 statistic to test for heterogeneity between trial re-
sults. We used the tests of heterogeneity at a significance level of alpha = 0.05 to examine 
whether observed variation in study results was compatible with the variation expected 
by chance alone. When possible, we pooled trial results by meta-analysis.
Assessment of reporting biases
We contacted authors to request missing data. To prevent language bias, we did not im-
pose a language restriction. Funnel plots were used to identify potential publication bias.
Data synthesis
If data were available, we performed statistical analyses using the Review Manager 
software (RevMan 2011). We standardized reported data on walking time and distance 
to effect sizes to enable the calculation of an overall standardized mean difference. For 
this purpose, the difference in outcomes of each study was expressed in the standard 
deviation (SD) observed in the study (Altman 1991). For articles with non-parametric 
data, SDs were calculated by dividing the SD by 1.35, according to Chapter 7.7.3.5 of the 
Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We calculated 
the standardized mean difference (SMD) using a fixed-effect model, as the results were 
presented on different scales (distance or time).
Subgroup analysis and investigation of heterogeneity
Potential heterogeneity in non-supervised exercise programs might exist as the result of 
differences in intervention components (ranging from structural “go home and walk” 
advice to a formal home-based exercise program). We performed a subgroup analysis by 
dividing non-supervised exercise programs into studies that treated participants with “go 
home and walk” advice and trials that used a home-based exercise program. Home-based 
exercise was defined as walking advice supplemented with some form of observation me-
thod (eg, exercise logs, telephone support, educational videos, step monitors) used by 
medically trained personnel. In studies that compared both non-supervised types with 
a supervised exercise program, the “shared” supervised group was split into two groups 
and included in two comparisons according to Chapter 16.5 of the Cochrane Handbook 
for Systematic Reviews of Interventions (Higgins 2011).
Sensitivity analysis
Individual study effects on the results were examined by removing each study one at a 
time to examine whether removing a particular study changed the results significantly. 
Studies with apparent risk of bias were excluded.
Results
Description of studies
See Characteristics of included studies; Characteristics of excluded studies; and Charac-
teristics of ongoing studies (in the online version of this Cochrane review).
Results of the search
For this update, a total of 240 potentially new studies were identified by the Cochrane Pe-
ripheral Vascular Diseases Group, and the hand search yielded four potential studies for 
inclusion. After title and abstract evaluation, 48 articles on supervised exercise therapy in 
participants with PAD remained for full-text analysis. The eight included and 19 excluded 
(27 in total) clinical trials identified in the initial review of 2006 were re-evaluated.
Selection process
One review author (HJPF) obtained full-text copies of the 75 articles (48 new articles and 
27 originally documented in the 2006 review) for further assessment. We (HJPF, BLWB, 
JAWT, MHP) excluded 53 articles of 53 studies (Characteristics of excluded studies) and 
included 20 articles based on 14 studies (Characteristics of included studies). In addi-
tion, we found one ongoing trial (two articles) with potentially usable outcome variables 
(Frans 2012).
Unpublished data
To avoid publication bias, we contacted six authors of included studies to obtain un-
published data for the assessment of secondary outcome variables. From four authors, 
we received additional data (Collins 2011; Nicolai 2010; Sanderson 2006; Treat-Jacobson 
2009). We were unable to obtain appropriate or adequate data for two studies (Cheetham 
2004; Gardner 2011).
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2 Included studiesFor this update, nine additional studies were included (Collins 2011; Gardner 2011; 
Gardner 2012; Hodges 2008; Nicolai 2010;Parr 2009; Sanderson 2006; Stewart 2008; Tre-
at-Jacobson 2009), making a total of 14 included studies. Three of the eight studies (Degi-
scher 2002; Nielsen 1975; Nielsen 1977) that were included in the previous version of this 
review were excluded in this update for the reasons given in Characteristics of excluded 
studies. The 14 included trials involved a total of 1002 participants; 589 received super-
vised exercise therapy (SET), and 413 received non-supervised exercise therapy. The trials 
were conducted in the United States (7), the UK (4), Australia (1), the Netherlands (1), 
and South Africa (1). Nine of the trials were relatively recent (2006 to 2012). Five trials 
were conducted from 1997 to 2005 and were reported in the original review.
Some of the included trials were small; seven included fewer than 30 participants 
(Hodges 2008; Kakkos 2005; Parr 2009;Regensteiner 1997; Sanderson 2006; Savage 2001; 
Treat-Jacobson 2009), and four others included fewer than 80 participants (Cheetham 
2004; Gardner 2011; Patterson 1997; Stewart 2008). Three trials included more than 140 
participants (Collins 2011; Gardner 2012; Nicolai 2010); the largest trial, which was con- 
ducted in the Netherlands, consisted of 304 participants and was the only multicenter-
based study (Nicolai 2010).
In three studies (Parr 2009; Sanderson 2006; Treat-Jacobson 2009), three different 
modes of exercise regimens were investigated. For this review, we used data from the 
supervised walk- ing groups and the regular non-supervised groups only. One trial was 
designed to investigate the effects of home-based exercise, but participants were treated 
with a supervised session once a week (Collins 2011). Therefore this study was included 
in the supervised group. Another trial (Gardner 2011) investigated the effects of super-
vised exercise in a three-armed randomized study. In this trial, a control group with “go 
home and walk” advice was compared with a group given home-based or supervised-
based exercise against a background of standard medical care. We (HJPF, BLWB, JAWT, 
MHP) decided to use the results of the non-supervised exercise groups (“go home and 
walk” advice and home- based exercise) separately in the subgroup analysis. The results of 
the supervised group therefore were equally split and were used as comparator.
Inclusion criteria
In six of the trials, in order to be eligible for inclusion, participants with intermittent 
claudication had to be stable for several months (Cheetham 2004; Kakkos 2005; Patterson 
1997; Regensteiner 1997; Sanderson 2006; Stewart 2008). This criterion was not menti-
oned in the other trials. In all trials, both males and females were included (Characte-
ristics of included studies), except for one trial, which included only male participants 
(Regensteiner 1997).
The mean age of participants in the SET and control groups was 65.3 years (range 57 
to 69) and 66.3 (range 61 to 70), respectively. In the four trials that used age restrictions, 
participants had to be older than 18 years of age (Treat-Jacobson 2009), older than 40 
years of age (Collins 2011), older than 50 years of age (Savage 2001), or between 50 and 75 
years of age (Patterson 1997). A diagnosis of PAD was an essential inclusion criterion in 
all trials. In one trial (Savage 2001), the diagnosis of intermittent claudication was based 
on a clinical history. In two other trials (Kakkos 2005; Parr 2009), participants were in-
cluded when intermittent claudication was clinically determined and a peripheral arterial 
lesion was found on ultrasound or angiography, or both. The remaining trials (Cheetham 
2004; Collins 2011; Gardner 2011; Gardner 2012; Hodges 2008; Nicolai 2010; Patterson 
1997; Regensteiner 1997; Sanderson 2006; Stewart 2008; Treat-Jacobson 2009) used a low 
ankle-brachial index (ABI) or a drop in ankle pressure after exercise to determine the cli-
nical diagnosis of PAD. Collins et al included participants with PAD and diabetes mellitus 
type 1 or 2 (medication use, diet control, or hyperglycemia) (Collins 2011).
Exclusion criteria
The exclusion criteria used by the included trials were variable. In general, ischemic rest 
pain, comorbid illness with limitations in an exercise therapy program, and recent vas-
cular surgery or percutaneous transluminal angioplasty (PTA) were mentioned. In one 
study, smoking habits (Savage 2001), and, in another, the presence of diabetes mellitus 
(Regensteiner 1997) were exclusion criteria. Kakkos 2005 and Nicolai 2010 excluded 
participants with a maximal claudication distance greater than 300 or with a maximal 
claudication distance less than 50 meters and greater 500 meters, respectively. Two trials 
excluded cases in which the results of the treadmill test differed by more than 25% in 
terms of absolute claudication distance derived from three screening tests (Kakkos 2005; 
Treat-Jacobson 2009). Collins excluded participants without a phone (Collins 2011), and 
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2 Sanderson 2006 did not include participants who lived farther than 50 km from the re-search center. Gardner et al excluded participants who used cilostazol or pentoxifylline or 
both (Gardner 2011; Gardner 2012).
Supervised exercise regimens
In general, the supervised exercise programs consisted of three exercise sessi-
ons a week for durations of six weeks (Parr 2009; Sanderson 2006), three months 
(Gardner 2011; Hodges 2008; Patterson 1997; Regensteiner 1997; Treat-Jacobson 2009), 
six months (Gardner 2012; Kakkos 2005), and 12 months (Nicolai 2010). However, in 
three trials (Cheetham 2004; Collins 2011; Stewart 2008), the supervised program was 
given as a weekly session during six months, a weekly session with phone call support 
during three months, and biweekly supervised therapy during three months, respectively. 
Generally, a training session involved walking on a treadmill with varying intensity until 
moderate or intense pain occurred; this was followed by a short period of rest. Three 
studies (Cheetham 2004; Parr 2009; Patterson 1997) described an alternative training 
regimen with walking training as the dominant exercise but with additional exercises for 
lower limb strengthening. In one trial, treadmill exercises were not performed and exerci-
ses were described as based on training of the lower extremity, but unfortunately this was 
not specified further (Stewart 2008). In all trials, the duration of each supervised exercise 
session varied between 30 and 70 minutes, except in Patterson 1997, in which a session 
lasted 20 to 40 minutes. Four trials with an initial supervised period of three months 
and an additional three months’ unsupervised follow-up were included (Patterson 1997; 
Savage 2001; Stewart 2008; Treat-Jacobson 2009). Cheetham and Kakkos treated parti-
cipants with six months of SET with an additional six months’ unsupervised follow-up 
(Cheetham 2004; Kakkos 2005). The remaining trials did not have a follow-up period 
without supervised therapy. In two trials (Patterson 1997; Savage 2001), participants were 
additionally educated weekly or monthly about PAD, and Treat-Jacobson 2009 described 
all non-supervised exercises in reports. 
Non-supervised exercise regimens
In ten trials, participants in the non-supervised exercise therapy groups were advised to 
walk (Cheetham 2004; Collins 2011 Gardner  2011;  Gardner  2012;  Hodges  2008;  Kak-
kos  2005; Nicolai 2010; Parr 2009; Sanderson 2006; Stewart 2008). This walking advice 
was given once and predominantly consisted of walking at least three times weekly with 
walking intensity ranging between tolerance and intense pain. Besides receiving this ad-
vice, participants in four trials were treated with standard medical therapy (Cheetham 
2004; Hodges 2008; Nicolai 2010; Sanderson 2006). Nicolai et al provided an additional 
brochure as well (Nicolai 2010). In five other trials, participants in the control group were 
treated with a home-based exercise program (Gardner 2011; Patterson 1997; Regenstei-
ner 1997; Savage 2001; Treat-Jacobson 2009).
Outcome  measurements
All trials used a treadmill walking test to measure the pain-free treadmill walking dis-
tance or time and the maximal treadmill walking distance or time. The treadmill tests 
used varied between trials and are reported in the table of Characteristics of included 
studies. Three trials used a fixed protocol (Cheetham 2004; Kakkos 2005; Stewart 2008), 
and the other eleven used a graded protocol. Seven of these studies (Collins 2011; Gard-
ner 2011; Gardner 2012; Hodges 2008; Nicolai 2010; Parr 2009; Savage 2001) used the 
Gardner Skinner protocol (Gardner 1991). Data on the maximal treadmill walking dis-
tance of Cheetham (Cheetham 2004) were calculated on the basis of the P value, and it 
was assumed that the standard deviations of both groups were equal. Data from Patter-
son (Patterson 1997) were extracted from the accompanying figures. Seven trials (Chee-
tham 2004; Gardner 2011; Gardner 2012; Kakkos 2005; Parr 2009; Stewart 2008; Treat-
Jacobson 2009) measured adherence to the exercise program by registering absence in 
the supervised groups. In the non-supervised groups, attendance was noted in three trials 
on the basis of self-reported logbooks (Cheetham 2004; Gardner 2011; Treat-Jacobson 
2009). Participant-reported outcomes were taken into account in nine trials (Cheetham 
2004; Collins 2011; Gardner 2011; Gardner 2012; Kakkos 2005; Nicolai 2010; Patterson 
1997; Regensteiner 1997; Savage 2001). The Medical Outcomes Study (MOS) Short Form 
(SF)-36 was used in seven trials (Cheetham 2004; Collins 2011; Gardner 2011; Kakkos 
2005; Nicolai 2010; Patterson 1997; Savage 2001); the MOS SF-20 was used in the trial 
of Regensteiner (Regensteiner 1997). Additionally, the Walking Impairment Question-
naire (WIQ) was used in four trials (Gardner 2011; Gardner 2012; Kakkos 2005; Nicolai 
2010), the Intermittent Claudication Questionnaire (ICQ) in one trial (Kakkos 2005), 
the Geriatric Depression Scale (GDS) in one trial (Collins 2011), and the Charing Cross 
Claudication Questionnaire (CCCQ) in one trial (Cheetham 2004).
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2 Excluded studiesFor this update, 34 additional studies were excluded (Ciuffetti 1994; Collins 2005; Crow-
ther 2008; Dahllöf 1976; Degischer 2002; Fakhry 2011; Fowler 2002; Gardner 2005; Green-
halgh2008; Grizzo 2011; Hobbs 2007; Krause 1974; Kruidenier 2011; Leicht 2011; Leon 
2005; Manfredini 2008; McDermott 2009; Menêses 2011; Mika 2005; Mika 2006; Mika 
2011; Murphy 2012; Nielsen 1975; Nielsen 1977; Ritti-Dias 2010; Saxton 2011; Schlager 
2011;  Schlager  2012;  Spronk  2009;  Tebbutt  2011; Tew 2009; Walker 2000; Wood 2006; 
Zwierska 2005). A summary of the excluded studies can be found in the table entitled 
Characteristics of excluded studies. Overall, 53 studies were excluded. Thirty-two studies 
compared SET with a non-exercising group or a group that maintained usual care with 
or without usual medical care. Seven trials (Ciuffetti 1994; Gardner 2005; Grizzo 2011; 
Krause 1974; Lepantalo 1991; Menêses 2011; Ritti-Dias 2010) compared SET with ano-
ther kind of supervised therapy, and six studies compared SET with an invasive procedure 
(Gelin 2001; Kruidenier 2011; Murphy 2012; Spronk 2009; Taft 2001; Taft 2004). Four 
trials (Fowler 2002; Leon 2005; Manfredini 2008; Tebbutt 2011) compared home-based 
exercise therapy with walk advice. In another study (Tisi 1997), participants were treated 
with a 4-week SET program. Five trials (Degischer 2002; Fakhry 2011; Nielsen 1975; Niel-
sen 1977; Wind 2007) were excluded because they used a non-randomized study design. 
Three of these had been classified as included studies in the original review (Degischer 
2002; Nielsen 1975; Nielsen 1977). However, because a greater number of eligible studies 
were available, we decided to include RCT designs only in the current update.
Ongoing studies
One trial (Frans 2012) was a description of a study protocol.
Risk of bias in included studies
See Figure 1; Figure 2.
Allocation
Sequence generation
Four studies did not detail the process of sequence generation (Patterson 1997; Regenstei-
ner 1997; Savage 2001; Treat-Jacobson 2009). All others (Cheetham 2004; Collins 2011; 
Gardner 2011; Gardner 2012; Hodges 2008; Kakkos 2005; Nicolai 2010; Parr 2009; San-
derson 2006; Stewart 2008) described an adequate sequence generation.
Concealment of allocation
Five studies described adequate concealment of allocation, using sealed opaque envelopes 
or a computer program with or without block randomization (Gardner 2011; Gardner 
2012; Nicolai 2010; Sanderson 2006; Stewart 2008). Allocation concealment was not de-
tailed in the remaining nine studies (Cheetham 2004; Collins 2011; Hodges 2008; Kakkos 
2005; Parr 2009; Patterson 1997; Regensteiner 1997; Savage 2001; Treat-Jacobson 2009).
Blinding
In trials that compared exercise programs with walking distance as the primary outcome, 
blinding of staff and participants is not possible and therefore was not considered. Two 
trials were judged to have a low risk of detection bias because a blinded analysis of the 
outcomes was performed (Cheetham 2004; Nicolai 2010).
Figure 1 Risk of bias graph: review authors’ judgements about each risk of bias item 
 presented as percentages across all included studies.
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2 Incomplete outcome dataAll included studies reported results of predefined primary outcome variables. Nicolai et 
al reported additional outcome variables, which were not published (Nicolai 2010). Ho-
wever, through contact with the author, these unpublished data were obtained. Five trials 
reported an intention-to-treat analysis (Collins 2011; Gardner 2011; Gardner 2012; Kak-
kos 2005; Nicolai 2010), and six other trials reported no dropouts or had minimal loss to 
follow-up and therefore did not perform an intention-to-treat analysis (Cheetham 2004; 
Regensteiner 1997; Sanderson 2006; Savage 2001; Stewart 2008; Treat-Jacobson 2009). 
Overall, 159 participants were lost to follow-up (15.9%). Two trials were unclear in their 
attrition bias description (Parr 2009; Patterson 1997), and Hodges et al reported no de-
tails on attrition (Hodges 2008).
Selective reporting
Reporting bias was difficult to determine. No study protocols of trials were obtained. 
All included studies reported commonly used primary outcome parameters, so a low 
reporting bias was assumed for these outcomes. In one trial, we assessed a high risk of 
reporting bias (Cheetham 2004). In this study, quality of life was measured with Medical 
Outcomes Study Short Form 36; however, we could not obtain usable data from the figu-
res. In another trial, reporting bias was just as unclear because quality of life was reported 
in a “Physical function score” only (Gardner 2011). Only one author replied with unpu-
blished SF-36 data (Nicolai 2010).
Other potential sources of bias
To detect publication bias, we analyzed the two best represented outcome variables 
(maximal walking distance at three and six months) with the use of funnel plots (Figure 
3; Figure 4). No asymmetrical plots were observed, leading to the conclusion that publi-
cation bias was minimal. Seven trials were judged to have an unclear risk of potential bias. 
The work of Collins 2011 was funded by the American Diabetes Association; however, 
no potential conflicts of interest relevant to this article were reported. Two studies by 
Gardner et al (Gardner 2011; Gardner 2012) could be influenced by participation bias. 
Participants in these trials were volunteers; therefore, they may represent those more in-
terested in exercise. Four other trials reported data in interquartile range (IQR) format, 
which had to be recalculated; this could have led to potential bias (Kakkos 2005; Nicolai 
2010; Patterson 1997; Stewart 2008). All other trials were judged to have low risk (Chee-
Figure 2 Risk of bias summary: review authors’ judgements about each risk of bias  
 item for each included study.
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2 tham 2004; Hodges 2008; Parr 2009; Regensteiner 1997; Sanderson 2006; Savage 2001; Treat-Jacobson 2009).
Figure 4 Funnel plot of comparison: Maximal treadmill walking distance after 6 months.
Figure 3 Funnel plot of comparison: Maximal treadmill walking distance after 3 months.
Effects of interventions
Primary outcome
Maximal treadmill walking distance or time
Data on maximal treadmill walking distance after six weeks of exercise therapy were avai-
lable in five trials (Gardner 2012; Hodges 2008; Kakkos 2005; Parr 2009; Sanderson 2006) 
with a total sample size of 234 participants. This outcome was repeated after three months 
in nine trials (n = 592) (Cheetham 2004; Gardner 2011; Hodges 2008; Nicolai 2010; Pat-
terson 1997; Regensteiner 1997; Savage 2001; Stewart 2008; Treat-Jacobson 2009), after 
six months (n = 686) in nine trials (Cheetham 2004; Collins 2011; Gardner 2012; Kakkos 
2005; Nicolai 2010; Patterson 1997; Savage 2001; Stewart 2008; Treat-Jacobson 2009), after 
nine months (n = 308) in two trials (Cheetham 2004; Nicolai 2010), and after 12 months 
(n = 321) in three trials (Cheetham 2004; Kakkos 2005; Nicolai 2010). We calculated 
the effect estimates after standardization of mean differences. At six weeks, the maximal 
treadmill walking distance was increased with an overall effect size (ES) of 0.52 (95% 
confidence interval (CI) 0.24 to 0.81) when the fixed-effect model was used in favor of the 
SET group. At three months, the overall effect size increased to 0.69 (95% CI 0.51 to 0.86). 
This translates to a difference in favor of the supervised group of approximately 180 m in 
increased walking distance, corresponding with an approximately 35% to 40% difference 
in increase between the groups. At six months, this effect was maintained with an overall 
effect size of 0.48 (95% CI 0.32 to 0.64). In two trials in which the outcomes were repea-
ted, the effect was present at nine months (ES 0.60, 95% CI 0.36 to 0.85) (Cheetham 2004; 
Nicolai 2010) and 12 months after exercise therapy (ES 0.61, 95% CI 0.37 to 0.84) (three 
trials: Cheetham 2004; Kakkos 2005; Nicolai 2010). We performed a subgroup analysis at 
three months and six months of follow-up by splitting the non-supervised group into a 
walking advice group and a home-based exercise group. At three months, the difference 
favored the supervised group, with an ES of 0.76 (95% CI 0.56 to 0.96) and 0.50 (95% CI 
0.17 to 0.83) for the walking advice group and the home-based group, respectively. No 
significant difference was found between the two subgroups (P = 0.19). At six months, the 
supervised exercise group was still in favor compared with both non-supervised groups. 
In addition, we found no significant differences between the two subgroups (P = 0.78). At 
six weeks, non-significant heterogeneity was noted with an I2 of 27% (P = 0.24). At three 
months, moderate heterogeneity was observed (I2 = 43%; P = 0.07). Use of the random-
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2 effects model for the results after three months resulted in a similar overall effect size of 0.69 (95% CI 0.43 to 0.94), indicating that this heterogeneity is of non-importance. At 
six months, significant heterogeneity was seen (I2 = 71%; P = 0.0006). With a random-
effects model, the effect size was increased from 0.48 to 0.58 (95% CI 0.24 to 0.91). This 
heterogeneity is likely due to the negative trial of Collins (Collins 2011). When a sensi-
tivity analysis was performed by excluding this trial, a non-important heterogeneity was 
achieved (I2 = 25%; P = 0.23). At other time points, moderate heterogeneity was noted at 
nine months (I2 = 82%; P = 0.02) and at 12 months (I2 = 64%; P = 0.06).
Figure 5 Comparison: Maximal treadmill walking distance after 3 months.
Secondary outcomes
Pain-free treadmill walking distance or time
Data on pain-free treadmill walking distance after six weeks were available in four tri-
als (Gardner 2012; Kakkos 2005; Parr 2009; Sanderson 2006) with a total sample size 
of 171. This outcome was repeated after three months in seven trials (n = 479) (Gard-
ner 2011; Nicolai 2010; Patterson 1997; Regensteiner 1997; Savage 2001; Stewart 2008; 
Treat-Jacobson 2009), at six months in eight trials (n = 630) (Collins 2011; Gardner 2011; 
Kakkos 2005;Nicolai 2010; Patterson 1997; Savage 2001; Stewart 2008; Treat- Jacobson 
2009), and at 12 months after exercise therapy in two trials (Kakkos 2005; Nicolai 2010) 
(n = 266). We calculated the effect estimates after standardization of the mean differen-
ces. At six weeks, the pain-free treadmill walking distance was increased, with an overall 
effect size of 0.51 (95% CI 0.18 to 0.84), when the fixed-effect model was used in favor 
of the SET group. At three months, the overall effect size increased to 0.70 (95% CI 0.52 
to 0.89). This translates to a difference in favor of the supervised group of approxima-
tely 150 m in increased pain-free walking distance. At six months and twelve months, 
this effect was maintained, with an overall effect size of 0.52 (95% CI 0.35 to 0.69) and 
0.50 (95% CI 0.24 to 0.76), respectively.We again performed a subgroup analysis in the 
non-supervised group at three months and six months of follow-up. At three months, 
the difference favored the supervised group, with an ES of 0.72 (95% CI 0.49 to 0.94) 
and 0.65 (95% CI 0.29 to 1.01) for the walking advice group and the home-based group, 
respectively. No significant differences were found between the two subgroups (P = 0.76). 
At six months of follow-up, the SET group was still in favor, with an ES of 0.45 (95% CI 
0.27 to 0.63) and 1.04 (95% CI 0.54 to 1.53) compared with the walk advice group and 
the home-based exercise group, respectively. However, a significant difference (P = 0.03) 
between the non-supervised subgroups was found in favor of the home-based group. No 
statistical heterogeneity was observed at six weeks (I2 = 0%; P = 0.45), at three months (I2 
= 0%; P = 0.56), and at 12 months (I2 = 0%; P = 0.54). However, at six months, substantial 
heterogeneity was reported (I2 = 64%; P = 0.007). After a sensitivity analysis that excluded 
the negative trial of Collins (Collins 2011), we found an unimportant heterogeneity (I2 = 
16%; P = 0.30). 
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2 MortalityIn five of the fourteen trials (Cheetham 2004; Kakkos 2005; Nicolai 2010; Patterson 1997; 
Stewart 2008), a total of thirteen participants died during the course of the study. In the 
trial of Patterson 1997, nothing is mentioned about the cause of death of the two parti-
cipants who died during follow-up (both from the supervised group). Cheetham 2004 
registered two deaths (one from each group), neither of which could be attributed to a 
vascular event. Kakkos (Kakkos 2005) described one death. This person died as the re-
sult of acute leg ischemia after undergoing an operation for bladder cancer. Nicolai et al 
mentioned three deceased people in the control group (coronary heart disease (n = 2), 
renal cell carcinoma (n = 1)) and four deaths in the supervised group (complication lo-
wer extremity bypass surgery (n = 1), lung carcinoma (n = 1), ruptured abdominal aortic 
aneurysm (n = 1), pancreatic cancer (n = 1)) (Nicolai 2010). One death occurred in the 
control group of Stewart (Stewart 2008). No deaths were reported in the remaining trials.
Adherence to exercise program
Five trials (Cheetham 2004; Gardner 2011; Gardner 2012; Parr 2009; Stewart 2008) stu-
died adherence to exercise training. Cheetham 2004 simply asked participants whether 
they walked “less than three times”, “three times”, or “more than three times” a week. 
Twice as many participants in the SET group as in the non-supervised group claimed 
to be walking more than three times a week. Gardner 2011 provided participants with a 
step activity monitor, and they were instructed to wear it for each exercise session. Ad-
ditionally, participants received an exercise logbook in which they were to record their 
walking sessions. Adherence to home-based exercise and supervised exercise was similar 
(82.5% vs 84.8% completion of exercise sessions, respectively). Unfortunately, no adhe-
rence data were available from the group that re-ceived walking advice at baseline only. 
The adherence ratio from the exercise group in Gardner 2012 did not differ greatly (74% 
completion) from that obtained in their earlier research, although a progressive decline 
in attendance was evident from the first two months to the final stage at six months (from 
86% to 63%). Kakkos 2005, Parr 2009, and Stewart 2008 noted the attendance of the su-
pervised group only (mean attendance: 60%, 80%, and 89%, respectively). Treat-Jacobson 
2009 revealed an adherence of 100% in 61% of participants in the SET group, and 97% of 
participants completed at least 75% of the prescribed training. Conversely, 75% of control 
group participants reported participation in outside exercise at least three times a week.
Patient-reported outcomes (quality of life)
In this update, we calculated the effect estimates after standardization of mean differen-
ces in SF-36 outcomes after three and six months. The SF-36 was used in seven trials after 
three months (Cheetham 2004; Collins 2011; Gardner 2011; Kakkos 2005; Nicolai 2010; 
Patterson 1997; Savage 2001), and the MOS SF-20 in the trial of Regensteiner (Regenstei-
ner 1997). However, Collins 2011 and Cheetham 2004 published SF-36 results as a change 
from baseline, but they were not usable. We contacted the study authors but were not able 
to obtain raw or unpublished data. Results of the physical function role were presented in 
five trials (Gardner 2011; Nicolai 2010; Patterson 1997; Regensteiner 1997; Savage 2001); 
both social function and the emotional role were noted in four trials (Nicolai 2010; Pat-
terson 1997; Regensteiner 1997; Savage 2001); and the remaining roles were mentioned in 
three trials (Nicolai 2010; Patterson 1997; Savage 2001). The role “general health” showed 
significant improvement with supervised exercise (ES 0.30, 95% CI 0.05 to 0.55) only. 
The other roles showed a positive trend toward the intervention; however, these changes 
are not statistically significant. A sub analysis of non-supervised exercise programs could 
not be made because of the small number of studies. SF-36 outcomes at six months were 
obtained in four trials (Kakkos 2005; Nicolai 2010; Patterson 1997; Savage 2001). Again, 
almost all roles showed a positive trend toward supervised exercise, except for the role 
of “pain”, which revealed a significant positive change (ES 0.25, 95% CI 0.00 to 0.49). SF-
36 outcomes at other time periods were not used because they could be obtained only 
from unpublished data of Nicolai 2010 and summary data of Kakkos 2005. No statistical 
heterogeneity was noted in all quality of life analyses, except for the vitality role, at three 
months’ follow-up (I2 = 79%; P = 0.008). Use of random-effects models resulted in a so-
mewhat increased overall effect size from 0.05 to 0.30 (95% CI -0.43 to 1.03), indicating 
that no important heterogeneity was present. Using the CCCQ, Cheetham 2004 reported 
a statistically significant difference between the two groups (P < 0.05) after nine months 
of exercise in favor of the SET group. Intragroup analyses of the WIQ and the ICQ sho-
wed less improvement or even reduction in the non-supervised group compared with an 
increase in score in the supervised group (Kakkos 2005; Regensteiner 1997). However, 
these changes were not compared between groups (Kakkos 2005; Regensteiner 1997).
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2 Discussion
Summary of main results
Primary outcome
We included data from 14 randomized trials enrolling a total of 1002 participants. Statis-
tically significant and clinically relevant differences in improvement in walking distance 
were consistently demonstrated in favor of SET compared with non-supervised exercise 
therapy regimens during the first year of treatment. A subanalysis was performed to in-
vestigate the influence of two types of non-supervised exercise regimens. No significant 
differences were found between “go home and walk” advice and a more structural home-
based exercise program. Despite the variability of prescribed exercise training and tread-
mill walking tests used to measure the outcome, heterogeneity was present only for the 
results of the maximal treadmill walking distance after six months. This is likely a result 
of the negative trial of Collins (Collins 2011). Indeed removing this trial from the analysis 
resulted in the absence of statistical heterogeneity. In addition to chance alone, several 
factors could contribute to the observed heterogeneity. First, the supervised exercise regi-
men used by Collins was described as home-based exercise and consisted of once-a-week 
supervised training only, thereby reducing the intensity of supervision compared with the 
other trials, which trained three times a week or biweekly (Stewart 2008). Furthermore, 
in the trial of Collins (Collins 2011), all participants had diabetes mellitus. Reported data 
on walking time and distance were standardized to allow calculation of the difference in 
increase between the two treatment groups. When the standardized data were translated 
back to walking distances, summary estimates of maximal treadmill walking distance 
showed a difference in increase of approximately 180 m in favor of the SET regimens over 
non-supervised therapy for three months. This difference was maintained at six, nine, 
and twelve months.
Secondary outcomes
In line with maximal walking distance, pain-free walking distance was more increased 
by supervised exercise than non-supervised exercise during the first year of treatment, 
with a maximal effect size of 0.76 (95% CI 0.57 to 0.95) at three months. This effect was 
maintained at six and twelve months. A significant difference was found in the sub ana-
lysis between “go home and walk” advice and a more structured home-based exercise 
program, probably as a result of the SET negative trial of Collins (Collins 2011). Further-
more, significant heterogeneity was found at six months. A sensitivity analysis excluding 
the trial of Collins (Collins 2011) resulted in non-important heterogeneity and no signi-
ficant difference between the two non-supervised exercise types. No obvious results in 
mortality registration were obtained. Thirteen of the 1002 participants died, but none of 
these deaths were related to exercise therapy. Participant-related outcomes (SF-36) were 
not significantly different between the two exercise regimens. This could be explained by 
an underpowered analysis. We obtained complete SF-36 data from three studies (n = 245) 
at three months of follow-up (Nicolai 2010; Patterson 1997; Savage 2001) and from four 
trials at six months of follow-up (n = 258) (Kakkos 2005; Nicolai 2010; Parr 2009; Savage 
2001). Five other studies did record SF-36 outcomes; however, we were not able to obtain 
the raw data. This could have led to a potential publication bias.
Overall completeness and applicability of evidence
Participants
Both inclusion and exclusion criteria were variable across studies, but they did not differ 
very widely from daily practice. Regensteiner 1997 included solely male participants, and 
Collins 2011 included participants with diabetes mellitus only.
Interventions
Most included studies were performed in hospital settings all over the world. One trial 
provided supervised exercise in part at the hospital and in part at home (Collins 2011). 
Another used community-based supervised exercise (Nicolai 2010). Kruidenier conclu-
ded that community-based SET appeared to be as effective as hospital-based SET, so it 
seems unlikely that these potential factors of heterogeneity limit the applicability of the re-
sults (Kruidenier 2009). In three trials, training sessions were complemented by strength 
training (Cheetham 2004; Parr 2009; Patterson 1997), and one trial was based on exercise 
therapy of the lower extremity without treadmill walking (Stewart 2008). There were no 
indications that these supervised sessions were less stringent than in the other studies. 
The effectiveness of different modes of exercise will be compared in another Cochrane 
review (Lauret 2012b). Six trials had a follow-up period without supervision. After a sen-
sitivity analysis was performed by removing four trials with a non-supervised follow-up 
period (n = 350; Patterson 1997; Savage 2001; Stewart 2008; Treat-Jacobson 2009), effect 
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2 size at six months did decrease slightly from 0.48 (95% CI 0.32 to 0.64) to 0.45 (95% CI 0.27 to 0.63). This suggests that exercise therapy with a period of supervision could have 
a prolonged effect on increasing walking distance and could be as effective as that descri-
bed in trials with a full follow-up trajectory.
Comparator
This review compared supervised with non-supervised exercise therapy. We found that 
non-supervised regimens showed a lot of heterogeneity from simple walking advice at 
the start of treatment to a structured home-based exercise program with some form of 
remote “supervision”. Therefore, we performed a sub analysis within the non-supervised 
exercise group, which was divided into a “go home and walk” advice group and a home-
based exercise group. In one three-armed trial (Gardner 2011), the results of the control 
group and those of the home-based treated exercise group were compared with results of 
the supervised group by splitting the supervised group into two groups.
Outcomes
All trials used treadmill exercise to investigate the effectiveness of supervision. Only three 
trials used a fixed protocol. Furthermore, we used standardized mean differences to re-
duce potential heterogeneity caused by differences in treadmill testing. To reduce hete-
rogeneity in secondary outcomes, we used SF-36 values only for participant-reported 
outcomes.
Applicability
To determine the clinical relevance of the ability to walk 180 m farther, one should re-
alize that a mean maximal walking distance at baseline is approximately 300 m with an 
even shorter pain-free walking distance of approximately 200 m. Regular exercise, such 
as walking, has been shown to significantly reduce cardiovascular events (Izquierdo 2000; 
Wannamathee 2001). Because claudicants have high cardiovascular morbidity and mor-
tality (30% mortality at five years) (Aquino 2001; Dormandy 1999; Hooi 2002), a habit 
of regular walking with increased exercise capacity could be of considerable importance. 
Results of our review reveal increased ability to perform on a treadmill. However, such 
an increase might not have any influence on walking behavior in daily life because some 
studies have found that supervised exercise does not affect day-to-day walking behavior 
(Crowther 2008; McDermott 2009).
Quality of the evidence
Unfortunately, the raw data from one study (Cheetham 2004) were not directly available 
and had to be derived by working backward from the reported P values. We assumed 
that the standard deviations of both groups were equal. Compared with other trials that 
reported equal standard deviations, this seemed reasonable. The data of Patterson (Pat-
terson 1997) were extracted from the accompanying figures. Previously included non- 
randomized studies were excluded (Degischer 2002; Nielsen 1975; Nielsen 1977). Other 
detailed information of quality is presented in the Assessment of risk of bias in included 
studies. We noted two important limitations in the quality of the evidence. The nature 
of the interventions made participant blinding effectively impossible. In addition, par-
ticipation bias may have influenced the results, in that enrollment in a study motivated 
participants to walk (Collins 2011).
Potential biases in the review process
Unfortunately, heterogeneity was noted in the non-supervised comparator group. We 
tried to minimize this by introducing a subgroup analysis. Furthermore, because of dif-
ferences in inclusion and exclusion criteria, such as age or gender restrictions or the 
presence of diabetes mellitus and smoking behavior, generalization of the results of this 
meta-analysis could be a topic of discussion. Not all outcome data were available for in-
clusion. This potentially introduced bias into our review and may reflect publication bias. 
Therefore, we conducted a formal analysis of publication bias by using a funnel plot. It is 
suggested from this analysis that publication bias is not a matter of importance (Figure 
3; Figure 4).
Agreements and disagreements with other studies or reviews
Several other systematic reviews have been performed that are in line with our findings. 
Watson et al suggested that exercise therapy should play an important part in the care 
of selected patients with intermittent claudication, to improve walking times and dis-
tances. Effects were demonstrated after three months of supervised exercise, although 
some programs lasted longer than one year (Watson 2008). Wind et al concluded that 
SET increases pain-free and absolute walking distances in participants with intermittent 
claudication as well (Wind 2007). A recent review of Fakhry et al. compared supervised 
exercise with no interventional observation. The authors concluded that supervised exer-
cise yielded significant clinical benefit (Fakhry 2012).
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2 Several plausible mechanisms might explain the beneficial results of SET over non-supervised regimens. A first explanation could be the fact that the exercise regimen of the 
SET group mainly consisted of treadmill walking, which involves a higher workload than 
level ground walking at “normal” speed as used by the non-supervised group (Degischer 
2002). It is very difficult to measure the intensity of training, but it is generally assumed 
that home training cannot be considered to be performed with the same energy as trai-
ning under supervision (Nielsen 1975). Second, a higher workload will lead to a larger 
positive effect of the general physical condition of the patient, possibly as the result of 
increased cardiovascular stress, providing a better stimulus for exercise-induced adap-
tations (Hamburg 2011). Furthermore, a supervised program could offer additional en-
couragement and motivation to patients resulting in a higher adherence rate, which can 
be explained in part by the Hawthorne effect as mentioned by Wind et al (Wind 2007). 
The Hawthorne effect describes the effect that the awareness of being under observation 
can alter the way a patient behaves or can positively influence the outcome. Nevertheless, 
when adherence is taken into account, and on the basis of the contrasting results between 
two trials (Cheetham 2004; Gardner 2011), nothing can be suggested about the influence 
of a supervised exercise regimen on adherence. However, adherence in a supervised exer-
cise setting is effortlessly measurable during the session in contrast to adherence during 
home-based intervals or in home-based settings.
Authors’ conclusions
Implications for practice
Supervised exercise therapy provides statistically significant benefits for treadmill wal-
king distance when compared with non-supervised regimens. The clinical relevance of 
this difference requires additional studies with a focus on quality of life or other disease- 
specific functional outcomes, such as walking behavior, patient satisfaction, and costs. 
The results of this review are consistent with those of previously performed studies and 
meta-analyses. All indicate that SET is an effective treatment that should be available as 
part of the care of patients with intermittent claudication. However, the availability of 
SET in clinical practice is far from optimal (Lauret 2012a; Makris 2012; Nicolai 2010; 
Shalhoub 2009). Professionals in the vascular field are obliged to take action to make 
supervised exercise therapy that is community or hospital based available for all patients 
with intermittent claudication.
Implications for research
Research to optimize exercise program components (eg, duration, exercise intensity, dif-
ferent modes of exercise, endurance training vs interval training, implementation of life-
style interventions) is needed. Future research should include people who have a more 
severe stage of PAD and other comorbidities, as this is more representative of the PAD 
population.
Most of the included studies in this review have focused on treadmill hospital-based 
exercise, although the effectiveness of community-based exercise programs is an inte-
resting consideration for future research (Kruidenier 2009), particularly because some 
form of conservative treatment should be initiated before an invasive revascularization is 
performed (Hirsch 2006; Norgren 2007). Others have shown that access to a conservative 
supervised exercise program is low across Europe (UK: 36.4%; Germany: 46.7%; Greece: 
10%) (Makris 2012). Research is needed to investigate the effects of community-based 
exercise programs on walking behavior, physical activity, and costs, and their long-term 
effects on morbidity, cardiovascular risk factors, and mortality (eg, the ClaudicatioNet 
concept, which was launched in The Netherlands; 100% SET access; Makris 2012). The 
concept aims to implement nationwide coverage of regional networks that provide qua-
lity care according to contemporary guidelines for patients with PAD (Fokkenrood 2012; 
Lauret 2012a).
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Introduction
Recently  governments, nongovernmental organizations, and the private sector were 
called to assess the social and economic consequences of peripheral arterial disease (PAD) 
and to explore the best strategies for optimum treatment and prevention of this disease(1). 
Although treatment strategies for PAD are well described in international guidelines(2-4) 
and advocate a multimodal approach, including medication, lifestyle changes and symp-
tomatic treatment, mentioning supervised exercise therapy (SET) as the primary treat-
ment option(3), the actual availability of these SET programs worldwide is limited (5-9). 
In contrast, The Netherlands have a high availability of SET programs (10). However, a 
proven effective SET program (performed by physiotherapists trained at improving car-
diorespiratory health status as well as life style factors and medication compliance) is in 
many cases not fully reimbursed. 
This reimbursement issue originates from a contradictory policy in the Dutch heal-
thcare system. In the Netherlands, healthcare insurance companies have an obligation 
to accept everyone for a basic healthcare insurance. The Dutch government determines 
coverage of the standard insurance. In case of patients suffering from intermittent clau-
dication (IC) the government decided not to cover the first 20 treatment sessions of a 
SET program, which have to be paid by the patient (either directly or through additional 
insurance). From the 21st session onwards all additional treatment sessions given in one 
year are covered by the basic health care insurance. Medication (prescribed by a physi-
cian) and invasive vascular interventions are both included in the standard package and 
fully reimbursed. As a consequence SET is largely underutilized. Patients may receive a 
proven insufficient and less cost-effective “go home and walk” advice(11-14) or a vascular 
intervention as an alternative first-line treatment strategy(5), which are contradictory to 
contemporary guidelines.  
The advocated treatment strategy in above-mentioned guidelines, could be incorpo-
rated into a so-called “stepped care” model (SCM)(5, 15, 16). This theoretical approach st-
rives to initially refer all IC patients to a SET program and restrict revascularization for 
only those, who are not responding to SET. Several cost-effectiveness analyses have been 
performed supporting such a SET first treatment strategy(13, 16-20). However no study was 
performed to investigate the overall economic consequences of a SCM implementation 
Abstract
International guidelines recommend supervised exercise therapy (SET) as pri-
mary treatment for intermittent claudication (IC). The aim of this study was to cal-
culate treatment costs in patients with IC and to estimate nationwide annual savings 
if a stepped care model (SCM, primary SET treatment followed by revascularization 
in case of SET failure) would have been followed.
Invoice data of all patients with IC in 2009 were obtained from a Dutch health 
insurance company (3.4 million members). Patients were divided into three groups 
based on initial treatment as followed after diagnosis (t0). The SET group received 
SET initiated at any time between 12 months before and up to 3 months after t0. 
The intervention group (INT) underwent endovascular or open revascularization 
between t0 and t+3 months. The third group (REST) received neither SET nor an 
intervention. All peripheral arterial occlusive disease (PAOD) related invoices were 
recorded during 2 years and average costs per patient were calculated. Savings fol-
lowing use of a SCM were calculated for 3 scenarios.
Data on 4954 patients were analysed. Initial treatment was SET (n=701, 14.1%), 
INT (n=1363, 27.5%) or REST (n=2890, 58.3%). Within two years from t0, invasive 
revascularization in the SET group was performed in 45 patients (6.4%). Additional 
interventions (primary at other location and/or re-interventions) were performed in 
480 INT patients (35.2%). Some 431 REST patients received additional SET (n=299, 
10.3%) or an intervention (n=132, 4.5%). Mean total IC related costs per patient 
were €2191, €9851 and €824 for SET, INT and REST, respectively. Based on a hypo-
thetical worst, moderate, and best case scenario, some 3.8, 20.6 or 33.0 million euros 
would have been saved per annum if SCM was implemented in the Dutch health 
care system.
Implementation of a SCM treatment for patients with IC may lead to significant 
savings of health care resources. 
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were also excluded (figure 1). Data on comorbidity (diabetes mellitus, COPD, hypercho-
lesterolemia and heart failure) were collected on the basis of prescribed medication. 
Definition of IC subgroups
Patients meeting inclusion criteria were subdivided into three groups based on their pri-
mary treatment as initiated by a vascular surgeon within three months after diagnosis (t0< 
t 3months) (figure 1). 
• SET group: community-based SET started in the period between 12 months 
prior to diagnosis up to 3 months after the diagnosis of IC by a vascular surgeon 
(graph 1). SET prior to diagnosis was possible in case of referral by a patient’s 
general practitioner (GP) who already initiated SET. 
• INT group: Any form of revascularization received within 3 months after the 
diagnosis of IC by a vascular surgeon.
• REST group: Neither SET nor INT group inclusion criteria were met (graph 1). It 
was assumed that these patients received a “go home and walk” advice or had no 
IC at all (this contradictory ‘no IC in an IC population’ phenomenon is explained 
later on in the sensitivity-analysis paragraph).
Graph 1 Referral of SET in the SET and REST group 12 months prior and after diagnosis (t0)
nationwide. We decided to perform a cost-analysis in case of SCM implementation in 
the Dutch healthcare system. Costs of IC treatment were calculated and compared to 
estimated costs associated with three hypothetical scenarios of nationwide SCM imple-
mentation.
Methods 
Inclusion and exclusion
The 2009 database of CZ, a large Dutch healthcare insurance company (n=3.419.604 in-
sured persons, approximately 21% of the Dutch population) was retrospectively analysed. 
Insured patients that had received an invoice related to the diagnosis “PAD Fontaine 2” 
corresponding to IC complaints as diagnosed by a vascular surgeon, were eligible for 
inclusion. Only patients that had been insured for at least two consecutive years at CZ 
were eligible, excluding crossover patients from other insurance companies (possibly 
harbouring an unknown 2-year history of PAD). In order to restrict the study to newly 
diagnosed IC patients, all patients that underwent vascular interventions in 2007 or 2008 
Figure 1 Flow-chart of study population and classification of subgroups
Notes: PAOD: peripheral arterial occlusive disease
 * straight line: primary treatment; dashed line: secondary treatment
 
 
Database of CZ (n=3.419.604 insured persons)
Inclusion criteria (PAOD Fontaine II)
n = 5824
Exclusion criteria (n870)
 -- insurance < 2 years
 -- vascular intervention in 2007 or 2008
Eligible patients
n = 4954
SET group
n = 701
REST group
n = 2890
t-12 t0 t3 t0 t3
INT group
n = 1363
t0 t3
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Secondary treatment was defined as a second intervention (primary at other location 
and/or re-interventions or SET) that was performed following primary treatment. This 
population included patients with either failure of primary treatment (re-intervention), 
treatment of the contralateral leg as well as treatment delay (treatment > t3months). Dif-
ferentiation between these groups was not possible due to the nature of the database. It 
was assumed that all patients received best medical treatment (BMT) prescribed at the 
discretion of the physician. 
Costs of PAD treatment 
A Fontaine classification by a vascular surgeon is always required for billing purposes in 
the Dutch healthcare system. All claudication related invoices (by physician and physio-
therapists) for primary as well as secondary treatment within two years of follow-up after 
t0 were screened. The majority of interventions in 2009 were performed by radiologists, 
based on a vascular surgeons indication. Total costs generated in the SET, INT and REST 
groups were calculated by adding all intervention costs for the group the patient was 
initially allocated to. Discrimination between a secondary ipsilateral intervention and a 
primary contralateral intervention was not possible due to the nature of the database, ai-
med at costs registration. Mean total costs (MTC) per patient per group were calculated. 
Expenditures for medication use were not incorporated into the calculations.
Sensitivity-analysis of the REST group
Patients in the REST group were supposed to have received a walking advice. When a 
patient is referred to a vascular surgeon for IC by a GP, a “PAD Fontaine 2” (synonymous 
to IC) invoice is registered. However, if IC is subsequently ruled out, the invoice is often 
not corrected into the proper invoice “ruling out IC”. In a prospective analysis of 100 con-
secutive patients we found that 30% of the GP referrals with presumed IC in fact received 
an alternative, non-IC diagnosis(21). This phenomenon is not financially driven since 
reimbursement of a “rule out” invoice appears €1.43 higher. This incorrect registration 
may have contaminated the composition of the REST group and it was decided to exclude 
the REST group from the SCM cost-analysis. However, a cost-analysis of the REST group 
was performed in an additional sensitivity analysis (SA), assuming 30% non-IC patients.
Cost-analysis of a nationwide adherence to a SCM
The costs of a SCM were estimated for patients in the SET and INT group. Successful 
treatment guided by a SCM depends on two critical success factors: 
1. the surgeons’ compliance (willingness) to refer each IC patient to SET. Despite 
the fact that, according to contemporary international guidelines, all patients 
with IC initially should be referred for SET(2-4), this ratio was hypothetically set 
to 80% (best), 50% (moderate) and 30% (worst) based on reimbursement issues, 
appreciation of SET by vascular surgeons and preference (although evidence to 
do so is lacking) for a revascularization in certain cases.
2. the patient’s motivation to participate in a SET program, which  largely depends 
on reimbursement issues (level of compensation by the insurance company) as 
well as a thorough understanding of the benefits of a SET program in compa-
rison to an invasive intervention. The latter is also strongly associated with the 
surgeon’s knowledge regarding SET and the willingness to refer. To allow for a va-
riation in patients’ willingness, this ratio was arbitrarily set at 80% in case of full 
reimbursement for all IC patients and optimal provision of information. On the 
other end, 25% was chosen for the current levels of reimbursement and informa-
tion provision. These ratios were also suggested by the results of a questionnaire 
completed by a cohort of Dutch vascular surgeons(9).
Combining doctor and patient factors in a comparative model resulted in six hypothe-
tical scenarios (80%-80%; 80%-25%; 50%-80%; 50%-25%; 30%-80% and 30%-25%). As 
both factors are interrelated (physicians will limit SET referrals if patients drop out due 
to reimbursement issues; conversely, physicians may not refer to SET due to presumed 
preference for an intervention), only the three most likely scenarios were considered: best 
(80%-80%), moderate (50%-80%) and worst case (30%-25%). In addition, extrapolation 
for the Dutch population was performed by multiplying total savings on the total group 
by a factor 4.94 (21% of the Dutch population is insured by CZ).
Data analysis
The insurance database was analyzed with SAS (SAS Institute Inc, New York, USA). Dif-
ferences between categorical variables were analyzed with a chi-square test. Statistical 
analyses were performed using SPSS 20 software (SPSS Inc, Chicago, USA). A two-sided 
p<.05 was considered statistically significant. Calculations of costs were calculated with 
Excel 2011 (Microsoft Office, Redmond, USA). Graphs were created with Graphpad 
Prism 5 (GraphPad Software Inc, La Jolla, USA). 
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SET and 491 a vascular intervention as initial treatment. Nationwide implementation of 
such an 80%-80% scenario SCM would result in a 33.0 million euros annual savings for 
the Dutch population (table 5). Implementation of the worst-case scenario (30%-25%) 
would still reduce the yearly costs of IC treatment with 3.9 million euros (table 5). In the 
sensitivity-analysis (SA), 2023 of 2890 patients remained in the REST group (30% non-
PAD exclusion) leaving 4087 eligible IC patients for analysis. In the best-case scenario, 
2868 of these patients would receive SET, 491 a vascular intervention and 728 a walking 
advice. Savings would still be reduced from 33.0 to 24.2 million with an 80%-80% SCM 
implementation after SA (table 5). 
Group
SET INT REST p
Number of patients (n - %) 701 (14%) 1363 (27%) 2890 (58%)
Age (years) 69 65 68 p<0.001
Gender (% male) 57.3% 64.8% 58.9% p<0.001
Diabetes II (%) 6.9% 7.0% 8.2% p=0.24
CARA (%) 8.1% 10.7% 10.1% p=0.17
Hypercholesterolemia (%) 30.5% 29.3% 27.4% p=0.16
Congestive heart failure (%) 9.6% 8.7% 12.0% p<0.01
Table 1 Patient characteristics
Results
Adherence to a SCM
A total of 5824 patients with “PAD Fontaine 2” (IC) were identified of which 871 patients 
were excluded for reasons listed in figure 1, leaving 4954 IC patients for analysis. Fourteen 
percent received SET, whereas 28% was primarily treated with an invasive intervention 
(INT). The remaining 58% (n=2890) did not receive any of these two treatment regimens 
within three months after diagnosis (REST). Patient characteristics of the three groups 
are shown in table 1. Significant differences between groups were found with respect to 
age, gender and congestive heart failure. Patients in the INT group were younger, more 
often male and had less often congestive heart failure.
 Primary and secondary treatments are depicted in table 2 and 3. A total of 45 
SET patients (6.4%) were secondarily treated with an endovascular (n=43) or open sur-
gical (n=2) procedure (table 2). A total of 1055 endovascular (aortoiliac lesions: 696; fe-
moro-popliteal lesions: 340) and 308 open surgical procedures were initially performed 
in 1363 INT subjects (table 2). In 480 of these patients (35.2%), an additional revascula-
rization procedure (endovascular: n=464; open: n=16) was performed within 2 years. In 
the REST group, 299 patients (10.3%) were additionally treated with SET and 132 patients 
(144 interventions, 4.6%) with an endovascular revascularization.
Costs of IC treatment
A wide range of costs was found regarding the physician based invoices. Bills ranged 
from a minimum of €99 and €2,515 to a maximum of €14,428 and €50,173 for the SET 
and INT group, respectively. Total costs ranged from a single visit at the patient outdoor 
clinic (€99) to a bilateral open surgical revascularization. Mean costs of SET declarations 
ranged from €28 to €7,187 in the SET group to a maximum of €12,886 in the REST group 
as related to the number of SET sessions (1 to 470 sessions; table 3). The MTC per patient 
in the SET group (€2,191) was almost five times lower compared a patient in the INT 
group (€9,851; table 4).
Cost-analysis of a hypothetical nationwide adherence to a SCM
The effects on cost-savings of a SCM with and without sensitivity analysis (SA) are shown 
in table 5. In the 2009 situation (14% SCM), the costs were 17.3 million euros. In the hy-
pothetical best-case scenario (80%-80%), 1573 of the 2064 eligible patients would receive 
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Table 4 Mean total costs per patient per group during two years of follow up
Table 3 SET sessions per group
Table 2 Revascularizations per group per anatomical section
Note:	 *	Unspecified	due	to	suboptimal	registration.	Ao-Il:	aorto-iliac,	FemPop:	femoral-popliteal
Primary 
treatment
Secondary treatment
INT - group SET - group INT - group REST - group
Patients with intervention (n - %)
1363 (100%) 45 (6.4%) 480 (35.2%) 132 (4.6%)
Interventions per section
Invoices of Radiology 
dept.
Bypass 
revascularization
8 2 8 2
Ao-Il,	 
(one sided) 
477 20 193 69
Ao-Il,	 
(both sides)
219 5 94 19
FemPop 
(one sided)
313 17 147 47
FemPop 
(both sides)
27 1 14 6
Crural  
(one sided)
12 0 8 1
Invoice of Surgery dept. Endovascular* 9 0 0 0
Open 289 2 16 0
Open  
(both sides)
19 0 0 0
Primary treatment Secondary treatment
SET - group SET - group INT - group REST - group
Patients with SET (n - %) 701 (100%) NR 141 (10.3%) 299 (10.3%)
Number of SET sessions (mean ± SD)
(min – max)
48 (± 42)
(1 – 271) NR
38 (± 35)
(1 – 176)
42 (± 47)
(1 – 470)
Group
SET
mean 
(min – max)
INT
mean 
(min – max)
REST
mean 
(min – max)
Physician based invoices (€) 890
(99	–	14,428)
9,745
(2,515	–	50,173)
705
(99	–	17,935)
Physiotherapist based invoices (€) 1,301
(28	–	7,187)
106
(28	–	4,914)
118
(28	–	12,886)
Mean Total Costs (MTC) € 2,191 € 9,851 € 824
Scenario Groups Costs Savings
SET 
(n)
INT 
(n)
Cost-analysis Group Sensitivity analysis
INT to SET* Dutch 
population
SET
(n)
REST
(n)
REST  
to SET*
(INT to SET) 
+
(REST to SET)*
Dutch  
population
Current 
(14% - NR%)
701 1363 € 14.953.716 NR NR 701 2023 NR NR NR
Best case 
(80%-80%)
1573 491 € 8.276.594 €	6,677,121 € 32.992.834 1996 728 -	€	1,770,685 €	4,906,436 €	24,237,794
Moderate 
case 
(50%-80%)
1246 818 € 10.780.515 €	4,173,201 € 20.620.521 1510 1214 -	€	1,106,678 €	3,066,523 €	15,148,624
Worst case 
(30%-25%)
803 1261 € 14.171.240 €	782,475 € 3.866.348 853 1871 -	€	207,502 €	574,973 €	2,840,367
Discussion
Three international guidelines recommend SET as a first line treatment for patients 
with IC(2-4), supported by cost-effectiveness analyses(13, 16-20). Unfortunately, the availability 
of SET programs in Europe is low(10, 22). Some consider the substantial investments to ob-
tain nationwide implementation of SET programs as a problem(13). Our findings implicate 
that the initial investments to increase SET availability in other countries may be benefi-
cial when guidelines and therefore the SCM are followed. Despite that the Dutch have a 
Note: * NR = not relevant
Table 5 Implementation of a stepped care model
Notes: NR . not relevant.
 a Based on CZ population.
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well-organised community based SET network should not be an excuse for other Euro-
pean countries but a motivation to implement such a network. Furthermore SCM imple-
mentation effects and thus cost-savings may even be larger since most foreign health care 
systems have low penetration of (community-based) SET programs and thus a potential 
lower threshold for invasive vascular interventions. Moreover the calculated savings of a 
SCM approach in this study are in euros, while a reduction of morbidity and mortality 
ratios might account as well.
Makris et al. claimed a 100% SET availability in the Netherlands in 2012(10). The pre-
sent study demonstrated that a mere 14% of the IC patients were actually referred to 
SET in 2009. The discrepancy between a relatively low percentage of SET referrals and 
high availability of SET programs might be explained by the combination of conflicting 
reimbursement issues, increased patients’ and physicians’ enthusiasm for interventional 
procedures(16), and a lack of appreciation of SET(9). The latter might be caused by ambigui-
ties in contemporary guidelines, which may be responsible for a too liberal use of invasive 
procedures in patients with IC due to aortoiliac lesions as stated in the TASC(4). In contrast 
the NICE guideline suggest to initiate this type of lesion with SET(3). Several large trials 
show inconclusive results concerning treatment of aortoiliac lesions(23-26). In the present 
study, 28% of the patients received a primary revascularization, of which 51% concerned 
aortoiliac lesions. More than half (58%) of the included patients were even assumed to 
have received a walking advice. The present study therefore clearly demonstrates that the 
TASC II / NICE guidelines (restricting interventions to patients not responding to SET) 
are largely neglected in Dutch practices. A nationwide implementation of a SCM might 
tackle these issues, whereas expected cost-savings as presented in this study may facilitate 
current conflicting issues in reimbursement.
Moreover, a SCM may have substantial influence on IC patients’ individual treat-
ment strategy.  It is known that patients suffering from IC, regardless of the severity of 
the walking restriction, have a range of other limitations(27). Initiating treatment with 
SET may provide awareness of important functional restrictions in daily life other than 
caused by IC (e.g. COPD, congestive heart failure, osteoarthritis, spinal stenosis, equi-
librium disorders). So following a SCM, may prevent potentially futile vascular inter-
ventions in multimorbid patients who are limited by more than just IC. Furthermore, 
once (successful) invasive treatment has been performed, recurrent ipsilateral or new-
ly developed contralateral obstructions are likely again treated by invasive means too, 
contributing to a high re-interventions ratio (35%) in the INT group. Surprisingly, this 
was also found by others(16) and is in line with reported patency rates of endovascular 
revascularizations(28, 29). Additionally, initiating a SET first policy might not meet the con-
temporary articulate and demanding patient, focused on a quick fix of the problem. Our 
findings suggest that a SCM, with a three-month trial period preceding invasive treat-
ment, in which patients not responding to SET are eligible for invasive treatment might 
decrease the number of interventions. 
Our study has limitations inherent to its retrospective character. Some might argue 
that selection bias may have influenced the results, since patients with more severe IC 
complaints or with a specific atherosclerotic lesion may preferentially have been treated 
by invasive means. However, all included patients had IC classified as Fontaine II and ac-
cording to contemporary guidelines should have received SET as a primary treatment(2-4). 
In addition, we applied a correcting factor, in our (best-case scenario) calculations refer-
ral rate was set at an 80% ratio (instead of the guidelines’ 100%), permitting the remaining 
20% to be treated based on personal preference of the patient or of the vascular surgeon.
Furthermore our study showed differences in patient characteristics between groups 
(age, gender and CHF). Unfortunately we were not able to adjust our analyses for these 
covariates due to privacy limitations of the insurance company database. Our findings 
reveal that young males were treated more frequently with revascularization compared to 
older patients or females. This phenomenon might reflect assumptions and indirect evi-
dence suggesting that invasive treatment should be preferred in a working age population 
as recovery is deemed faster. The same might be the case in the assumption that since en-
dovascular treatment for aortoiliac lesions is more durable compared to femoropopliteal 
lesions, this warrants an intervention in aortoiliac lesions(28). However, as far as we know, 
no evidence substantiates such an invasive first line treatment for certain IC subgroups. 
A formal cost-effectiveness study could not be performed since the insurance com-
pany’s database lacks data on treatment effect or outcome. Furthermore, costs related to 
an intervention of the ipsi- or contralateral leg could not be identified which may have 
biased total costs of the INT group. However, this limitation is relative as walking exercise 
pertains to both legs. 
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Future perspectives
Reimbursement issues in the Dutch health care system remain an issue. Optimization 
of a SCM depends on political decision-making and awareness of health care insurers 
concerning the functional and financial advantages of SET. The impact of a SCM imple-
mentation on the Dutch as well as European society should be subject to future research.
Conclusion
In addition to the solid evidence supporting SET as first line treatment for patients 
with IC, introduction of and adherence to a SCM may lead to significant savings of health 
care resources associated with the treatment of patients with intermittent claudication.
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Abstract
Background
Supervised exercise therapy (SET) is recommended as the primary treatment for pa-
tients with intermittent claudication (IC). However, there is concern regarding the 
safety of performing SET because IC patients are at risk for untoward cardiovascular 
events. The Dutch physical therapy guideline advocates cardiac exercise testing be-
fore SET, if indicated. Perceived uncertainties concerning safety may contribute to 
the underuse of SET in daily practice. The objective of this review was to analyse the 
safety of supervised exercise training in patients with IC.
Methods:
Two authors independently studied clinical trials investigating SET. Data were ob-
tained from MEDLINE, EMBASE, and The Cochrane Central Register of Control-
led Trials. Complication rates were calculated and expressed as number of events 
per number of patient-hours. The usefulness of cardiac screening before SET was 
evaluated in a sub analysis. 
Results:
Our search strategy revealed 2703 abstracts. We selected 121 articles, of which 74 
met the inclusion criteria. Studies represent 82,725 hours of training in 2876 IC 
patients. Eight adverse events were reported, six of cardiac and two of noncardiac 
origin, resulting in an all-cause complication rate of one event per 10,340 patient-
hours.
Conclusions: 
SET can safely be prescribed in patients with IC because an exceedingly low all-
cause complication rate was found. Routine cardiac screening before commencing 
SET is not required. Our results may diminish perceived uncertainties regarding 
safety and will possibly increase the use of SET in daily practice. 
Introduction
Some 50% to 80% of patients with peripheral arterial disease (PAD) are sympto-
matic with intermittent claudication (IC).(1) IC is deﬁned as muscle discomfort in the 
lower limb(s) elicited by exercise that resolves after a short period of rest.(1) IC is associ-
ated with signiﬁcant disability, reduced quality of life,(2,3) and an increased risk of death.
(4) A recent study found a signiﬁcant difference in survival when patients with and 
without PAD were compared; for instance, the all-cause and cardiovascular mortality 
rates were 24% and 7.7% in patients with PAD vs 9.5% and 2.4% in patients without 
PAD, respectively.(5) The unfavourable prognosis associated with PAD is dominated 
by the concomitant presence of cerebral and coronary artery disease (CAD) due 
to generally accepted risk factors (smoking, hypertension, diabetes mellitus, hyper-
lipidaemia).(6-8) The estimated overall prevalence of atherosclerotic CAD in PAD is 
72%, with an obstructive nature in 61% to 98% in certain subgroups.(9,10) The Quebec 
Cardiovascular Study reported that the risk of fatal and nonfatal cardiovascular events 
in men with IC was twice as high compared with men without known cardiovas-
cular disease.(11) International guidelines state that treatment of IC should consist of 
a multimodal approach that includes cardiovascular risk reduction combined with 
symptomatic treatment.(1,7) First-choice symptomatic treatment, demonstrated by Level 
I evidence, is daily-supervised exercise therapy (SET).(12-17) Apart from symptomatic im-
provement, a 12-week SET program also reduced overall cardiovascular mortality by 
52% and morbidity by 30%.(18) Although it is generally accepted that SET should be 
part of the initial treatment for each patient with IC, this therapeutic tool is seriously 
underused in clinical practice.(19-21) A study among surgeons in the United Kingdom 
revealed that only 24% of IC patients had access to SET.(21) Moreover, a large variation 
was found in the proportion of eligible patients referred to such an exercise program. 
Lack of knowledge on referral criteria was also observed in a recent nationwide 
survey among Dutch vascular surgeons. Approximately 70% of the interviewed 
surgeons were convinced that coexisting cardiopulmonary comorbidity or aortoiliac 
stenosis or occlusion, or both, were relative contraindications for participation in a 
SET program.(20) These doubts are strengthened by a worry among physical thera-
pists providing SET because they fear the onset of cardiovascular events that may 
possibly occur during exercise. Moreover, physical therapy guide- lines advocate 
cardiac screening before SET,(22) although evidence to support such a strategy is 
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currently lacking. SET is often described as well tolerated, and two studies re- ported 
cardiovascular complications were rare.(23,24) The aim of the present study was to 
analyze the safety of SET in patients with IC in terms of onset of untoward (cardio- 
vascular) events.
Methods
Participants 
We included studies that investigated the role of SET in patients diagnosed with 
IC (Fontaine II/ Rutherford 1-3).
Types of studies
Eligible studies examined SET alone or in a comparison model with other treatments 
such as endovascular treatment, vasoactive medication, or non- SET. Randomized 
and nonrandomized studies were included. Although treadmill walking is conside-
red an important component of a SET program, uncertainty remains regarding the 
most effective content of such a program.(25) All types of SET programs  were  there-
fore included (eg, pole-striding and strength training). The search was limited to stu-
dies in humans and articles written in Dutch, German, or English. No limitation to 
date of publication was considered.
Search strategy
We performed a search in MEDLINE (1966 to June 2013) using the following Medi-
cal Subject Heading terms: “peripheral arterial diseases,” “peripheral vascular disea-
ses,” “intermittent claudication,” “peripheral arter* occlus*,” “claudica*,” “isch* limb*,” 
“exercise,” “exercise therapy,”  “exercise  movement  techniques,” “walk*,” “runni*,” 
“exerc*,” “train*,” and “treadmill.” Additional articles were found by matching a pre-
vious search of Cochrane Central Register of Controlled Trials (1966 to September 
2012) and EMBASE (1974 to June 2013) and removing duplicates. We also searched 
bibliographies of included articles. After screening titles and abstracts, two reviewers 
(L.G., H.F.) independently selected articles, based on a full-text evaluation. Disagree-
ment between reviewers was discussed and resolved by consensus.
Data extraction and management
Two authors (L.G., H.F.) used a standardized data extraction form to extract the fol-
lowing data: details of the study population, country, research setting, number of 
participants, number of dropouts/lost to follow-up, reasons for dropout, age, gender, 
inclusion and exclusion criteria, description of the supervised exercise protocol, fre-
quency, duration, content, all types of reported complications related to SET, and the 
use of cardiopulmonary exercise testing (CPET). To exclude the potential inﬂuence 
of medication, only results obtained from participants in the placebo control group 
of randomized controlled trials were included. If studies did not explicitly report pos-
sible occurrence of adverse events, we used information on the number of dropouts 
and reasons for dropout. Studies that contained dropouts due to medical causes were 
excluded. An E-mail was sent to authors who reported unclear data regarding SET-
related complications or reasons for dropout to obtain details on the occurrence of 
untoward events. Studies of authors who did not respond to this e-mail were also 
excluded.
Figure Flow chart of study selection. 
2	703	potentially	relevant	records	identified:	 
titles and abstracts were screened
121 potentially relevant articles:
full text reviewed
2 574 records excluded: not relevant
65 articles excluded:
Systematic review or meta-analysis (5)
Different research scope (6)
Insufficient	data*	(10)
Language (2)
No supervised exercise therapy (19)
Preliminary results or duplicate data (23)
74 studies included in review
18 articles added by hand search
Notes:  *Defined	as	missing	data	on	complications	during	supervised	exercise	training	SET)
	 incomplete	data	on	reasons	for	dropout,	
	 or	nonresponse	on	e-mail	request	as	a	final	attempt	to	obtain	information.
Safety of supervised exercise therapy in patients with intermittent claudication.
97
4
Innovative strategies for intermittent claudication 
96
4
Statistical analysis and data synthesis
Data were analyzed using SPSS 18.0 software (SPSS Inc, Chicago, Ill). The total 
number of patient-hours was calculated as the number of patients multiplied by the 
number of training sessions corrected for the mean duration of each session. When 
information on the exact duration of training sessions was lacking,  an  approxima-
tion  of 30 minutes was assumed. Adverse events were character- ized as cardiac or 
noncardiac. The role of cardiac screening was studied by performing a sub analysis. 
We calculated separated event rates based on the use of CPET before SET.
Results
Study selection
We identiﬁed 2703 records resulting in the study of 121 relevant articles. Overall, 74 
studies (Supplementary Appendix, online only) with a total of 2876 IC patients met 
inclusion criteria (Fig). Patients represented 82,725 patient-hours of SET.
Study characteristics 
Most of the SET studies were performed in Western Europe and North America. 
Mean patient age ranged from 54 to 76 years, and more men than women parti-
cipated (Table I). Frequently reported patient exclusion criteria were IC presenting 
with pain at rest, critical ischemia, exercise capacity limited by symp- toms of angina, 
congestive heart failure, chronic obstructive pulmonary disease, arthritis, and poorly 
controlled hypertension. Exercise programs consisted of treadmill training (n = 49), 
mixed exercise therapy (n = 8), circuit training (n = 11), strength training (n = 2), 
arm ergometry (n = 2), or pole-striding (n = 2). Duration of the exercise programs 
ranged from 2 weeks to 12 months. Training frequencies varied from one to seven 
times a week, and 30 to 120 minutes per day (Table II).
Main outcome measurement
Potential adverse events were explicitly reported in 35 of the 74 studies. Another 32 
studies reported no dropouts or dropouts without medical cause. The remaining se-
ven studies were included after positive e-mail conformation. Eight adverse described 
during >80,000 patient-hours of SET, resulting in an all-cause complication rate of one 
event in 10,340 patient-hours. Therefore, the risk of complications during SET is consi-
dered exceedingly low. Focusing on the two major cardiac complications, an even lower 
event rate of one event in 41,362 patient-hours was calculated. These results are in line 
with a prospective registry on complications during exercise for cardiac rehabilitation re-
porting an almost similar rate of one event per 49,565 patient-hours.(26) Moreover, these 
rates may even be considered relatively high because events that were reported in stu-
dies from >30 years ago were also included. Medical treatment has greatly improved the 
overall prognosis, potentially resulting in even lower current event rates. CPET has been 
used for >60 years for risk stratiﬁcation in patients with heart diseases,(27) but this 
technique is no longer recommended as a screening tool for myocardial ischemia in 
people without known CAD, as suggested by a recent guideline of The National Insti-
tute for Health and Clinical Excellence.(28) Prediction of a future severe cardiac event 
during exercise is very difﬁcult, if not impossible.(26) In the present review, 28 studies 
(32% of total patient-hours) included cardiac screening, but because an equal num-
ber of adverse events (n ¼ 4) was found in studies with or without cardiac screening, 
the results may indicate that cardiac screening in IC patients is indeed not useful. 
However, by the observational and retrospective design of our study, ﬁrm conclusi-
ons cannot be drawn. Yet, given the very low complication rate, cardiac screening as 
a tool for a safe execution of SET seems clinically irrelevant.
There is also a downside using CPET as a screening technique. As all screening tests do, 
CPET also inherently carries a risk of false-positive testing (29); for instance, a 15%events 
of cardiac (n = 6) and noncardiac (n = 2) origin were reported (Table III). One fatal 
adverse event was reported. The total all-cause event rate was one event per 10,340 
patient-hours. Total cardiac and noncardiac event rates were one per 13,788 and one 
per 41,363 patient- hours, respectively (Table IV). Sub analysis on cardiac screening. 
Of 28 studies (26,790 patient-hours of SET [32%]) that included cardiac screening 
before SET was initiated, 23 used electro- cardiography registration. Four of the eight 
adverse events were reported in these 28 studies. The remaining four, including a fatal 
myocardial infarction, were found in the 46 remaining studies that did not included 
cardiac screening (55,935 patient-hours of SET [68%]). Six studies reported results of 
1703 CPETs before SET inclusion. Abnormal CPET ﬁndings resulted in 59 patients 
(3.5%) being excluded from SET participation.
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Characteristics Mean (range) or No.
Age,	years 64 (54-76)
Men,	% 71 (30-100)
Countrya
Europe 44
Asia 2
North America 18
South America 4
Oceania 5
Africa 1
Author and year  
of publication
Country N Mean 
age
% 
male
Supervised exercise program Adverse 
events
Dura-
tion 
(weeks)
Frequen-
cya
(per week)
Content
(main  
component)
Andreozzi 2008 Italy 74 65 91 6 3 Treadmill None 
Andreozzi 2007 Italy 22 67 100 6 3 Treadmill None 
Arosio 2001 Italy 12 65 NR 2 7 Treadmill None 
Badger 2007 Ireland 8 70 NR 6 2 Treadmill None 
Beckitt 2012 UK 27 68 98 12 2 Circuit 
training
None 
Beckitt 2012 UK 42 66 69 12 2 Circuit 
training
None 
Bendermacher 2007 Netherlands 93 64 63 24 2,5 Treadmill None 
Cachovan 1994 Germany 21 62 NR 4 5 Treadmill None 
Carlon 2008 Italy 41 NR NR 12 3 Treadmill None 
Cheetham 2004 UK 30 65 NR 24 1 Circuit 
training 
None 
Ciuffeti 1994 Italy 15 56 >99 12 2 Mixed 
exercises
None 
Collins 2005 USA 27 70 98 24 3 Pole 
striding 
None 
Collins 2012 USA 103 66 93 24 3 Treadmill 
+ pole 
striding 
None 
Collins 2011 USA 72 66 75 24 1 Walking None 
Cousin 2011 France 31 56b 97 4 5 Treadmill  None 
Crowther 2008 USA 11 71 50 52 3 Treadmill None 
Degischer 2002 Switzerland 46 68 NR 12 1 Treadmill None 
Franz 2010 USA 101 72 46 12 3 Treadmill None 
Gardner 2005 USA 77 NR 88 24 3 Treadmill  None 
Gardner 2011 USA 40 66 45 12 3 Treadmill None 
Gardner 2002 USA 31 68 NR 24 3 Treadmill None 
Gardner 2012 USA 106 67 86 24 3 Treadmill None 
Gibelline 2000 Italy 20 65 99 4 5 Treadmill None 
Greenhalgh 2008 UK 127 65 63 24 1 Treadmill None 
Grizzo Cucato 2011 Brazil 34 67 60 12 2 Circuit 
training
None 
Hiatt 1996 USA 29 61 NR 20 3 Treadmill None 
Hiatt 1990 USA 25 67 100 12 3 Treadmill None 
Hiatt 2011 USA 30 66 83 24 0,29 Treadmill None 
Hobbs 2007 UK 9 NR 78 12 2 Circuit 
training 
None 
Hodges 2008 UK 14 67 NR 12 2 Treadmill None 
Jones 2012 USA 30 69 60 12 3 Treadmill None 
Kakkos 2005 UK 12 61 92 6 3 Treadmill None 
Kiesewetter 1987 Germany 15 64 70 6 5 Treadmill None 
Krause 1978 Germany 63 66 77 6 5 Mixed 
exercise 
None 
Table 1 Demographic characteristics (N = 2876)
Note: a = Number of studies performed in listed continents.
Table 2 Characteristics of included studies 
>> >>
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Krause 1976 Germany 55 65 74 6 5 Mixed 
exercise
1 myocardial 
infarction  
Kruidenier 2011 Netherlands 35 67 63 24 2,5 Treadmill None 
Lee 2007 UK 33 68 67 12 3 Circuit 
training 
None 
Leicht 2011 Australia 12 64 50 52 3 Treadmill None 
Lundgren 1989 Sweden 25 61 79 24 2 Mixed 
exercise 
None 
Mannarino 1991 Italy 10 63 67 24 2 Treadmill None 
Mannarino 1989 Italy 8 69 75 24 2 Treadmill None 
Martinez 2009 Israel 84 69 66 37 2 Treadmill None 
Mazari 2012 UK 60 69 62 12 3 Circuit 
training 
None 
McDermott 2009 USA 103 NR 52 24 3 Treadmill 1 cardiac 
arrest,
1 chest pain
McDermott 2004 USA 24 70 50 12 3 Treadmill 1 heart 
arrhythmias,	 
1 chest pain 
McGuigan70 2001 Australia 11 61 36 24 3 Circuit 
training 
None 
Mika 2011 Poland 34 64 90 12 3 Treadmill None 
Mika 2005 Poland 49 64 85 12 3 Treadmill None 
Murphy 2012 USA + 
Canada
43 69 49 26 3 Treadmill None 
Nawaz 2001 UK 52 69 83 6 2 Treadmill None 
Ng 2005 UK 16 NR 63 8 3 Walking None 
Nicolaï 2010 Netherlands 202 62 67 52 2,5 Treadmill None 
Parr 2009 South-Africa 17 68 30 6 3 Strength 
training 
None 
Patterson 1997 USA 27 NR 53 12 3 Mixed 
exercise
None 
Perkins 1996 UK 26 65 NR 24 2 Mixed 
exercise 
None 
Regensteiner 1997 USA 10 NR NR 12 3 Treadmill None 
Ritti Dias 2010 Brazil 34 62 67 12 2 Strength 
training
None 
Sanderson 2006 Australia 28 66 39 6 3 Treadmill None 
Savage 2001 USA 11 68 68 12 3 Treadmill None 
Saxton 2011 UK 71 60 79 24 2 Treadmill None 
Scheffler 1994 Germany 15 69 70 4 5 Treadmill 
+ walking 
None 
Schlager 2011 Austria 20 66 65 24 2 Treadmill None 
Slørdahl 2005 Norway 18 66 NR 8 3 Treadmill None 
Spronk 2009 Netherlands 75 68 52 24 2 Treadmill None 
Stewart 2008 UK 30 62 67 12 2 Circuit 
training 
None 
Streminski 1992 Germany 30 69 67 4 5 Treadmill 1 increased 
heart rate + 
dyspnea; 
1 worsening of 
osteoarthritis; 
1 ischialgia 
Tew 2009 UK 27 69 NR 12 2 Arm 
ergometry 
None 
Tisi 1997 UK 22 67 69 4 1 Mixed 
exercise 
None 
Treat-Jacobson 2009 USA 37 76 33 12 3 Treadmill 
or arm er-
gometry
None 
Tsai 2002 Taiwan 27 68 81 12 3 Treadmill None 
Villemur 2011 France 11 72 NR 2 5 Treadmill  None 
Wang 2007 Australia 22 54 100 12 3 Treadmill None 
Winterfeld 1983 Germany 17 64 NR 12 2 Circuit 
training
None 
Wood 2006 Australia 7 65 72 6 3 Treadmill None
Notes:	 NR	=	not	reported,	
 a	=	recalculated	to	frequency	per	week,	
 b = median age
>>
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Table 3 Overview of adverse events occurred during supervised exercise training (SET)
Table 4 Complication rates during SET 
Note: a = expressed as 1 event per number of patient-training hours
Event No (N=8)
Heart arrhythmias (n=1)
Angina pectoris (n=2)
Cardiac arresta (n=1)
Myocardial infarctionb (n=1)
Increased heart rate and dyspneac (n=1)
Worsening of osteoarthritisc (n=1)
Ischialgiac (n=1)
Number of events Complication ratesa
All cause 8 1:10,340
Cardiac 6 1:13,788
Non-cardiac 2 1:41,363
Discussion
The aim of this review was to identify SET-related complications in patients with IC 
as a means to determine its safety. To our knowledge, this is the ﬁrst study addressing the 
safety issue of SET. Eight complications were false-positive rate is observed in patients 
with chest pain, whereas this percentage is even higher in asymptomatic patients.(30) A 
false-positive test result will incorrectly and unnecessary exclude IC patients from a ﬁrst-
choice treatment.(1,7) In addition, false-positive results may lead to unnecessary (invasive) 
interventions (eg, coronary angiography) with accompanied morbidity, mortality, and 
costs. The risk of a false-negative test result after CPET is also present, as illustrated by 
one study.(31) A cardiac arrest was reported during exercise although no obstructive CAD 
was found during prior testing. Cardiac screening may therefore create a false sense of 
safety. Moreover, CPET itself also harbors a risk of cardiac complications. Approximately 
one to ﬁve complications per 10,000 tests were reported,(27,32) a percentage that clearly ex-
ceeds any risk caused by SET. Some have suggested that CPET is useful in detecting si-
lent ischemia.(33) Because most patients with IC will experience myocardial ischemia 
as anginal pain during exertion, some 17% to 47% will be asymptomatic (ie, silent 
ischemia type I).(34) Extensive research has been done in patients with diabetes mel-
litus, a condition associated with an even higher prevalence of silent ischemia.(35) A 
difference between silent and symptomatic CAD with respect to prognosis was never 
found.(34,36,37) Patients with IC may potentially beneﬁt from routine CAD screening 
through detection of silent ischemia; however, considering the high prevalence of 
silent ischemia and assuming that these patients were also present in our review, a 
larger number of incidents would have been expected. The value of CPET is therefore 
also questionable from this perspective. Lastly, CPET is potentially useful as a tool 
allowing for training optimization. A recent review attempted to identify the most 
important exercise components resulting in an optimal training protocol for patients 
with IC. The study concluded that intensity, duration, and program con- tent were 
not independently associated with improvement of maximal of pain-free walking 
distance.(25) Therefore, selection of SET components based on CPET does not seem 
to be a useful strategy.
Our study has limitations associated with its retrospective methodology and the pos-
sibility of publication bias. Only 35 of 74 studies explicitly reported the possible occur-
rence of adverse events, whereas a detailed description was sometimes lacking. Therefore, 
it remains uncertain whether all reported events indeed occurred during SET. On the 
other hand, some complications may have been missed. However, these were most likely 
minor events pre- venting the patient from stopping any activity. By our strategy of using 
information on dropouts, the number of patient-hours was increased, as was the chance 
on some extra uncertainty. The included studies were very heterogenic in content of 
the SET program, and an exact description of intensity was often lacking. Therefore, 
identifying any potential as- sociation between intensity of SET and complication 
risk was not possible. Subgroup analyses were impossible due to the small number 
of adverse events. An additional disadvantage of the present study is that the most of 
the participants were men. Consequently, the safety of SET is not demonstrated in 
female IC patients, although gender differences regarding the response to SET were 
never reported.
Notes: a  = successfully resuscitated
 b = fatal outcome
 c = no treatment needed
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A major methodological concern is that some studies excluded patients with li-
mited exercise capacity due to angina, heart failure, chronic obstructive pulmonary 
dis- ease, arthritis, poorly controlled hypertension, or recent myocardial infarction. 
Exclusion of these vulnerable cardiac patients might have resulted in an underesti-
mation of the number of adverse events. Therefore, generalizing these results to IC 
patients with major comorbidities is hazardous. On the other hand, one must ap-
preciate that exercise training also reduces the all-cause mortality in patients with 
congestive heart failure by 11%.(38) Others demonstrated in patients with stable CAD 
that a 12-month program of regular physical exercise resulted in superior event-free 
survival and exercise capacity compared with percutaneous coronary angioplasty 
(88% vs. 70%; P ¼ .023).(39) As a consequence, patients with  (cardiac) comorbidity 
should not routinely be excluded from SET in daily practice. However, each patient 
obviously requires careful monitoring.
Conclusions
The present review demonstrates that SET can safely be prescribed in IC patients be-
cause cardiovascular complication rates associated with this type of therapy are extremely 
low. However, caution should be taken when applying these results in patients with major 
comorbidity.
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Abstract
Increasingly unaffordable health care costs force care providers to develop eco-
nomically viable and efficient health care plans in the near future. Nowadays, only 
a minority of all newly diagnosed peripheral arterial occlusive disease (PAOD) pa-
tients receives an efficient and structured conservative treatment for their disease. 
The aim of the present article is to introduce an innovative effective treatment model 
termed ClaudicatioNet. This concept was launched in the Netherlands as a means 
to tackle these shortcomings and stimulate cohesion and collaboration between sta-
keholders
The overall goal of ClaudicatioNet is to stimulate quality and transparency of 
PAOD treatment by optimizing multidisciplinary healthcare chains on a national 
level. Improved quality is based on stimulating both a theoretical and practical base 
of knowledge, while eHealth and mHealth technologies are used to create clear in-
sights of provided care to enhance quality control management. These technologies 
can be used to stimulate patient empowerment thereby increasing efficacy of PAOD 
treatment even more. This online community consists of a web portal with public 
and personal information supplemented with a mobile application. By connecting 
these tools, a social community is created where patients can meet and keep in touch 
with fellow patients whereas useful information for supervising healthcare profes-
sionals is provided.
The ClaudicatioNet concept will likely create a more efficient and cost effective 
PAOD treatment by simply improve the quality of supervised training (SET) pro-
grams, extending its possibilities and stimulating patient empowerment by using 
eHealth and mHealth solutions. A free market principle is introduced by creating 
transparency of provided care by using objective and subjective outcome parame-
ters. Cost effectiveness is achieved as SET programs will possibly substitute or post-
pone expensive invasive vascular interventions.
Introduction
In the near future, the increasingly unaffordable health care costs in Europe (from 
13% of national income in 2012 to 31% in 2040 in the Netherlands, comparable for other 
European countries), necessitates a more economically viable and efficient healthcare.1 
In a recently released document titled “Healthcare, how much is it worth?” the Dutch 
ministry of health, welfare and sport notes several reasons for this increase.(1) The aging 
population explains 25% of this rise, while a larger amount is clarified by the growth 
in prosperity including the introduction of new technologies, change of expectations of 
healthcare in society and increasing life expectancies. Additionally the change in epi-
demiologic factors, causing an increase in patients with chronic diseases, will lead to a 
rise in demand for healthcare, again resulting in a rise of costs. These changes in society 
and its influence on healthcare are well reflected in peripheral arterial occlusive disease 
(PAOD). PAOD is a chronic systemic disease caused by the manifestation of atherosclero-
sis. The atherosclerotic process of narrowing and hardening of arteries can occur in each 
artery of the human body although it mainly affects coronary, cerebral and peripheral 
arteries (especially those in the lower extremities).(2) PAOD has a high prevalence in the 
general population affecting up to 20% in persons over 70 years.3 These numbers indicate 
that PAOD affects over 27 million individuals in North America and Europe.2 The mani-
festation of PAOD varies from absence of symptoms to tissue loss that may eventually re-
quire amputation of an affected limb. PAOD patients commonly present with symptoms 
of typical intermittent claudication (IC, which means ‘to limp’) in 20-50% of the cases.(2) 
IC is defined as muscle discomfort in the lower limb elicited by exercise and relieved by 
rest within 10 minutes.(2) IC has a significant impact on quality of life. New insights to op-
timize PAOD (IC) treatment are based on non-invasive conservative as well as (minimal) 
invasive strategies. However, restructuring the provided healthcare system might support 
an efficient PAOD treatment even more. The aim of this article is to introduce an inno-
vative treatment model based on the WHO chronic care framework in combination with 
an optimized multidisciplinary healthcare chain and the implementation of innovative 
eHealth & mHealth technologies.
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Efficient conservative treatment of PAOD 
Several international guidelines (the American College of Cardiology/ American 
Heart Association (ACC/AHA) and the Trans-Atlantic Inter-Society Consensus on Ma-
nagement of Peripheral Arterial Disease (TASC II) describe an overall strategy and basic 
treatment for patients with symptomatic PAOD.(2,4) Treatment of PAOD should consist of 
a multi-component therapy of cardiovascular risk reduction by pharmacology interven-
tions and lifestyle coaching (1) and symptomatic treatment (2).(5) 
The first component aims to prevent cardiovascular events (myocardial infarction, 
stroke) and related morbidity and mortality. The prevalence of cerebrovascular disease in 
patients with PAOD is about 25-50%.(6) In a subgroup of patients with severe and symp-
tomatic PAOD a 15-fold increase in mortality rate was found.(7) For IC, a 5-year mortality 
rate of 19.2% is described, of which 70% is due to cardiovascular causes. Cardiovascular 
risk reduction is important to prevent cardiovascular events (myocardial infarction or 
stroke) and related morbidity and mortality. The most important modifiable risk factors 
for atherosclerosis are smoking, hypertension, diabetes mellitus, hyperlipidaemia and 
obesity.(8) According to international guidelines, all symptomatic patients with or without 
a history of cardiovascular disease are generally prescribed antiplatelet therapy in combi-
nation with a statin.(9) 
The second component aims at relieving symptoms related to PAOD. An initial tre-
atment modality is exercise therapy, first suggested by Erb in 1898.(10) This approach was 
supported more than a century later by a Cochrane review. In this review, an overall 
improvement in maximal walking time with a mean difference of 5.12 minutes (CI 4.51 
– 5.72) was found in favor of exercise therapy compared with usual care or placebo.(11) In 
daily practice, lack of adequate individual supervision appears to be an important barrier 
for the initiation and continuation of exercise therapy in patients with PAOD. A Co-
chrane review by Bendermacher et al. and a RCT by Nicolai et al. showed that supervised 
exercise therapy (SET) was superior to a non-supervised program.(12,13) In a cohort study, 
community-based SET appeared to be as effective as hospital-based SET.(13) Community-
based SET has the advantage of providing a larger capacity of care and is feasible in close 
proximity to the patient’s home environment. With this body of evidence, it is clear that 
SET provided by a physical therapist (PT) in combination with cardiovascular risk ma-
nagement (CVRM) must be offered to all patients with IC.
Current status and problem statement for the Dutch situation
Unfortunately, only a minority of all newly diagnosed IC patients receives an efficient 
and structured treatment of their disease. We are convinced that the underlying contribu-
ting factors impeding full-scale implementation of SET & CVRM programs are: 
• Outdated national guidelines. 
 The guidelines of the Dutch Association of General Practitioners and the CBO  
guideline followed by Dutch vascular surgeons are at best ambiguous and do  
not mention the need of SET.(14,15) In contrast, the contemporary international  
guidelines for PAOD explicitly state supervision as a necessary component in  
exercise therapy. 
• Availability of a valid and established SET program
 When medical specialists and General Practitioners (GP) have carried out the 
indication and initiated referral for SET correctly. Whom to refer to? Insights in 
PTs who provide qualitative SET programs were not available. Transparency and 
accessibility to quality SET programs are required. 
The vast majority of the 23,000 Dutch PT’s are not adequately trained according to the 
Royal Dutch Society for Physical Therapy guideline for IC. Those who are, do not always 
have sufficient experience to provide this form of therapy in a correct way.  Moreover a 
SET program has a broader scope than physiotherapy alone. An essential feature of SET 
is that full attention is paid to existing comorbidities and modifiable lifestyle factors. If 
these aspects are not addressed appropriately, suboptimal results and loss of resources 
will occur. Adequately trained PT’s should ideally be able to perform individual training, 
recognise symptoms, provide lifestyle counselling and monitor medication adherence. 
• Reimbursement issues
 A major problem is the fact that the Dutch healthcare system does not stimulate 
the use of conservative treatment modalities for patients with IC. Cardiovascular 
risk management and invasive vascular interventions are fully compensated by 
the Dutch basic healthcare insurance. However, for patients with IC, the first 20 
treatment sessions of a SET program are not covered in this basic health care 
insurance (since January 1st, 2012) and have to be paid for by the patient (ei-
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ther directly or through additional insurance). From the 21st session onwards all 
additional treatment sessions given in one year are covered by the basic health 
care insurance. This peculiar reimbursement policy results in a financially driven 
motivation to be treated by a vascular surgeon with a minimal invasive vascular 
intervention (e.g. angioplasty) or even bypass surgery (both fully reimbursed). 
This in spite of the associated risk of morbidity (<0,5 - 10%) and even mortality 
(2-3% for bypass surgery).9  
• A knowledge gap
 ▷ In a recent nationwide survey among Dutch vascular surgeons, it appeared  
 that around 70% of vascular surgeons believe that co-existing significant  
 cardiopulmonary comorbidity and/or an aorta-iliac stenosis or occlusion  
 are arguments not to refer for a SET program. Recent evidence shows that  
 these arguments seem to be out-dated.(16) 
 ▷  In severe or invalidating IC cases, as subjectively as these may be, invasive  
 vascular interventions are performed without awaiting the possible positive  
 effects of a SET program. 
Introducing The ClaudicatioNet Concept
To tackle the present shortcomings and optimize the cohesion and collaboration 
between all stakeholders (including the patient and insurance companies), the Claudica-
tioNet concept was launched in the Netherlands in 2011. The goal of ClaudicatioNet is to 
improve the quality and transparency of PAOD treatment. Including an optimal working 
referral system by stimulating multidisciplinary healthcare supported with innovative 
eHealth solutions. The ClaudicatioNet concept aims at a nationwide enrolment. Regional 
networks, based on the 12 Dutch provinces and local hospital coverage are created. 
The role of a GP or vascular surgeon in the ClaudicatioNet 
concept
Setting up a regional network is initiated by vascular surgeons introducing the concept 
to apprehensive healthcare professionals together with local, enthusiastic and motivated 
PTs. Subsequently all healthcare professionals need to be familiarized with the concept 
and their respective roles. The first step in the patient’s pathway is determining the di-
agnosis of IC by a physician (GP or vascular surgeon). Subsequently, a GP or a vascular 
surgeon initiates a treatment strategy (conservative vs. invasive) and supports the coordi-
nating healthcare professional (CHP) in complex cases. 
Figure 1 Schematic overview of role models within the ClaudicatioNet (CNet) Concept.
 
Notes: PT: Physical Therapist; CHP: Coordinating Healthcare Professional; AUX TREAT: auxiliary treatment 
professional; SET: Supervised Exercise Treatment; CVRM: Cardio vascular Risk Management; T.: treatment; 
SCP: Social Community Platform.
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The role of a coordinating healthcare professional in the 
ClaudicatioNet concept
A CHP (e.g. GP’s and vascular surgeons or their supporting staff), is pivotal within the 
ClaudicatioNet concept and the management of the multidisciplinary treatment of PAOD 
patients. As can be seen in Fig. 1 the collaboration between CHP, PT and patient is essen-
tial in the ClaudicatioNet model. The supporting staff member of a physician (vascular 
nurse, GP practice assistant) accepts/takes the role of CHP. The CHP functions as a care 
manager coordinating a patient’s CVRM and SET and comprehends the availability of 
high quality care in the vicinity of the patient. Furthermore the CHP collaborates closely 
with the PT’s in the regional network overseeing the quality of care provided. Ultimately 
these CHP need to embrace, participate and manage their regional network based on tre-
atment results and opinions of treated patients. Auxiliary treatment by specialized heal-
thcare professionals (CVRM prevention and/or diabetic treatment teams) could support 
the CPH by providing specialized care for the patient.
The role of a specialized PT in the ClaudicatioNet Concept.
PTs need to understand the 3 year specialisation program. At the forefront of the treat-
ment program are specialized PT´s providing SET and, if applicable, stimulate lifestyle 
changes and medication adherence. PTs are required to treat patients with contemporary 
SET programs. To guarantee this quality, ClaudicatioNet provides a professional develop-
ment program for specialisation in the field of PAOD. This program is complementary to 
existing specialisations in chronic illness or cardiopulmonary rehabilitation (e.g. COPD, 
heart failure). Apart from acquiring a sound theoretical base of knowledge, PTs gain prac-
tical knowledge by increasing their experience by regularly treating patients with PAOD. 
The role of the patient in the ClaudicatioNet concept
The patient fulfils an important role in the concept, by delivering objective as well as 
subjective feedback of provided care to all stakeholders (figure 1). SET outcomes like 
maximal walking distance, functional walking distance, quality of life and information 
on smoking cessation and medication compliance are useful in evaluating quality of pro-
vided care. 
Creating an efficient referring system 
A three months SET program that actually starts 2 weeks before a three months evalu-
ation appointment precludes evaluation of a first line conservative treatment approach 
and is therefore not efficient. Delay in the initiation of a SET program occurs frequently, 
both due to patient as well as or PT factors (holiday’s, waiting lists, postponing the first 
appointment by the patient etc.).This will be prevented by a web-based referring system 
(automated patient - PT allocation and software that locates and notifies the PT closest to 
the patient’s home). The PT should contact the patient within a limited time frame (for 
example 2 working days) and initiate the SET program within 5 working days. In case a 
PT does not make contact with the patient within two working days, a nearby PT is noti-
fied automatically. The first responder is then awarded by the possibility to treat a patient 
and subsequent reimbursement.
Quality of provided care
All PTs can join a regional network, however they have to meet a set of criteria. Com-
pletion of a registered course ‘Intermittent Claudication’ is obligatory. As well as a well-
equipped practice and a broad patient orientation, so that other limitations are recognized 
and reported. After these primary criteria are met, the PT enters a specialisation program 
and is entered into an online web-based ‘care-finder’ directory. This website is used by 
patients as well as CPHs to choose a PT based on aspects such as location (address or 
postal code) and personal portfolio data (figure 1). During this three-year specialisation 
program, PTs need to comply with a progressive set of criteria to ensure participation. 
If these criteria are not met, visibility on the care-finder ends and so receiving referrals.
Participation criteria 
1. The PT delivers care according to up to date evidence based guidelines in PAOD 
SET treatment. 
2. The PT provides standardised feedback of results, motivation and medication 
adherence to the CHP  
3. The PT keeps a correct patient administration, including outcome and process 
indicators of all patients. 
4. The PT actively participates in a life long learning in the field of peripheral arte-
rial disease and concomitant disease. Fifteen hours of CNet accredited courses 
annually and presence (every other year) at the yearly organised ClaudicatioNet 
congress are mandatory. 
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5. The PT maintains an up to date web based personal portfolio (www.claudicatio-
net.nl). In this profile all items of a PTs specialisation progress is visualized. Items 
like attendance at additional relevant courses, on site visitation reports, contact 
information, a photograph (recognition of caregiver) as well as space for some 
personal (ambition) statements are registered in this portfolio. 
Transparency of provided care
ClaudicatioNet improves transparency of provided care by creating clear and exten-
sive portfolios on the care-finder website. Portfolios will be updated with real-time out-
come information as soon as a connection is made between the national Claudicatio-
Net database and currently existing patient managing software. As of 2013, patients and 
CHP’s will have access to this data through a user-friendly dashboard in order to visualize 
a clear overview of outcome results (figure 1). This will also allow patients to gain direct 
feedback onto their own results in a patient’s personal web portal (www.etalagebenen.nl). 
CHP’s will be able to effectively monitor the progress of their patients and, more im-
portantly, monitor outcome results of their own regional network by comparing these 
with a nationwide benchmark. The development of this innovative online feedback sys-
tem enhances quality control management and strengthens the multidisciplinary health 
care chain. PTs with outstanding results can easily be identified and showcased. Others 
with suboptimal results will be stimulated to learn from these colleagues or, if needed, 
removed from the care-finder directory.
Improving patient empowerment
Stimulating self-management causes the patient to learn and become more engaged 
in their own health process. This is useful in PAOD treatment, because of the importance 
of lifestyle changes and a proactive attitude. Implementation of e-Health & m-Health 
technology is promising and has the potential of a significant reduction in healthcare 
costs.
e-Health solutions
Structural feedback from patients regarding the quality of provided SET in a simple short 
questionnaire, offers tremendous possibilities (figure 1). For example, patients will be 
asked about their opinions of involved caregivers (GP, VS, CPH and PT) and the provi-
ded SET program. This information is then compared and analysed with objective SET 
outcome results (maximal walking distance, functional walking distance, QoL surveys). 
To improve the patient’s own responsibility in the treatment of PAOD, a part of the 
numerous SET sessions can be utilized to introduce patients with the personal web-por-
tal. Patients gain access to an online community specifically geared to PAOD patients. 
This portal brings together a wealth of information for patients through highly accessible 
online resources. The website will have two components, namely a public domain and 
a personal portfolio. The public section contains general disease information on PAOD 
and information regarding treatment modalities (figure 1). Together with a social com-
munity platform, where patients can view public profiles and engage with peers, as well 
as a notice board where patients can post messages for other network participants (figure 
1). Patients can exchange experiences, knowledge or even get in touch with each other 
(by chat, forums or through a video call connection). The personal section allows access 
to a patient’ own journal (with outcome results registered by their PT), their treatment 
plan and questionnaires in order to monitor, evaluate and benchmark the care provided. 
It also allows synchronous and asynchronous contact with healthcare providers through 
modalities as mail, chat and video call.
m-Health solutions
The omnipresence of mobile technology offers unique opportunities for the healthcare 
industry. It has the potential to make healthcare better, faster, cheaper and more acces-
sible. M-Health can improve the quality of care in that it helps patients and clinicians gain 
a better understanding of the disease through the wealth of personalized information 
generated by remote health monitoring devices and apps. It increases the access and effi-
ciency by allowing patients and physicians to monitor and analyse (real-time) health data 
and empowering patients to learn and become engaged in their health process. Lastly, it 
can significantly reduce healthcare costs by eliminating unnecessary treatment and faci-
litating patients to self-manage their condition through automated and highly personal 
tools. 
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ClaudicatioNet is developing a mobile application to augment the patient personal 
digital portfolio. The ‘Walk Mate’ app is an innovative application that has several fea-
tures to help reinforce self-management and patient empowerment through peer sup-
port, gamification and telecoaching. The app features an ambient location radar in order 
to search for fellow patients or volunteers within the WalkMate network, a pre-recorded 
audio coach for walking advices and stimulation, GPS tracking device to register walking 
distances and speed, live coaching by (schooled) peers and coach (PT) support through 
an audio/video call system (figure 1). The diversity and the ability to personalise the avai-
lable functions, the presence of virtual and live coaching and the facilitation of social 
interaction and support makes this application a powerful tool in adjunction to SET. Ul-
timately, outcome parameters of the WalkMate app will be incorporated into the personal 
patient’ portfolio on the personal domain of web portal website (www.etalagebenen.nl). 
This app will go live in 2013.
Conclusion
Physicians, CHP’s, PTs and most of all patients will benefit from participation in a 
regional ClaudicatioNet network. By referring patients to ClaudicatioNet PTs, health-
care professionals are guaranteed of transparent and standardised high quality treat-
ment. Through ClaudicatioNet all caregivers are collaboratively able to provide the best 
standards of practice. In time, other treatment goals such as lifestyle counselling and mo-
nitoring medication adherence will be taken up by all involved caregivers to extend the 
possibilities of SET. 
Optimizing the concept will stimulate the effectiveness of a multidisciplinary heal-
thcare chain that is nowadays required. An economic recession in combination with an 
aging population will cause associated increase of costs. The ClaudicatioNet concept is 
likely to create a more efficient and cost effective PAOD treatment. First of all by simply 
improve the quality of provided SET by offering PTs a controlled specialization program. 
Secondly by introducing a free market principle in healthcare by creating transparency 
of provided care through the usage of objective outcome parameters. Furthermore SET 
extended with a focus on cardiovascular risk reduction in a high risk population should 
be effective because of the reduction in morbidity and mortality caused by diseases with 
a cardiovascular origin. Cost effectiveness is achieved for the simple reason that a SET 
program will substitute or at least postpone expensive invasive vascular interventions. 
Encouraging patient empowerment by using innovative eHealth and mHealth solutions 
will create an online community, thereby informing and connecting fellow patients. 
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Abstract
Background
The Ankle–Brachial Index (ABI) obtained after a treadmill challenge is often used to 
confirm the diagnosis of intermittent claudication (IC). However, some patients fail 
treadmill testing due to (temporary) orthopedic or neurologic comorbidity or fear 
of falling. Aim of this study was to evaluate the role of bicycle testing as an alterna-
tive for treadmill testing. It was hypothesized that ABIs obtained after bicycle tests 
were not different compared to values after standard treadmill testing.
Methods:
In this validation study, newly diagnosed IC patients (Rutherford 1-3) underwent a 
standard treadmill test (TT, ‘gold standard’) and two bicycle protocols, one with a 
continuous resistance submaximal character (submaximal bicycle test, SBT) and a 
second with an incremental ramp form having a maximal character (maximal bicy-
cle test, MBT). ABI of both legs were obtained prior to and twice after each of these 
three different exercise tests. Healthy individuals matched for age and gender served 
as controls.
Results:
The study population consisted of 32 patients (age 68±11, 21 male). ABIs of each leg 
(n=64) obtained after TT correlated significantly with values obtained after either 
bicycle test (TT vs SBT, r=0.90, p<0.001; TT vs MBT, r=0.88, p<0.001). Drops in 
ABI after both types of exercise were significantly correlated (TT vs SBT: r=0.66, 
p<0.001; TT vs MBT, r=0.32, p<0.01). A 98% sensitivity and a 86% specificity for 
the diagnosis IC was observed after SBT.  After MBT, these values were 98% and 
43%, respectively. Healthy controls (n=13) always demonstrated ABI values >0.9 
after cycling.
Conclusions: 
Both a submaximal and a maximal bicycle test may serve as an alternative nonin-
vasive tool for detecting intermittent claudication. Bicycle tests may potentially be 
used in patients unable to perform a treadmill test.
Introduction
The diagnosis intermittent claudication (IC) is usually suspected following a medical 
history and physical examination. Noninvasive diagnostic vascular examinations are of-
ten used as an adjunctive tool to confirm a clinical diagnosis IC or to screen patients who 
have associated risk factors. Calculation of the ankle-brachial index (ABI) is a relatively 
simple and inexpensive method to confirm the suspicion of peripheral arterial occlusive 
disease(1). ABI measurements can be obtained before and after a standard exercise to un-
mask occlusive disease that is not apparent from studies during resting states. Exercise 
augments the pressure gradient across stenotic lesions thereby optimizing test sensitivity 
in patients with a typical history of IC(2, 3).
According to the Trans-Atlantic Inter-Society Consensus on Management of Perip-
heral Arterial Disease (TASC II) guidelines, treadmills are preferentially used for chal-
lenging patients suspected of IC(3). Other forms of tests such as cycling are not frequently 
performed for this purpose. A simple explanation may be that an IC patient typically pre-
sents with impaired walking rather than impaired cycling. Therefore, a walking test may 
seem an obvious choice for eliciting symptoms of IC. Moreover, an unknown portion of 
referred patients are (temporarily) unable to walk on a treadmill due to a recent operation 
or fear. This group of mostly elderly individuals often requires more training and proper 
supervision before treadmill testing is sufficiently discriminative. Cycling tests may pos-
sibly serve as an alternative diagnostic challenge test for vascular obstructive disease in 
these patient groups(4). Cycling is weight independent and possibly better tolerated by 
some of these patients. 
An additional advantage of bicycle testing is the convenient incorporation of cardio-
pulmonary exercise monitoring equipment such as an electrocardiogram and blood pres-
sure registration. These supporting tools may be advantageous given the high incidence 
of cardiovascular comorbidity in an IC population(5). It is presently unknown if bicycling 
testing is as sensitive as treadmill testing in diagnosing IC. The goal of the present study 
was to determine the correlation between treadmill testing and bicycle testing in IC pa-
tients. We hypothesized that bicycle testing is a viable alternative for treadmill testing in 
confirming the diagnosis IC.
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Methods
Subjects
The medical ethical board of the Máxima Medical Centre (MMC), Veldhoven, The Ne-
therlands, approved this study. Patients with IC were selected in the outpatient vascular 
clinic between March 2011 and June 2011. Inclusion criteria were newly diagnosed pa-
tients with symptoms of IC >3 months and an ABI <0.9 at rest or an ABI <0.9 after exerci-
se or a fall in ankle systolic pressure by more than 20 percent from its baseline value after 
exercise. Patients with rest pain, tissue loss or severe cardiopulmonary disease (>NYHA 
class II) or problems understanding the study protocol were excluded. 
Studying healthy controls was deemed necessary in order to verify if bicycle testing 
altered ABI values after exercise. Individuals matched for age and gender with recently 
corrected minor non-vascular surgical morbidity not reporting IC were asked to serve 
as controls. All participants were unaware of the study hypothesis and gave verbal and 
written informed consent. 
Sample size and statistical power
A minimum of 26 patients was required to detect a minimal 0.15 difference in ABI index 
between measurements after a treadmill test and a bicycle test with 80% of power using a 
two-sided t-test and a 0.05 significancy level. To allow for a 25% dropout rate, a total of 32 
patients was required. A sample size of 8 controls was calculated for attaining a significant 
difference compared to IC patients.
Study Protocol
A vascular surgeon performed history taking and physical examination and checked 
whether patients met inclusion criteria. They underwent treadmill and bicycle tests in 
random order. A Doppler probe (Nicolet Vasoguard, VIASYS Healthcare, USA) measu-
red systolic pressures of right brachial artery, right posterior tibial artery (RPTa) and left 
posterior tibial artery (LPTa) in fixed order. If RPTa or LPTa were absent, measurements 
were obtained from the pedal dorsal artery (PDa). ABI measurement of just a single foot 
artery (and not both) was performed as a means to minimize the elapsed time between 
consecutive measurements. If signals over the PDa were also absent, the patient was ex-
cluded. ABI values were calculated as ratios to brachial systolic pressure. Control subjects 
only performed bicycle testing.
Treadmill test
Resting ABI values were measured prior to treadmill testing after participants rested in 
a supine position for 5 minutes. A treadmill test (TT) operated at a speed of 3.0 km 
per hour with an 8% slope for a 5 minute maximum. Duration until onset of IC (initial 
claudication duration, ICD, in seconds) and maximum duration (absolute claudication 
duration, ACD, in seconds) were noted after 5 minutes of walking (or after exhaustion). 
ABIs were obtained from both sides as fast as possible three times during a 6-minute time 
period after discontinuation of the test. Right and left legs were subsequently measured, 
whereas measurements were always started in the right leg. As timing of these latter mea-
surements showed a too large variance, only the first two values were used for further 
analysis. 
Submaximal and maximal bicycle tests
Prior to bicycle testing, participants were allowed a 5-minute rest in supine position. ABI 
values were obtained with a hand-held Doppler probe (Huntleigh Dopplex D900, Hunt-
leigh, United Kingdom). An automatic pneumatic blood pressure monitor was used to 
obtain systolic blood pressures of the right brachial artery.
Cycling tests were performed using an electronically braked computer-controlled cy-
cle ergometer bicycle (LODE® Excalibur Sport, Lode, The Netherlands). Seat and steer 
height of this bicycle were optimally adjusted to the subject’s own posture. Individuals 
were instructed to perform a submaximal bicycle test (SBT) for a 5-minute maximum pe-
riod with 65 rounds per min (rpm) and continuous resistance (‘Step form’). The amount 
of resistance was computed to approach a similar workload (in VO2) as performed during 
the walking tests using the American College of Sports Medicine (ACSM) leg ergometry 
and walking equations(6). Duration until onset of IC and maximum duration were noted 
after 5 minutes of this cycling exercise (or earlier if the subject stopped in case of exhaus-
tion or IC). ABI values of both sides were subsequently obtained two times immediately 
after each other, again the right leg was measured first. After a 10 minute resting time 
(including the 6 minute measurement period), a maximal bicycling test (MBT) was star-
ted using an incremental approach (‘ramp’). Aim of this heavier protocol was to expose 
patients to a maximal exercise test with continuously increasing resistance towards a peak 
after approximately 10 minutes. A questionnaire was used prior to this exercise test to al-
low for an estimation of this peak tolerance. If unbearable pain or exhaustion occurred, 
ABI values of both legs were again subsequently registered.
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Statistical analysis
Statistical analysis was performed using SPSS Statistics (MAC OS X version 20.0). De-
mographic data were analyzed using Pearson’s chi-square, or Fisher’s exact tests in case 
of cells with small numbers. It was assumed that both legs could be used as independent 
parameters in the analysis as each leg of a patient may respond differently to testing. ABI 
values were analyzed for skewness and kurtosis. A Wilcoxon Signed Rank test and Spear-
man’s correlations were utilized to compare values in case of non-normal distribution 
whereas a paired Students T-test and Pearson’s correlations analyzed normal distributed 
variables. Bland Altman plots (BA plots) were used to verify agreement between tread-
mill and bicycle tests. In this BA diagrams the differences between treadmill and bicycle 
testing (y-axis) were plotted against the averages of these two exercise types (x-axis). As 
a result the mean difference and its 95% confidence limits are shown. P values less than 
.0.05 were considered statistically significant. 
Results 
A total of 40 patients and 14 controls were eligible and consented to the study. Eight 
patients were excluded (ABI > 0.9 after exercise n=2, incompressible arteries n=3, inabi-
lity to perform TT because of psychological reasons or equilibrium discomfort n=3) as 
was 1 ‘healthy’ control (rest ABI <0.9). Therefore, a total of 32 patients (64 legs) and 13 
controls (26 legs) were used in the analyses. There were no differences in demographic 
data between the two groups (table 1). ABI values obtained from patients who performed 
a treadmill test (TT) first (n=17) were not different from data of subjects performing a 
bicycle test first (n=15).
Correlations in patient legs with an ABI <0.9 (n=64)
56 of 64 patient legs demonstrated an ABI<0.9 after TT. ABI values of all 64 legs obtained 
after both cycling tests correlated significantly with ABIs measured after treadmill testing 
(TT vs SBT, r = 0.90, p<0.001; TT vs MBT, r = 0.88, p<0.001; figure 1 & 2). The average 
discrepancy (bias) between the TT/SBT is 0.04±0.14 (Bland-Altman plot, Figure 3). A 
substantial scatter is visible throughout the whole range of measurements. However, there 
was no converging or diverging trend visible in the scatterplot (figure 3). 
Figure 4 depicts the correlation (r = 0.66, p<0.001) between the absolute fall of ABI 
after a treadmill exercise (ΔABI, TT) compared to the drop of ABI after a SBT (ΔABI, 
SBT). A weak correlation was also observed between these values after ΔABI, TT and 
MBT (r = 0.32, p=0.01, graph not shown).
Correlations in patients legs with ABI >0.9 in rest (n=22)
22 of 64 patient legs demonstrated an ABI>0.9 in rest. ABI values of these legs obtained 
after both cycling tests correlated significantly with ABIs measured after treadmill testing 
(n=22, TT vs SBT, r = 0.77, p<0.001; TT vs MBT, r = 0.51, p<0.02).
Sensitivity and specificity
ABI values of 64 patient legs were used in a sensitivity analysis whereas ABI<0.9 after TT 
was used as golden standard. The SBT revealed a 98% sensitivity for the diagnosis IC and 
a 86% specificity with an ABI cut off value of 0.89 (AUC: 0.98; figure 5). Positive predicted 
values (PPV) and negative predicted values (NPV) were 98% and 86%, respectively. The 
MBT showed a 98% sensitivity and a 43% specificity with a 0.92 ABI cut off value (AUC 
0.95; graph not shown) and a PPV of 93% and NPV of 75% respectively.
ABIs of healthy controls were always >0.9 after both bicycle tests.  (n=26; ABI prior to 
testing: 1.16±0.10, 1th ABI measured directly after SBT: 1.09±0.10, ABI measured directly 
after MBT: 1.02 ± 0.12). 
Figure 1 Pearson’s correlation of ABI measured directly after treadmill testing (TT) and sub 
 maximal bicycle testing (SBT). 
Note: Dotted line is line of identity.
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Figure 2 Pearson’s correlation of ABI measured directly after treadmill testing (TT) and 
 maximal bicycle testing (MBT). 
Figure 3 BlandeAltman plot of ABI values of treadmill testing (TT) versus submaximal bicycle  
 testing (SBT) directly after exercise (n ¼ 64). 
Note: Horizontal	bold	line	depicts	the	mean	difference	(bias),	whereas	the	dotted	lines	show	the	95%		
	 limits	of	agreement,	which	are	defined	as	the	mean	difference	±1.96	times	the	standard	deviation	of		
 the differences.
Note: Dotted line is line of identity.
Figure 4 Pearson’s correlation of absolute fall of ABI between rest and post treadmill exercise  
 (Δ ABI TT) and the fall of ABI between rest and after submaximal cycling (Δ ABI SBT). 
Figure 5 ROC curve of submaximal bicycle test (SBT) and maximal bicycle test (MBT).  
Note: Dotted line is line of identity.
Note: Dotted line is line of identity.
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Discussion and Conclusion
Up to 50% - 80% of patients with peripheral arterial occlusive disease (PAOD) are 
symptomatic, and half of these demonstrate complaints of IC(1). A resting ABI measu-
rement with additional exercise testing using a standard treadmill test is a simple, in-
expensive and effective non-invasive diagnostic method for IC with a high sensitivity 
(79-95%) and specificity (95-100%)(7). However, some patients are not able to adequately 
perform such testing, occasionally due to fear or (temporary) orthopedic or neurological 
causes. In the present trial, 7.5% of the patients were not able to safely/reliably complete 
a treadmill test. Other studies reported that 22-45% of the eligible patients were unable 
to undertake a treadmill test, mainly because of cardiac and pulmonary problems(8). An 
alternative stress test may allow for a proper identification of IC in these patients. The 
present study was designed to validate two protocols of different intensity using a bicycle 
ergometer as an alternative diagnostic tool in patients suspected of IC. Findings of this 
study indicate that data obtained from bicycle testing are closely correlated with data after 
treadmill testing. Moreover high sensitivities for the diagnosis IC were obtained. Both a 
submaximal as well as a maximal bicycle test appeared valid methods and may serve as 
an alternative to treadmill testing in patients with IC.
Several theoretical advantages associated with a bicycle test may be identified. The 
method is ‘non-weightbearing’ allowing the testing of patients with orthopedic disease 
or with equilibrium problems. Bicycles can be used in patients who do not feel confident 
with treadmill testing. As in treadmill testing, diagnostic bicycle tests may also serve as a 
screening tool for determining cardiovascular risk(9, 10). For instance, a 10-year mortality 
rate due to cardiovascular disease of 62% for men with PAOD compared to 17% in the 
population of men without was found(5). Others already demonstrated that bicycle testing 
is predictive of cardiovascular events and all-cause death. Furthermore, bicycling testing 
may have additional advantages in a subgroup of patients with severe cardiopulmonary 
disease or with very mild IC as the workload is more easily administered and monitored. 
These issues are particularly relevant in cyclists suffering from IC at high intensity exer-
cise due to vascular flow limitation in the iliac arteries(11). Furthermore, other characte-
ristics of bicycle testing such as pedal forces are potentially useful in quantifying IC or 
PAOD. One could hypothesize that diminished blood flow in affected arteries will result 
in declining muscle strengths. As a consequence, pedal forces may also decline after pain 
symptoms are reported. Therefore, a bicycle may serve as a tool in several areas including 
the diagnostic, therapeutic and research arena 
A fair correlation between ABI after walking tests and bicycling tests was earlier found 
in a small IC population (r=0.51-0.86)(12). The present study confirmed in a twice as large 
group that ABI after walking and bicycling were strongly correlated (r=0.88-0.90). Bland-
Altman plots, traditionally considered a robust reflection of agreement between different 
two tests, demonstrated minimal differences between both exercise methods. However, a 
substantial dispersion was observed indicating a considerable variability. This inconsis-
tency may possibly be explained by an error in reproducibility. Earlier research suggested 
that an up to 19% difference between two consecutive ABI values may just be attributed 
to intra-observer errors(13). A comparable magnitude of error was also observed in the 
present study as ABIs of 23% of the measured legs demonstrated an absolute ABI dif-
ference >0.15 prior to testing.
It is doubtful whether ABI drops after a cycling test reflect alterations obtained after a 
treadmill test. Although expected, one group of researchers did not find a significant cor-
relation between absolute fall in ABI after both types of exercises(12). It was hypothesized 
that this absent correlation was possibly due to a different haemodynamic response in the 
lower extremity after either cycling or walking. Motivation, experience and joint stiffness 
may also have added to the remaining variability in performance ability(14). Cycling was 
deemed less useful as a diagnostic tool. In contrast the present study found a significant 
correlation (ICC=0.66, p<0.001, figure 4) between ABI falls after either challenge. It may 
well be that systemic and local factors may play a less important role than previously sug-
gested. Moreover, this finding also contributes to the confidence we have in the potential 
of a bicycle test as a useful diagnostic tool.
Which bicycle test may be preferred as an alternative diagnostic tool in future IC 
populations? The present study tested two different protocols. The first was a ‘submaxi-
mal’ regimen characterized by identical energy expenditure and mode of administration 
(direct and continuous submaximal exercise). By using such an exercise design, a possible 
confounding effect of workload or differences in energy expenditure was minimized. A 
second ‘maximal test’ was introduced to maximize these effects. As sensitivity of both 
bicycle tests were high (98%) whereas the SBT demonstrated a higher specificity, it is 
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advised to standardly use a submaximal regimen. Moreover, the risk on a cardiovascular 
event during submaximal testing may be reduced.
In conclusion, the present study indicates that bicycle exercise testing is a valid al-
ternative tool in diagnosing patients with intermittent claudication (IC). Bicycle testing 
confers additional advantages including incorporation of a cardiovascular screening 
program. Patients suspected of having IC harbouring (temporary) contraindications for 
treadmill testing (neurological, orthopedic, fear) may safely be diagnosed using a bicycle. 
Submaximal testing is preferred to maximal testing because of optimal sensitivity and 
specificity whereas a risk on (cardiovascular) complications is lowest.
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Abstract
Objective
Disease severity in patients with intermittent claudication (IC) is often assessed 
using walking distances and treadmill tests. The aim of this study was to determine 
the agreement between walking distance as estimated by the patient, as measured 
during outside walking and as determined using a non- (NGTP) and an incremental 
graded (Gardner Skinner) treadmill protocol (GSP). 
Methods
In this prospective observational study, 30 patients with IC estimated their maxi-
mum walking distance (MWD) and completed a ‘Walking Impairment Questi-
onnaire’ (WIQ). Outside walking was determined using a measuring wheel and a 
GPS controlled device. Primary outcomes were differences in MWD and variability 
(coefficient of variation, COV). Secondary outcomes were results of WIQ and dif-
ferences in walking speed.
Results
Estimated walking distance was significantly higher than MWD as objectively mea-
sured during outside walking (400m vs 309m, respectively P=.02). A substantial 
variability (COV=55%) was found between both parameters. A small 35m MWD 
difference between outside walking and GSP was found with a substantial scatter 
(COV=42%). In contrast, a much larger 122m MWD difference was present between 
outside walking and NGTP (COV: 89%). Patients walked significantly faster in the 
open air than on treadmills (median outside walking speed=3.8 km/h, GSP=3.2 
km/h, NGTP=2.8 km/h; P<.001). 
Conclusions
An incremental graded (Gardner Skinner) treadmill protocol demonstrated the best 
agreement to outside walking. Discrepancies between treadmill tests and outside 
walking may be explained by a difference in walking speed. A single determination 
of a walking distance is a poor reflection of true walking capacity.
Key words: peripheral arterial disease, walking speed, variability, treadmill testing.
Introduction
Intermittent claudication (IC) is a classical symptom reflecting peripheral arterial dis-
ease (PAD). IC limits walking capacity and daily functioning(1). Overall treatment strat-
egies are well described in international guidelines(2-4). Limitations in walking distance 
play an important role in the assessment of disease severity. However, the value of various 
walking distance assessments is disputed. For instance, patients’ estimations of walking 
distances do not properly reflect objectively measured daily life walking distances(5-7). A 
disease specific questionnaire such as the Walking Impairment Questionnaire (WIQ) 
may quantify walking impairments in IC patients better but correlations with walking 
distances appeared weak(6).
Standardized treadmill tests are widely used for the objective assessment of walking 
distances(2-4). However, there is a substantial variability in treadmill protocols(8). In previ-
ous studies, fixed inclination was compared with flat off-treadmill walking (in- and out-
doors)(5,6,9,10). Interestingly, none of these comparing studies used a graded incremental 
treadmill test, while such type of testing is recommended in the guidelines for physical 
therapy because of its high reliability(11,12). Furthermore, previous studies used corridor 
walking as an imitation of daily life walking(5,6,10). IC patients are mostly limited during 
outside walking with variations in speed, weather condition and surface. Compared to 
corridor walking, outside walking might be a more reliable reflection of daily life walking. 
This study aims to compare the results in walking distances in a group of IC patients 
using four different tools that are frequently used by physical therapists in the assessment 
of IC severity. Results of a graded and a non-graded treadmill protocol, patient estima-
tions and outside walking were compared in a single model.
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Methods
Subjects
This study was approved by the Medical Ethics Committee of the Catharina Hospital, 
Eindhoven, The Netherlands. Thirty consecutive patients with complaints of IC, confir-
med by non-invasive testing (<0.9 Ankle-Brachial Index (ABI) at rest or a fall in systolic 
ankle pressure by more than 20% after exercise), were recruited from the vascular out-
patient  clinic. Patients with comorbidity possibly limiting walking apart from IC (i.e. 
neurological disorders, severe COPD, congestive heart failure, orthopedic impairments) 
or with insufficient knowledge of the English or Dutch language were excluded. All par-
ticipants provided verbal and written informed consent. 
Study Protocol
Baseline characteristics, comorbidity, medical history and cardiovascular risk factors 
were recorded. All patients performed an open air distance measuring test and com-
pleted two treadmill protocols on one day. The order of the three tests was randomized 
using ‘Randomizer’ (Kwixo Designs, lite version) for Android smartphones. Three phys-
iotherapy students were trained to standardize patients’ encouragement. Pairing of pa-
tient and physiotherapy student was also randomized. To minimize a difference in grade 
of encouragement, these tests were all performed under supervision of the same student. 
Patients rested for 20 minutes (supine or seated) between tests as ABI values are known 
to recover within this time interval(13) Primary study outcomes were maximal walking 
distance (MWD) as determined by the patient’s estimation, as obtained during outside 
walking and during the two treadmill tests. In addition, walking speed and the WIQ 
results were analyzed. 
Self-reported MWD
Before testing, patients were asked to estimate their MWD, defined as ‘the maximum 
distance (meters) you can walk before you are forced to stop by leg pain’.
Outside walking
To approximate a real ‘daily life’ maximal walking distance, patients were asked to walk a 
standardized outside walking course on the parking lot of our training facility. They wal-
ked mostly in straight lines on the sidewalk and and were not interrupted by traffic, traffic 
lights, cyclists or otherwise. The course  is a big square that is paved with regular stones 
and has a few curbs. One of the team of three researchers always walked some 3-5 me-
ters behind the patient. The degree  of encouragement during outside walking or during 
treadmill testing were similar. Each patient was instructed to continue until they were 
forced to stop by leg pain. MWD was recorded using both a measuring wheel (Stanley 
Black & Decker Inc., New Britain USA) and a GPS controlled device (iPhone 4s; Apple, 
Silicon Valley, USA). Walking time was recorded using the iPhone. 
Treadmill tests
Two different treadmill protocols were used. A graded incremental test (Gardner-Skinner 
Protocol, GSP) allows patients to walk at 3.2 kilometer per hour (km/h) with a 0% incline 
that increases by 2% every 2 minutes 14. The maximum test duration is 20 minutes. The 
non-graded treadmill protocol (NGTP) has a fixed 0% incline and allows the patient to 
walk with a favorite walking speed which was set during the first 30 seconds of the tread-
mill testing. The use of handrails during treadmill walking was not permitted. Results are 
expressed as MWD.
Walking Impairment Questionnaire
Patients were asked to complete the WIQ evaluating several components of daily walking 
ability including an estimation of walking distance, speed and stair-climbing ability 15. 
Patients were instructed to rank the degree of difficulty for each component using a 0 to 
4 Likert scale. A validated Dutch version of the WIQ was used 16.
Walking Speed
Average walking speed of outside walking was calculated by dividing walking distance 
by time and was expressed in kilometer per hour (km/h). 
Statistical analysis
It was assumed that outside walking reflected daily life walking most closely, and was 
therefore used as reference value. The distance  in  meters as obtained with the measuring 
wheel was used as reference value in all analyses. The Friedman two-way analysis of vari-
ance test determined differences between multiple assessments. A Wilcoxon Signed Rank 
test was used for comparison of two measurements. A Bonferroni method was used as 
post-hoc procedure for correction of multiple comparison testing.  
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Various methods were used to assess study outcomes. Overall reliability was assessed 
by means of an Intraclass Correlation Coefficients (ICC) with 95% confidence intervals 
(CI). Variability in measurements was assessed using coefficient of variation (COV). The 
COV was calculated as the standard deviation of the absolute difference between two 
assessments (outside walking vs. patient’s estimation, outside walking vs. GSP, outside 
walking vs. NGTP) divided by the mean of the averages. Reproducibility was analyzed 
in Bland-Altman plots. These plots were used to visualize agreement between two mea-
surements and were presented with 95% limits of agreement, calculated as the mean dif-
ference ± 1.96 standard deviation (SD). The mean of both measurements was depicted 
on the horizontal axis whereas the difference was illustrated on the vertical axis. Linear 
regression analysis was performed and mean difference (bias) was calculated. Spearman 
rank correlations were estimated to compare WIQ scores with walking distances and 
speed. A correlation coefficient was considered strong if ≥ 0.7, moderate if between 0.3 
and 0.7, and weak if ≤ 0.3. P values less than 0.05 were considered statistically significant. 
Statistical analysis was performed using SPSS Statistics for Windows (version 20.0).
Results
Patients
Demographics and baseline characteristics of the 30 patients are presented in table 1.
Walking distances
Walking distances and walking speeds are listed in table 2.
Outside walking versus estimated walking distance
A moderate reliability was found between these outcomes (ICC=0.62). The median pa-
tients’ estimated MWD was 400m, which is significantly higher than measured during 
outside walking (median=309m, P=.02) (table 2). The mean difference found in the 
Bland-Altman plot in MWD between both outcomes was 122m (95% limits of agree-
ment: -677.4m – 433.6m). A substantial and significant divergent scatter was reflected by 
the Bland-Altman plot (figure 1) indicating that the agreement between outside walking 
and estimated distances decreased when patients judged that their walking distance was 
longer than it actually was. This variability between outcomes was confirmed by a 55% 
COV value. 
Outside walking versus Gardner Skinner Treadmill Protocol (GSP)
Again a moderate reliability was found between these outcomes (ICC=0.67). No sig-
nificant differences were found in median MWD as measured during outside walking 
(309m) and GSP (250m, P=.70, table 2). The mean difference in MWD as shown in the 
Bland Altman plot between outside walking and the GSP was 35m (95% limits of agree-
ment: -328.5m – 399.0m) (figure 2). A 42% COV was found, dropping to 19% after remo-
ving two extremes (figure 2). 
Outside walking versus Non Graded Treadmill Protocol (NGTP)
A moderate reliability was found between these outcomes (ICC=0.46). No significant 
differences in median MWD were found comparing outside walking (309m) with NGTP 
(317m, P=.20, table 2). A -122m mean difference (95% limits of agreement: -920.5 – 676.4) 
was calculated and depicted in the Bland Altman plot (figure 3). A significant negative 
scatter trend was seen (figure 3) indicating that the agreement between outside walking 
and the NGTP outcomes was lower in patients with larger walking distances. An 89% 
COV variability was found, which dropped to 32% after removing two extreme outliers.
WIQ scores and correlations
The WIQ distance score correlated well with values of MWD as estimated by the patient 
or as measured during outside walking or following GSP or NGTP testing (table 3). In 
contrast, the WIQ total score correlated moderately with these distances (table 3). 
Walking speed
Walking speed during outside walking was significantly faster than during the GSP and 
NGTP (medians: outside walking=3.8 km/h, GSP=3.2 km/h, NGTP=2.8 km/h; P<.001, 
table 2). Outside walking speed correlated moderately with the WIQ speed score (r = 
0.62, p<.001).
Outside walking measuring methods
Median MWD as measured with the iPhone (309m) were not different compared to va-
lues obtained with a measuring wheel (290m, P=.064). A strong correlation was observed 
between these values (ICC=0.997).
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Figure 1 Bland-Altman plot with linear regression analysis MWD OW – ED
Note:	 ED,	Estimated	Distance;	MWD,	Maximum	walking	distance;	OW,	outside	walking.
Figure 2 Bland-Altman plot with linear regression analysis MWD OW – GSP.
Note:	 GSP,	Gardner-Skinner	protocol;	MWD,	Maximum	walking	distance;	OW,	outside	walking.
Characteristics Value (total population n=30)
Patient	characteristics,	median	(range)
Age,	years 67 (44-87)
Body	mass	index,	kg/m2 27 (18-37)
Patient	characteristics,	No.	(%)  
Male 63
Diabetes Mellitus 23
Hypercholesterolemia 17
Hypertension 17
Smoking
Current 40
Former 47
Never 13
Cardiovascular history
MI 20
CABG 3
Other 13
None 63
Chronic Obstructive Pulmonary Disease 17
Arthritis 23
Table 1 Baseline characteristics
Figure 3 Bland-Altman plot with linear regression analysis MWD OW – NGTP
Note:	 MWD,	Maximum	walking	distance;	NGTP,	non-graded	treadmill	protocol;	OW,	outside	walking.
Note: CABG: Coronary artery bypass grafting; MI: Myocardial infarction;
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Outcomes
GSP, 
Median 
(IQR)
NGTP,
Median 
(IQR)
OW,
Median 
(IQR)
ED
Median 
(IQR)
Overall 
P  
Valuea
Per Comparison
Difference  
P Valueb
ICC (95% CI), 
P Value
OW-
GSP:
.70 0.67	(0.42-0.83),	
P<.001
MWD,	m 250 
(178-463)
317 
(190-546)
309 
(178-478)
400 
(188-740)
.05 OW-
NGTP:
.20 0.46	(0.14-0.70),	
P=.004
OW-ED: .02 0.62	(0.34-0.80),	
P<.001
OW-
GSP:
<.001 0.08	(-.12-0.34),	
P=.226
Walking 
Speed,	
km/h
3.16 
(3.11-3.18)
2.76 
(2.48-3.44)
3.81 
(3.21-4.50)
n.a. <.001 OW-
NGTP:
<.001 0.41	(-.10-0.75),	
P<.001
GSP-
NGTP:
.08 0.10	(-.23-0.42),	
P=.287
WIQ distance score WIQ total score ED
ED 0.81 0.69 -
GSP MWD 0.80 0.66 0.86
NGTP MWD 0.73 0.64 0.76
OW MWD 0.77 0.70 0.74
Table 2 Walking distances and walking speed
Notes:	 CI,	confidence	interval;	ED,	estimated	distance;	GSP,	Gardner-Skinner	protocol;	ICC,	Intraclass	correlation		
	 coefficient;	IQR,	Interquartile	range;	MWD,	maximum	walking	distance;	NGTP,	non-graded	treadmill	
	 protocol;	n.a.,	not	available;	OW,	outside	walking;
 a = Considering a Friedman two-way analysis of variance test.
 b	=	Considering	a	Wilcoxon	signed-rank	test.	A	bonferroni-corrected	significance	level	of	P<0.02	indicates		
	 statistically	significant	difference.
Table 3 WIQ and estimated: correlations
Notes:	 ED,	 Estimated	 difference;	 GSP,	 Gardner-Skinner	 protocol;	 MWD,	 Maximum	 walking	 distance;	 NGTP,	 
	 non-graded	 treadmill	 protocol	 ;	 OW,	 outside	 walking;	 VAS,	 Visual	 Analogue	 Scale;	 WIQ,	 Walking	 
 Impairment Questionnaire.
 Values shown represent Spearman rank correlations (all: p<0.001).
Discussion
 
The efficacy of treatment strategies for clinical decision-making and research purposes in 
patients with IC is often evaluated on the basis of changes in walking distances(2-4). Such 
distances may be estimated by the patient or measured using a treadmill. The value of 
both assessments is debatable as these parameters merely provide insight into walking 
capacity, which not necessarily reflects the patient’s perceived disability(6,11). Self-report-
ed walking capacity appeared a poor reflection of objectively measured MWD(5-7,10). The 
present study confirms these findings. 
Our results may indicate that treadmill testing provides a reliable reflection of the out-
side walking distance in IC patients. Differences between MWD after either a treadmill or 
outside walking were not significant. However, only moderate ICCs and substantial COVs 
were found regarding these parameters. Others found MWD variation in a single patient, 
when repeatedly measured, which probably contributes to these large COV values(17). 
Some judged that differences in MWD following treadmill walking and off treadmill cor-
ridor were due to the inclination in treadmill protocols(6). Although this explanation may 
seem adequate, the present study challenges this assumption as worse results regarding 
variability, reproducibility and reliability of a NGTP compared to a GSP with regard to 
outside walking were found. Another possible explanation for this discrepancy is the dif-
ference in walking speed. Walking at a faster pace might give a patient the impression 
of longer distance coverage, while a higher walking speed causes a higher metabolic de-
mand leading to lower walking distances. In other words, the incremental inclination in 
the GSP may compensate for the increased outside walking speed. Surprisingly, patients 
did not walk faster during NGTP testing, possibly causing the poor results in variability, 
reproducibility and reliability values. Although precautions were made to ensure that pa-
tient encouragement did not differ during testing, the influence of a researcher (one of a 
team of three) who was escorting the patient during the outside walking test could not be 
excluded. In conclusion, a single MWD assessment is not a proper reflection of walking 
impairment in IC patients and may not necessarily correspond with daily life walking.
The findings of our study have implications for the evaluation of outcomes in clinical 
practice and future research. Researchers should realize that the frequently used MWD 
outcome shows substantial variability. Additionally, our study confirms results of other 
Agreements and discrepancies between the estimated walking distance, non-graded 
and graded treadmill testing and outside walking in patients with intermittent claudication
155
7
Innovative strategies for intermittent claudication 
154
7
studies indicating that a functional impairment questionnaire such as the WIQ may be 
an adequate instrument for monitoring walking capacity in IC(6,18). However, one should 
realize that the Spearman rank correlation coefficients to analyze WIQ data may have 
been overestimated when compared to our ICC values. Spearman’s coefficients do not 
correct a systematic measurement error. Nevertheless, future research should focus more 
on patient-reported outcomes of health related quality of life, perceived disability and 
burden of disease. These parameters can be of more importance than the determination 
of a patients’ walking capacity alone as is currently obtained by a WIQ. In addition, walk-
ing (exercise) behavior should be monitored over prolonged periods of time to provide a 
more reliable reflection of a patients’ walking impairment (outside walking). A 6-minute 
walking test, a shuttle walking-test or GPS-based accelerometers (physical activity mon-
itors) may be alternatives to treadmill testing. The present data also indicate that a ded-
icated application on a smartphone is a valid alternative for a measuring wheel. Future 
novel applications for measuring walking behavior in combination with an assessment of 
disease burden in daily life could contribute to a better understanding of the impact of 
walking limitations in IC patients.
Study Limitations
The present study harbors methodological shortcomings. Although the test order was 
randomized, a potential ‘training effect’ could have biased our results. Furthermore, 
walking distances and speed were assessed as a one-time measurement whereas a mul-
tiple assessment might have strengthened our conclusion. Patients were not blinded to 
distance and time while walking the treadmill tests. In addition, a relatively small popu-
lation was studied although its size is similar or even larger compared to most previous 
studies(7,10,14,19).
Conclusions
An incremental graded treadmill protocol in IC patients reflects outside walking best 
compared to a patient’s estimated walking distance or a non-graded protocol. A single 
MWD assessment is not a proper reflection of the walking impairment in IC patients, 
probably due to the wide intra-variability in walking distances. Treadmill walking may 
not necessarily correspond with daily life walking. Future research should focus on walk-
ing behaviour over prolonged periods of time and patient-reported outcomes of health 
related quality of life and burden of disease.
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Abstract
Objectives
Daily life physical activity (PA) of patients with peripheral arterial disease (PAD) 
may be severely hampered by intermittent claudication (IC). From a therapeutic as 
well as research standpoint, it may be more relevant to determine improvement in 
PA as outcome measure in IC. Aim of this study was to validate daily activities using 
a novel type of tri-axial accelerometer (MoveMonitor) in IC patients.
Methods
IC patients were studied during a hospital visit. Standard activities (locomotion, ly-
ing, sitting, standing, shuffling, number of steps and “not worn” detection) were 
video recorded and compared with activities scored by the MoveMonitor. Inter-rater 
reliability (expressed in Intraclass Correlation Coefficients (ICC)), sensitivity, speci-
ficity and predictive values (PPV) were calculated for each activity.
Results
Twenty-eight hours of video observation were analysed (n=21). Our video annota-
tion method (gold standard) appeared accurate for most postures (ICC>0.97) except 
for shuffling (ICC=0.38). The MoveMonitor showed high sensitivities (>86%), speci-
ficities (>91%) and PPV (>88%) for locomotion, lying, sitting and the “not worn” de-
tection. Moderate accuracy was found for standing (46%), while shuffling appeared 
not detectable (18%). A strong correlation was found between video recordings and 
the MoveMonitor regarding the “number of steps” calculations (ICC=0.90).
Conclusions
The MoveMonitor provides accurate information on a diverse set of postures, daily 
activities and number of steps in IC patients. However, the detection of low ampli-
tude movements such as shuffling and “sitting to standing” transfers is a matter of 
concern. This tool is useful to assess the role of physical activity as a novel clinically 
relevant outcome parameter in IC.
Introduction
In daily life, patients with symptomatic peripheral arterial disease (PAD) may be se-
verely limited due to symptoms of intermittent claudication (IC). Disease severity and 
effect of treatment modalities are often assessed by outcome measures such as maximum 
and pain-free walking distance. However, a large discrepancy and variability has been 
reported between walking ability and claudication walking distances as measured on a 
treadmill, suggesting that treadmill assessments may not be representative of daily life 
walking ability(1-3). Assessment of IC using patient reported outcome is subjective, insen-
sitive and a poorly reproducible tool for determining severity of symptoms(4-6). Objective 
clinical measurements such as Doppler ultrasonography and angiography provide only 
information on vessel patency and lesion severity. These imaging techniques are registe-
red under standardized conditions and do not take the patients’ coherent daily ambula-
tory limitations into account.
A clear call was made for alternative tests to determine walking capacity over a pro-
longed period of time(1, 2). Moreover, despite the fact that IC patients have an increased 
risk for cardiovascular or cerebrovascular events(7), current PAD treatment is mainly fo-
cussed on the limitation in walking distance. However an increased walking capacity 
does not automatically imply a change in a patients’ exercise behaviour. From a therapeu-
tic as well as research standpoint, it may be more relevant to determine physical activity 
(PA) as outcome measure for treatment modalities of IC. Improved levels of PA might be 
indicative of an increased exercise behaviour resulting in cardiovascular event risk reduc-
tion and improvement of Quality of Life (QoL) on the long term(8, 9).  Formerly, habitual 
PA was frequently ascertained using questionnaires or diaries, but patients are known 
to report inaccurately and results tend to be biased due to socially desirable answers(4-6). 
Therefore, it seems necessary to obtain an objective measure of the patient’s PA over a 
prolonged period of time.
Nowadays PA levels can be measured with activity monitors. Tri-axial accelerometers 
measure accelerations in three dimensions that can be converted to intensities and me-
tabolic equivalents (METs) enabling a quantification of overall PA. The Dynaport Move-
Monitor (DP) is such an activity monitor and is easily applicable in a daily life setting 
and is optimized for clinical research assessments. The DP was previously validated in an 
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elderly population(10), in Parkinsons disease(11, 12) and COPD patients(13-15). To our know-
ledge, studies validating the DP in detecting daily activities in a PAD population were not 
previously reported. However, IC symptoms may significantly influence the DP outcomes 
due to altered walking patterns which may have impact on the detection of gait and pos-
tures(16-18). Furthermore, all previous studies were performed in a laboratory setting with 
patients walking a specific trajectory(10-13). Moreover, the number of observation hours 
was rather limited and obtained from small groups(10, 11, 13, 15). One study excluded pa-
tients with walking impairments(13) and two other studies used out-dated accelerometer 
technology(14, 15). Overall, most studies suffered from substantial methodological short-
comings when using the DP for assessing daily life ambulatory activities in patients with 
walking impairments due to IC. 
The aim of the present study is to validate the Dynaport MoveMonitor in symptoma-
tic IC patients in a near real-life setting. If valid, the accelerometer can be used for the 
assessment of PA as a potential outcome measure in these populations. 
Methods
Recruitment
Patients with IC (PAD stage 2-3 according to the Rutherford classification) and visiting 
the vascular outpatient clinic of our hospital between August and November 2012 were 
eligible for this study. This study was conducted with approval of the local medical ethics 
committee of the Catharina Hospital (Eindhoven, the Netherlands).
Inclusion criteria
Inclusion criteria were >3 months symptoms of IC, and an <0.9 ABI at rest or a fall in sys-
tolic ankle pressure by more than 20% after treadmill testing. A treadmill protocol with a 
fixed inclination of 8% at 3.2 km/h for a maximum of 5 min was used. 
Exclusion criteria
Patients with walking difficulties other than due to IC were excluded (e.g. prior ampu-
tation, severe arthritis, COPD GOLD 3-4, congestive heart failure (>NYHA class II) as 
was the use of walking aids. Patients with recent (less than 12 months) vascular surgical 
intervention prior to the study were also excluded as were patients unable to understand 
all specifics of the study protocol or having insufficient knowledge of the Dutch language. 
Video Observation and activity monitoring
Specifics of patient’s medical and surgical history were obtained followed by a physical 
examination and a check of inclusion and exclusion criteria. After signing an informed 
consent, a DP (DynaPort, McRoberts BV, The Hague, the Netherlands) attached to a neo-
prene belt was strapped around the patient’s waist at the level of the midlower back (figure 
1). The patient’s hospital visit (e.g. waiting room, doctor’s visit, vascular laboratory as-
sessments, treadmill testing, etc.) was then continuously video-recorded (GZ-HM335BE, 
JVC, Yokohama, Japan). Consequently, patients were asked to walk the hospitals car par-
king lot as abnormal walking due to IC would possibly occur during this effort. Subjects 
were instruct to act and move as they would normally do. Patients were filmed anony-
mously. Two observers were randomly assigned to perform all video recordings. Video 
recording of the activities was considered as ‘gold standard’.
Figure 1 A patient wearing the dynaport movemonitor (DP) 
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Categorizing movements by video
Table I depicts seven standard categories associated with daily activities including ly-
ing, sitting, standing, shuffling, locomotion, (device) ‘not worn’, and ‘activity not recor-
ded’ (private actions such as visit to restroom). Specifics of each category and transitions 
between the seven categories were described in detail. A concise description of catego-
rical and transitional activities formed the basis for a subsequent evaluation of all video 
recordings. All recorded activities were scored in time per activity (in seconds) using 
annotation software (ELAN 4.4.0, Max Planck Institute for Psycholinguistics, Nijmegen, 
the Netherlands) and exported as Microsoft Excel files. Additionally, the number of steps 
of all walking activities per patient were counted. All video recordings were scored in 
duplicate by two observers allowing inter-rater reliability (IRR) verification. 
DynaPort MoveMonitor (DP)
We chose to use the tri-axial DP accelerometer (84 × 50 × 8mm, 70 g) to monitor activi-
ties. Compared to other activity monitors, the DP showed high correlations between in-
direct calorimetry and generated MET output whereas walking speed was correctly mea-
sured in a population with chronic obstructive pulmonary disease(19). The device consists 
of a tri-orthogonal orientated piezo-capacitive acceleration sensor, a rechargeable bat-
tery and removable SD card to store the acceleration data. A DP stores digital data for 
a maximum of seven days. The raw acceleration data lend itself to a pattern recognition 
approach using logical algorithms (MoveMonitor analysis software, version 2.6) for the 
classification of postures (lying, sitting and standing) and motions (locomotion and shuf-
fling). The detection algorithm consists of 5 major parts as published previously(11, 12). 
The first step is gait period detection based on an intensity threshold. These potential 
gait periods are scanned using frequency analysis and a validated step detection method 
resulting in 3 categories: walking, active (but not walking), and static periods. Second, 
transition detection is performed to identify upward or downward transitions. The result 
is the identification of either up (standing) or down (lying or sitting). Subsequently, angle 
calculation based on sensor tilt is used to determine whether the down part of this vector 
can be identified as lying (<30°) or sitting. Next, shuffling separation divides the active 
(not walking) parts into 2 categories: shuffling and transitions. Shuffling is defined as all 
movement from A to B that is not walking. Thus, if the number of steps is less than 3 or 
the intensity and direction of the motion do not comply with the characteristics of wal-
king, the movements are classified as shuffling. The results of the software analysis were 
returned in comma separated value (CSV) files. The reports listed six of the described ac-
tivities per second (table 1), except for the “activity not recorded” category. Data obtained 
from the DP were synchronized with data generated by video recording (ELAN 4.4.0, 
Max Planck Institute for Psycholinguistics, Nijmegen, the Netherlands).
Category Interpretation
Lying • Lying
• From standing to lying: starting from the sitting position
• Sitting with straight legs
Sitting • Sitting
• From	standing	to	sitting:	starting	from	flexion	of	the	hip
• From lying to standing when subject is sitting >5 s during the transition
• Trunk movements during sitting
• Dressing and undressing during sitting
Standing • Standing
• From sitting to standing: starting from extension of the hip
• A pause during walking >5 s
• Shuffling	<5	s	before	a	transition	from	standing	to	lying/sitting
• Dressing and undressing during standing
Locomotion • Walking
• Walking upstairs
• A pause during walking <5 s
• Shuffling	<5	s	before	a	transition	from	walking	to	lying/sitting
• Shuffling	<5	s	before	a	transition	from	standing	to	walking
Shuffling • Shuffling
• Shuffling	>5	s	between	two	other	activities
• Shuffling	>5	s	before	a	transition	from	standing/walking	to	lying/sitting
Device not worn • The time period in which the DP is picked up from a table and attached to the patient
• The time period in which the patient is not wearing the DP during a video record
      measurement
Not recorded • The	time	period	in	which	the	DP	already	is	measuring	data,	but	video	recording	is
      not yet started
Data analysis
The first analysis of data was aimed at determining inter-rater reliability (IRR) of video 
recording itself, considered as the gold standard. The duration of activity (in 0.1 seconds) 
per category was summed for each patient. These values were analyzed for skewness 
and kurtosis to obtain an impression of the distribution. In case of normally distributed 
data, IRR of video recording were determined by comparing total duration per activity 
Table 1 Annotation Protocol
Note: DP: DynaPort MoveMonitor
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between both observations using intraclass correlation coefficients (ICC) with a two-way 
mixed model and absolute agreement.
Aim of the second analysis was to validate the DP by using two types of analyses. 
Transformation in an “activity per second” format was required for annotation files. For 
this purpose, a computer program was developed (MATLAB 7.14, MathWorks, Massa-
chusetts). The software converted the annotated duration of activities into an “activity per 
second” format. Activities defined by the DP and by video recordings were than compa-
red by matching each activity per second for the six overlapping categories (except for 
the “not recorded” category). The agreement between the DP and the gold standard was 
calculated per subject by adding up the duration that the activity codes matched and was 
expressed as a percentage of the total duration that an activity was observed on video. 
Non-agreement percentages per subject were defined as: (total duration that the video 
observation and the DP corresponded at the same moment for not ‘activity category’ 
/ total duration that not ‘activity category’ was observed on video) x 100%. Sensitivity, 
specificity and predictive values were calculated by taking the mean of agreement or non-
agreement values respectively for each activity category as suggested by Dijkstra et al.(11). 
The second type of determining the validity of the DP was using ICCs for step count. 
Gait characteristics as observed on video were again considered as ‘gold standard’. Steps 
performed on the treadmill (to obtain ankle brachial indexes) were analyzed separately 
from walking during a patients’ hospital visit. “Not recorded” periods >5 seconds were 
excluded from analysis. Outliers of agreement were estimated per activity category and 
defined as four times the standard deviation (SD) of agreement. ICC were considered 
strong if ≥ 0.7, moderate between 0.3 and 0.7, and weak ≤ 0.3. P-values < 0.05 were con-
sidered statistically significant. Statistical analysis was performed using SPSS Statistics 
(MAC OS X version 20.0).
Results
A total of 27 patients were eligible and all consented to this study. However, data of 6 
patients were excluded for reasons listed in figure 2. Patient characteristics of the remai-
ning 21 participants are shown in table 2. Bilateral IC symptoms were observed in 71% of 
the population. More than half (13/21, 62%) had undergone peripheral vascular surgery 
but still reported IC symptoms. A total of 27.9 hours of video film was obtained and ana-
lysed. Mean video time was 83 minutes per patient (range: 48 – 110 min). 
Inter-rate reliability (IRR) of video observations
IRR data were normally distributed. IRR between both video observers was excellent 
for most activity categories (ICC of 1.00 for lying, sitting and walking, 0.98 for standing, 
p<0.005). Moreover, the ICC for “device not worn” and “not recorded” detections were 
also excellent (1.00 and 0.99, respectively (p<0.005)). However, the ICC for shuffling was 
poor (0.38). 
Validity of the DynaPort MoveMonitor
Mean duration (±SD) of the postures standing, locomotion, lying and sitting per patient 
were 8.7 (± 6.1), 15.8 (±5.9), 15.2 (±6.9) and 35.3 (±17.1) minutes, respectively. Total 
Figure 1 Flowchart of study population allowing validation of MoveMonitor
Notes:	 *PAD:	Peripheral	Arterial	Disease,	ABI:	Ankle	Brachial	Index,	IC:	Intermittent	Claudication,	 
	 COPD:	Chronic	Obstructive	Pulmonary	Disease,	sd:	standard	deviation	
 
 
Eligible PAD patients (n=27)
Excluded:
•	 Walking	limited	due	to	COPD,	or	pain		
 other than claudication (n=4)
• Using walking aids (n=1)
Patients meeting inclusion and exclusion criteria (n=22)
MoveMonitor data loss (n=1)
Exclusion of outliers in postures (>4sd):
• Lying (n=1)
• Sitting (n=1)
• Not worn (n=1)
Patient data used for statistical analysis (n=21)
 Used data
Physical activity monitoring in patients with peripheral arterial disease: validation of an activity monitor
169
8
Innovative strategies for intermittent claudication 
168
8
duration of these four postures ranged from 183 to 707 minutes (table 3). In contrast, 
shuffling was measured for a mere 5 minutes (mean (±SD) per patient: 24±18 sec) and 
occurred in twelve patients only. The “device not worn” category was registered in just 
seven participants with a total measured time of 160 minutes (mean (±SD) per patient: 
22.9±9.8 min). Just 22 seconds (<0.1% of total time registered) were labelled as a “not 
recorded” event leading to removal from further analysis. In total, 5 of the 126 obtained 
activities (3.9%) were defined as outliers (>4 times SD of agreement) and were detected 
in the categories locomotion, sitting and “not worn” (table 5). These activities were also 
removed from analysis. Table 5 shows these outliers; activity as observed by video recor-
ding compared to the result of DP detection.
The agreement between video observation and DP data of observed activities is de-
picted in table 3. High levels of sensitivity were found for locomotion (86.1%), lying 
(96.8%), sitting (90.6%) and ‘device not worn’ (88.7%). High specificities and PPVs were 
also found regarding these four categories (>88.3%; table 4).
In contrast, the DP showed a low 46.2% sensitivity value (table 3). In reality “sitting” 
was performed in 37.1% of this ‘standing’ time (table 3). This poor agreement is likely 
due to aberrant data obtained from 10 of the 21 patients. Eight of these 10 patients were 
actually sitting (instead of standing) in 49.9 to 74.9% of the videoed time. In the two other 
measurements, the patient was moving in 27.5% and 29.3% of the “standing” time res-
pectively. Video observations and DP data did also show a low agreement regarding the 
category shuffling (17.5%; table 3) although a high specificity (98.7%) was found.
Data of walks during patient’ hospital visit (mean number of steps: 1561 ± 675 steps) 
and treadmill walking (mean number of steps: 473 ± 155 steps) were normally distributed 
and used for step analysis. The ICC of calculated steps between video observation and DP 
data was 0.90 (95% confidence interval (CI): 0.77 - 0.96, p=.001) and 0.84 for treadmill 
walking (95% CI: 0.63 – 0.93). One patient performed 2199 steps while the DP detected 
just 908 steps. Analysis revealed that this patient wore the DP upside down. The data set 
of this patient was defined as outlier and excluded for the activity analysis (“locomotion 
activity”, table 5) but not for the step analysis.
Table 2 Patient demographics
Notes:	 BMI:	body	mass	index,	CABG:	coronary	artery	bypass	grafting,	 
	 COPD:	chronic	obstructive	pulmonary	disease,	ABI:	Ankle	
	 Brachial	Index,	PCI:	percutaneous	coronary	intervention,	
	 PTA:	per	cutaneous	transluminal	angioplasty,	TEA:	thrombo-	
 endarterectomy
Analysed population (n = 21)
Gender (% male) 62
Age (years ± sd) 67 ± 10
BMI	(kg/m2 ± sd) 26 ± 4
Affected side
Left 24%
Right 5%
Both 71%
ABI
Rest,	worst	lega (mean ± sd) 0,70	±	0,21
Rest,	best	legb (mean ± sd) 0,92	±	0,17
Post-exercise,	worst	lega (mean ± sd) 0,49	±	0,28
Post-exercise,	best	legb (mean ± sd) 0,79	±	0,28
Cardiovascular medical history
PTA 35%
Leg surgery 25%
CABG	/	PCI 40%
Other 25%
Comorbidity
COPD 29%
Arthritis 14%
DynaPort data
Total video  
observation 
(min)
Locomotion* 
(mean % ± sd)
Lying
(mean % ± sd)
Shuffling
(mean % ± sd)
Standing 
(mean % ± sd)
Sitting*
(mean % ± sd)
Not worn**
(mean % ± sd)
Locomotion 315 86.1 ± 11.8 0.5 ± 0.9 2.3 ± 1.6 8.8 ± 7.2 2.8 ± 4.6 0.0
Lying 319 0.5 ± 0.7 96.8 ± 3.9 0.3 ± 0.4 0.4 ± 0.9 1.9 ± 2.7 0.0
Shuffling 5 6.6 ± 7.0 0.0 17.5 ± 13.8 49.2 ± 24.5 26.7 ± 30.6 0.0
Standing 183 5.3 ± 8.2 3.5 ± 4.3 5.9 ± 3.9 46.2 ± 19.0 37.1 ± 22.2 0.4 ± 1.9
Sitting 707 0.3 ± 0.4 0.5 ± 0.8 0.4 ± 0.5 7.4 ± 11.8 90.6 ± 12.3 0.9 ± 3.9
Not worn 160 0.0 ± 0.1 4.9 ± 3.6 0.2 ± 0.2 5.8 ± 10.1 0.2 ± 0.2 88.7 ± 9.3V
id
eo
- o
bs
er
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Table 3 Agreement and non-agreement between video observation and DynaPort 
 MoveMonitor (DP) data per activity
Notes: Values are presented in percentages. Video observation data is used as gold standard. DP’s sensitivity   
 values of  categorized activities are depicted in the grey shaded cells.
 * One outlier was excluded
 ** Three outliers were excluded 
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Table 4 Specificity and positive predictive values of the DynaPort Movemonitor
Activity Specificity (%) Positive Predictive Value (%)
Locomotion 99.0 94.9
Lying 98.6 94.1
Shuffling 98.7 3.7
Standing 93.9 47.8
Sitting 91.4 88.3
Not worn 99.6 95.4
Activity as categorized by the DynaPort
Observed 
activity  
(by video registration)
Total  
duration 
(s)
Locomotion 
(% of time)
Lying
(% of time) 
Shuffling
(% of time) 
Standing
(% of time) 
Sitting
(% of time) 
Not worn 
(% of time)
Locomotion 1346 38.9 0.2 5.4 35.7 19.4 0.0
Sitting 876 0.2 0.7 0.1 59.8 39.1 0.0
Not worn 1875 0.0 98.7 0.3 0.5 0.4 0.0
Not worn 162 0.0 0.0 0.0 100 0.0 0.0
Not worn 469 0.0 1.9 1.3 95.1 1.7 0.0
Discussion
Symptoms of intermittent claudication might influence daily life activities. Moreover, 
IC may have profound consequences for exercise ability, behavior and levels of physical 
activity (PA). Findings of this ‘real life’ design study indicate that activities detected by 
the DP showed high sensitivity and specificity values for most activity categories except 
for “standing” and “shuffling”.
Measuring inter-rate reliability (IRR) characteristics is an important step in the evalu-
ation of a ‘gold standard’ that is used to validate novel tools such as the DP. Strong corre-
lations concerning the IRR were found in 6 out of 7 activity categories. In contrast, a poor 
IRR was found for shuffling (ICC of 0.38). High IRRs were previously found in a similar 
but smaller video study of 5 elderly patients (ICC of 0.95, 0.78, 0.99 and 0.98 for walking, 
Note: Video observation data is used as gold standard.
Table 5 Data of removed outliers per activity
sitting, standing and lying, respectively)(12). The poor ICC for shuffling is probably due 
to ambiguities in our annotation protocol (table 1). Furthermore, transitions per se were 
difficult to score using a ‘per second’ time window analysis method, whereas the duration 
of a particular transition between activities is often a matter of seconds, a phenomenon 
that was also reported previously(11).
 
A poor sensitivity of 46.2% of the DP was found for the activity “standing” (PPV: 
47.8). These results are somewhat lower as compared to other studies with community-
dwelling patients and Parkinsons disease patients (80.2% and 81.4%, respectively) (10). 
Additionally, we found a large standard deviation (19.0%) for the “standing” activity, 
which can be explained by 10 aberrant measurements. It is thought that the DP missed 
several transitions between sitting and standing that may have considerably influenced 
outcomes, especially due to increased durations of activities. The low PPV of ‘shuffling’ 
(3.7%) is particularly striking and induced by a low IRR and a difference between the an-
notation protocol and the algorithms that were used by the DP in allocating transitions 
to specific activities. According to our protocol, observers assessed transitions between 
activities as part of the previous activity, while in contrast the DP scored them as shuff-
ling. Therefore conclusions regarding shuffling cannot be drawn from this study. Howe-
ver, it should be appreciated that shuffling activities were just observed during a relatively 
short period (1% of total time recorded). Therefore, the effect of shuffling on overall PA 
performance is very limited.
An overestimation of gait duration (10.7%) and underestimation of number of steps 
(7.4%) in Parkinsons disease patients was previously found(12). However, these studies 
were performed in a laboratory setting with relatively short distances and just 236.8 mi-
nutes of video observation per study. Despite that walking patterns are altered in IC pa-
tients(16-18), the present study that was executed under daily life conditions using prolon-
ged video observation periods demonstrated that the DP can accurately measure number 
of steps in a IC population.
Studying PA levels and ambulatory activities in daily life may yield important in-
formation regarding quality of life, health status or mortality in chronic diseases such 
as COPD and PAD/IC. There is an increasing interest in understanding associations 
between sedentary activities and their impact on quality of life(20-22). As a consequence, 
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research interest may shift from focussing on measurement of exercise capacity (maximal 
or pain-free walking distances) to determining daily activities over a prolonged period 
of time. Our study shows that the DP can correctly measure most types of ambulatory 
activities in daily life. Future research should aim to determine the value of PA as a novel 
outcome measurement in IC related topics such as in the comparison between IC treat-
ment modalities.
Study limitations
Video-observers and the DP scored shuffling differently. In retrospect, positional change 
would have been marked as ‘shuffling’. Furthermore, reference values of physiological or 
walking intensity parameters were not obtained although the DP is capable of determi-
ning the intensity of periods of locomotion (movement intensity)(23). Therefore, a vali-
dation of energy expenditure values could not be made. Although movement intensity 
may be of importance in IC patients, the present study focused on validation of periods 
of activities rather than intensity. The assessment and the effect of treatment strategies on 
physical activity and daily activities in PAD patients should be subject of future research. 
Conclusion
A tri-axial MoveMonitor activity monitor provides accurate information on a diverse 
set of daily activities in IC patients when compared to a video technique. However, the 
detection of low amplitude movements such as shuffling and “sitting to standing” trans-
fers is a matter of concern. This tool is useful to assess the role of physical activity as a 
novel clinically relevant outcome parameter in IC. 
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Abstract
Introduction
Reduced physical activity (PA) is associated with a higher mortality rate and more 
rapid functional decline in patients with intermittent claudication (IC). The newest 
generation of accelerometers can assess both direction and intensity of activities 
three-dimensionally and may also adequately calculate energy expenditure in daily 
life. The aim of this study was to quantify daily PA level and energy expenditure of 
newly diagnosed patients with IC and healthy controls. PA outcomes are compared 
with contemporary public health physical activity guidelines.
Materials & methods
Before initiating treatment, 94 patients with newly diagnosed IC and 36 healthy con-
trols were instructed to wear a tri-axial seismic accelerometer for 1 week. Daily PA 
levels (in metabolic equivalents, METs) were compared to the ACSM/AHA public 
health PA minimum recommendations (≥64 METs·min·day, in bouts of ≥10 min). 
A subgroup analysis assessed the effect of functional impairment on daily PA levels.
Results
Data of 56 IC patients and 27 healthy controls were available for analysis. Patients 
with IC demonstrated significantly lower mean daily PA levels (± S.D.) compared 
to controls (387 ± 198 METs·min vs. 500 ± 156 METs·min, p=0.02). This difference 
was solely attributable to a subgroup of IC patients with the largest functional im-
pairment (WIQ-score <0.4). Only 45% of IC patients met the public health physical 
activity guidelines compared to 74% of the healthy controls (p=0.01). 
Conclusion
More than half of patients with intermittent claudication (IC) do not meet recom-
mended standards of physical activity (PA). Considering the serious health risks as-
sociated with low PA levels, these findings underscore the need for more awareness 
to improve physical exercise in patients with IC.
Introduction
Intermittent claudication (IC) is closely associated with cardiovascular and cerebro-
vascular disease.(1-3) Compared to healthy adults, IC patients are burdened with a low 
health-related quality of life and functional impairment during daily activities.(4, 5) A re-
duced exercise capacity and lower daily free-living physical activity (PA) level are both 
strong predictors of long-term mortality. In contrast, higher PA levels are associated with 
less functional decline.(6-9)
The ACSM/AHA have issued recommendations on types and amounts of PA nee-
ded for (older) adults to improve and maintain health.(10) Specific recommendations are 
provided that apply to adults >65 years of age or to adults aged 50-64 years with chronic 
conditions or physical functional limitations.(11) All adults are advised to engage in mode-
rate-intensity aerobic exercise for a minimum of 30 minutes during five days a week, or 
vigorous-intensity aerobic PA for a minimum of 20 minutes at three days a week.  Activi-
ties should be performed in bouts of at least 10 minutes. Combinations of moderate- and 
vigorous-intensity aerobic PA can also be performed to meet these recommendations. 
Metabolic equivalents (METs) are used by the ACSM/AHA as a means to express 
the energy expenditure or energy costs of physical activities. The total amount of PA is a 
function of its intensity, duration and frequency. Accordingly, vigorous intensity activities 
(>6.0 METs) performed for a particular duration and frequency generate greater energy 
expenditure than moderate-intensity activities (3.0-6.0 METs) of the same duration and 
frequency. When combining the recommendations on moderate- and vigorous-inten-
sity physical activity, the daily minimum goal of PA should be in the range of 64-107 
METs×min.(10, 11)
In literature, PA is defined and determined in different ways. Frequently used definiti-
ons of PA are ‘time spent in different activities (sedentary/ambulatory), number of steps, 
duration of walking events or the score on a specific exercise test or questionnaire’(8,12-15) 
PA objectively measured by energy expenditure is seldomly performed in patients with 
IC.(15-17) Regularly described methods for PA measurement are PA questionnaires, pedo-
meters or activity monitors. However, only the latter method is found capable of adequa-
tely assessing energy expenditure.(18, 19)
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The newest generation of activity monitors are based on tri-axial accelerometer tech-
niques measuring accelerations in three dimensions that can be converted to intensities 
and METs. In contrast to unilateral accelerometers (or vertical accelerometers), tri-axial 
accelerometers also measure activities that do not include vertical movement. As such, 
PA is determined more precisely as demonstrated with high correlations between indirect 
calorimetry and generated MET output at different walking speeds.(18, 20, 21) To our know-
ledge, no studies are available on the use of a tri-axial accelerometer in patients with IC 
compared to healthy adults.
The purpose of this prospective observational study was to objectively determine the 
PA using a tri-axial accelerometer in patients with IC and healthy adults. Furthermore, 
number and percentage of participants meeting the lower limit of the ACSM/AHA re-
commendations for PA and public health are determined. It was hypothesized that heal-
thy adults had a higher PA level and complied more frequently to these minimum recom-
mendations compared to IC patients.
Materials & Methods
Participant selection
Patients with clinical manifestations of IC were recruited at the outpatient clinic of Vas-
cular Surgery of the Catharina Hospital, Eindhoven and Maxima Medical Center, Veld-
hoven/Eindhoven, The Netherlands. Healthy individuals recruited from family or friends 
of healthcare workers served as controls. All subjects gave written informed consent and 
all procedures described in this study were approved by the Medical Ethical Committee, 
Catharina Hospital, Eindhoven.
Eligibility assessment
IC group
Patients without any previous history of peripheral arterial occlusive disease (PAOD) pre-
senting with new onset clinical manifestations of IC underwent an ankle-brachial index 
(ABI) measurement using standard equipment. Patients with values below 0.90 at rest or 
a drop in value of more than 0.15 after a standard treadmill test were considered eligible. 
Exclusion criteria included serious cardiopulmonary limitations (NYHA class 3-4), criti-
cal limb ischemia or previous lower-limb amputation, use of walking aids, psychiatric in-
stability or other serious comorbidity which possibly limited the patient’s walking ability.
Control group
Healthy volunteers aged >45 years without a history of PAOD, cardiac or pulmonary 
disease were included if they were able to walk without any limitations or walking aids. 
Participants were excluded if an ABI measurement was below 0.90 at rest or decreased 
more than 0.15 after a standard treadmill test.
Functional impairment and health-related quality of life scores
After consenting to the study specifics, a Dutch validated version of the Walking Im-
pairment Questionnaire (WIQ), 12-item Short Form Physical Functioning Sum-
mery (SF-12 PCS) and 12-item Short Form Mental Functioning Summery (SF-
12 MCS) were assessed prior to treatment in the IC patients and in controls.(22, 23) 
Evidence based conservative treatment was subsequently started in the IC group. Each 
patient received cardiovascular risk management including antiplatelet therapy and a sta-
tin.
Physical activity monitoring
Dynaport tri-axial seismic accelerometer
Both groups of study participants were asked to wear a tri-axial seismic accelerometer 
(Dynaport MoveMonitor, McRoberts B.V., The Hague, The Netherlands) during a 1 week 
time period. The Dynaport MoveMonitor (size 84mm X 50m X 8mm; weight 55 g) con-
tains three orthogonal piezo-capacitive acceleration sensors, each measuring at a sample 
rate of 100Hz. The accelerometer has a direct current response to the Earth’s gravitational 
field, and used a seismic or a proof mass suspended by a spring structure in a case. The 
case has a micro USB connection and a rechargeable battery and stores the raw data on 
a Micro-SD card. The Dynaport MoveMonitor is placed in a belt that is strapped around 
the waist. It is positioned at the base of the lumbar column just cranial to the buttocks. 
The Dynaport technology is validated for counting steps, detecting time spent in different 
activities, activity-related energy expenditure and assessment of reproducibility.(18, 21, 24-28)
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Monitoring protocol
All participants were instructed to correctly wear the Dynaport MoveMonitor for 7 con-
secutive days. As the device is not waterproof, participants were asked to take off the 
device when taking a shower or a bath. Furthermore, to achieve better compliance, par-
ticipants were instructed not to wear the device during sleeping. They were instructed to 
perform their regular daily activities during this week. Supervised exercise therapy (SET) 
was initiated after this one week monitoring period in IC patients. SET was provided by 
a specialised physical therapist in a community-based setting. According to the quality 
standards and guidelines of the Dutch ClaudicatioNet Network and Royal Dutch Soci-
ety for Physical Therapy, the physical therapist assessed the pain-free walking distance 
(PFWD) and maximum walking distance (MWD) at baseline according to a standardised 
graded treadmill protocol.(29, 30)
Outcomes
Primary outcomes
• The daily PA level (measured in METs×min)
• The daily PA level performed in bouts of >10 minutes moderate- or vigorous-
intensity PA (measured in METs×min)
• The number and percentage of participants meeting the lower limit of the 
ACSM recommendation for PA and public health (67 METs×min a day) 
Secondary outcomes
• The average daily time spent in different activities (Lying, Standing, Sitting, Wal-
king, Shuffling) and the time spent not wearing the device
• The average daily number and highest number of steps walked in one period (top 
period of steps) 
• The average daily time spent in light-, moderate- or vigorous-intensity activity. 
Sedentary activity is activity with an intensity of <1.5 METs, light activity is acti-
vity with an intensity of 1.5-3 METs, moderate activity is activity with an inten-
sity of 3-6 METs and vigorous activity is activity with an intensity of 6-9 METs.
Data Analysis
Daily checks were made to assure proper use of the device. By definition, the device was 
worn correctly if it detected at least 20 steps and if it was ‘worn’ ≥10 hours and ‘not worn’ 
for ≥5 hours a day. Participants with less than 5 days of correctly wearing the device were 
arbitrarily excluded from analysis. Daily average outcomes were determined for each par-
ticipant depending on the number of ‘correctly worn days’. 
Subgroup analysis
The IC group was divided into two subgroups according to the WIQ score (<0.4 or ≥0.4) 
in order to evaluate the hypothesis that IC patients with more functional impairment 
have a lower daily PA level. The WIQ-score was used because it takes both the patient’s 
effort to walk and his perceived impairment into account, while estimated or treadmill 
walking distances do not reflect walking distances in daily life.(31) A lower WIQ-score 
reflects higher functional impairment. A cut-off value of 0.4 was arbitrarily chosen to 
establish even groups.
Statistical analyses
All analyses were performed using IBM SPSS Statistics Version 21 (SPSS Inc., Chicago, 
IL, USA). Categorical variables are presented as frequencies with percentages. Nominal 
variables are depicted as the mean ± standard deviation in case of a normal distribution. 
Statistical differences between the groups were calculated with a Pearson Chi-Square test 
for categorical variables, an Independent sample T-test for continuous variables between 
two groups and a One-Way between-groups ANOVA for continuous variables between 
more than two groups. In case of significant differences between more than two groups, 
post-hoc Tukey tests were performed to assess a possible significant difference between 
groups. A p-value <0.05 was used for statistical significance.
Univariable and multivariable linear regression analysis were used to evaluate which 
pre-specified variables predicted daily level of physical activity. In the univariable regres-
sion analysis, each variable is included in a separate regression analysis. In the multivari-
able regression analysis, all statistically significant variables, identified by the univariable 
regression analysis, are included in one regression analysis, using the enter method. In-
cluded pre-specified variables were age, BMI, sex, resting ABI, IC symptoms of both legs, 
cardiac history, pulmonary history, WIQ score, SF-12 PCS score, SF-12 MCS score, and 
maximal walking distance measured at baseline.  Multivariable linear regression analysis 
using the backward elimination method was used to identify the variables included in 
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the final regression equation. The backward method starts with all the variables in the 
equation and in every step variables that do not have a statistically significant influence 
are excluded. The criterion for removal from the regression model was a p-value of more 
than 0.10. The quality of the regression models was expressed with the R2  (explained 
variance) for linear regression analysis.
IC subgroup 1 (n = 30)
WIQ <0.4
IC subgroup 2 (n = 26)
WIQ ≥ 0.4 Control group (n = 27) P-value
N (%) Mean S.D. N (%) Mean S.D. N (%) Mean S.D.
Male gender 14 (46.7) - - 16 (61.5) - - 13 (48.1) - - 0.49a
Both legs  
symptomatic 18 (60.0) - - 12 (46.2) - - n.a. - - 0.30
a
Pulmonary 
history 8 (26.7) - - 4 (15.4) - - n.a. - - 0.31
a
Cardiac history 11 (36.7) - - 11 (42.3) - - n.a. - - 0.67a
Days correct 
worn device - 5.80 0.61 - 5.80 0.76 - 6.37 0.74 0.001
b
Age (years) - 69.6 8.8 - 69.4 8.3 - 62.9 9.9 0.002b
BMI - 28.0 4.4 - 26.2 3.1 - 26.7 4.2 0.23b
Resting ABI - 0.60 0.18 - 0.66 0.18 - 1.10 0.08 <0.001b
WIQ score - 0.19 0.12 - 0.62 0.15 - 0.93 0.16 <0.001b
SF-12 PCS 
score - 31.7 8.8 - 40.7 9.8 - 52.0 6.8 <0.001
b
SF-12 MCS 
score - 52.6 9.6 - 52.1 7.9 - 52.4 10.1 0.98
b
PFWD (m) - 155 136 - 233 129 - n.a. n.a. 0.06c
MWD (m) - 296 225 - 486 274 - n.a. n.a. 0.008c
Results
Group baseline characteristics
A total of 130 participants were considered eligible (IC, n=94; controls, n=36). Analy-
sis of the accelerometer data demonstrated that 56 IC patients and 27 controls met all 
Notes:	 ABI	=	ankle	brachial	index,	BMI	=	body	mass	index,	WIQ	=	Walking	Impairment	Questionnaire,		
	 SF-12	PCS	score	=	Short	Form-12	Physical	Component	Summary	score,	SF-12	MCS	=	Short	
	 Form-12	Mental	Component	Summary	score,	PFWD	=	pain-free	walking	distance,	 
	 MWD	=	maximum	walking	distance,	n.a.	=	not	applicable
 a	Pearson	Chi-Square	Test,	b	One-way	between-groups	ANOVA,	c Independent Sample T-test
Table 1 Baseline characteristics
criteria of a correctly worn device. A significant group difference regarding age, number 
of correctly worn days, resting ABI, WIQ-score, SF-12 PCS score and MWD was found 
between both groups. (Table 1) 
Time spent in different activities or intensity-levels
IC patients spent almost 8.5 hours a day sitting (508 ± 108 minutes), more than 2.5 hours 
a day standing (165 ± 60 minutes), more than 2 hours a day lying (132 ± 101 minutes), 
1 hour a day walking (65 ± 33 minutes) and 21 ± 12 minutes a day shuffling. (Table 2) 
Compared to the control group a significant difference was found in the time spent sitting 
and ‘device not worn’. A significant group difference was also found regarding vigorous-
intensity activities (IC: 4 ± 8 vs. Controls: 11 ± 10 minutes a day, p=0.002). 
IC group (n = 56) Control group (n= 27) P-value a
Mean S.D. Mean S.D.
Lying (hours:min) 2:12 101 2:10 62 0.92
Sitting (hours:min) 8:28 108 9:20 80 0.03
Standing (hours:min) 2:45 60 2:33 47 0.34
Walking (hours:min) 1:05 33 1:16 29 0.14
Shuffling	(hours:min) 0:21 12 0:26 12 0.10
Not Worn (hours:min) 9:13 50 8:16 47 <0.001
Light activity (hours:min) 1:18 33 1:33 55 0.13
Moderate activity (hours:min) 1:23 37 1:35 29 0.11
Vigorous activity (hours:min) 0:04 8 0:11 10 0.002
Step analysis
Daily number of steps in the IC subgroups was significantly fewer compared to the con-
trol group (IC subgroup 1: 4663 ± 3104 vs. IC subgroup 2: 5761 ± 2371 vs. Controls: 6682 
± 2701, p=0.03). The highest number of steps walked in one period (top period of steps) 
was also significantly lower in IC patients (IC subgroup 1: 1601 ± 1414 vs. IC subgroup 2: 
2546 ±1894 vs. Controls: 4584 ± 4680, p<0.001).
Table 2 Average duration of different daily activities and intensity levels
Notes: a	Independent	Sample	T-test,	Light	activity	=	activity	with	an	intensity	of	1.5-3	METs,	Moderate		
	 activity	=	activity	with	an	intensity	of	3-6	METs,	Vigorous	activity	=	activity	with	an	intensity	of	6-9		
 METs)
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Daily physical activity level
A statistically significant difference (p = 0.02) in both daily PA level and daily PA in bouts 
of >10 minutes of moderate- or vigorous intensity exercise, was found between the IC 
subgroups and the control group. (Figure 1, 2) Post-hoc analyses showed that this dif-
ference was solely due to a significant difference between IC subgroup 1 (WIQ < 0.4) and 
the control group (p=0.018). In contrast, no significant difference in daily PA level was 
found between IC subgroup 2 (WIQ ≥ 0.4) and the control group (p=0.28).
Analysis of the number of participants achieving the lower (67 METs×min a day) and 
upper (107 METs×min a day) limit of the ACSM minimum recommendations showed 
a significant difference (lower limit: p=0.01, higher limit: p=0.02) between the IC sub-
groups and the control group in favour of the healthy controls. (Figure 3) 
Prediction model for daily physical activity level
Univariable regression analysis revealed that age, a previous history of pulmonary disease, 
MWD and the WIQ, SF-12 MCS and SF-12 PCS score, all independently influenced the 
daily PA level. (Table 3) Multivariable regression analysis including five variables (age, 
pulmonary history, SF-12 PFS, SF-12 MFS, MWD) explained 53% (p<0.001) of the vari-
ance in daily PA level: 
Daily PA level of IC patients (METs×min) = 369.23 – 7.65 x Age + 4.73 x SF-12 PCS 
score + 6.53 x SF-12 MCS score + 0.18 x MWD (– 138.65 if pulmonary history is present)
Table 3 Linear regression models for daily physical activity level (METs•min) of participants  
 in the IC group
Univariable linear regression Multivariable regression c
Final  
regression d
Constant a B b P-value
R 
square B
P-
value B
P-
value
Age 1015.33 -9.04 <0.05 0.15 -7.66 0.003 -7.65 0.002
Gender (male) 403.83 -29.09 0.59 0.01
Both legs symptomatic 425.05 -70.58 0.19 0.03
Cardiac history 417.02 -75.79 0.16 0.04  
Pulmonary history 432.78 -212.51 <0.05 0.20 -140.18 0.01 -138.65 0.01
BMI 381.92 0.20 0.98 0.00
Resting ABI 333.86 85.05 0.57 0.01
WIQ score 300.1 223.83 <0.05 0.08 -63.96 0.55
SF-12 PCS score 111.22 7.69 <0.05 0.16 5.51 0.04 4.73 0.04
SF-12 MCS score 18.19 7.04 <0.05 0.10 6.57 0.01 6.53 0.01
MWD 282.57 0.27 <0.05 0.13 0.20 0.03 0.18 0.04
Notes: a The Constant (in METs×min) of the regression equation is the interception of the regression line  
 on the Y-axis. b The B of the regression equation of the regression equation is the slope of the  
	 regression	line	and	gives	information	about	the	direction	of	the	association	and	the	influence	of	each		
	 individual	variable	(in	METs×min).	The	bigger	the	B,	the	bigger	the	influence	per	unit	on	the	daily		
 physical activity level.
 c Total model: R2	=	0.53,	P	<0.001,	Constant	=	357.62.	d Total model: R2	=	0.53,	P	<0.001,	 
 Constant = 369.23
Figure 1 Daily physical activity level (mean ± S.D.)
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Figure 2 Daily physical activity level in bouts >10 min of moderate or vigorous activity 
 (median, IQR)
Figure 3 Adherence to ACSM recommendations for physical activity
Discussion
This study hypothesized that IC patients would demonstrate a lower PA level and 
would comply less frequently to the lower limit of the ACSM/AHA recommendations for 
PA and public health compared to healthy adults. In a two-day assessment of PA using a 
vertical accelerometer and a pedometer, one other study found that daily PA level of IC 
patients was 42%-45% lower compared to healthy subjects of similar age.(17) Also using 
a vertical accelerometer, a second study demonstrated that patients with peripheral ar-
terial occlusive disease (PAOD) had markedly lower PA levels compared to non-PAOD 
participants (803 ± 364 kcal/wk vs. 1750 ± 1296 ± kcal/wk).15 Ever since the ACSM/AHA 
issued minimum recommendations on PA and public health were issued, studies descri-
bing to what extent IC patients meet these criteria in relation to healthy adults were not 
performed. 
The present study using newest generation of tri-axial accelerometers found that fe-
wer than half of IC patients meet the ACSM/AHA minimum recommendations while 
more than one-quarter of older healthy adults do not meet these criteria. 
Moreover, the daily level of PA of IC patients (387 ± 198) is much lower compared 
to healthy adults (500 ± 156). IC patients reporting substantial functional impairment 
(WIQ score <0.4) had the lowest mean daily PA level of all groups. Interestingly, the PA 
group difference was solely attributed to this subgroup.  Only minor functional impair-
ment in IC patients apparently does not result in lower daily PA level. 
A tri-axial accelerometer allows for separately identifying various activities such as 
sitting, standing, lying or walking. The present study found significant group differences 
regarding time of sitting and ‘not wearing the device’. Healthy adults appearly sit approxi-
mately one hour longer and might sleep less compared to IC patients. In contrast, walking 
time did not differ among groups, although the daily number of steps and highest num-
ber of steps were significantly lower in the IC group. This difference is possibly explained 
by a slower walk pace or cadence associated with IC. A previous study also suggested that 
patients with IC take fewer steps and have a lower daily average cadence compared to 
healthy adults.(32)
Variables influencing daily PA level in IC patients were hitherto not identified. The 
present study revealed that age, previous history of pulmonary disease, MWD and the 
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WIQ, SF-12 MCS and SF-12 PCS score all independently influence these levels. Pulmo-
nary history appeared the strongest factor. However, patient with serious pulmonary con-
ditions (affecting the patient’s walking ability) were excluded from this study. Therefore, 
the effect of pulmonary history on the daily PA level in an IC patient is probably unde-
restimated. Patients with COPD are markedly inactive in daily life compared to healthy 
adults.(33) Therefore, physicians need to realize that patients with IC and COPD are much 
less active compared to IC patients without pulmonary history or healthy adults. 
A low daily PA level is generally considered a strong predictor of mortality and functi-
onal decline in patients with IC.(6-9) More than light-intensity weekly PA improves 5-year 
survival rate significantly compared to light-intensity or no physical activity.(7) 
For this reason, one could argue that the PA level is a valid outcome parameter in 
evaluating treatment effects of any intervention for IC. Current outcome parameters in-
cluding maximum- or pain-free walking distances only describe the patient’s exercise 
capacity while it does not reflect to what extent this capacity is used. In contrast, daily PA 
levels, provide objective information on the frequency, duration and intensity of exercise. 
Combined with a functional impairment score such as the WIQ-score, physicians may 
objectively monitor the patient’s treatment progress.
Future studies should focus on the effects of different treatment strategies on PA. A 
rehabilitation program such as supervised exercise therapy (SET) improves walking per-
formance and functional impairment. Most programmes promote, besides supervised 
sessions, daily home-based exercise in order to increase the patient’s daily PA. No studies 
have substantiated the effect of SET on the daily level of PA yet. Therefore, accelerometer 
studies before and after different treatment strategies may shed light on these issues.
Study limitations
The present study is limited by the number of excluded participants. In total, 38 partici-
pants in the IC group (40.4 %) and 9 controls (25.0 %) were excluded because the device 
was not correctly worn for ≥5 days. By definition, a correctly worn day was considered 
a day that the device was worn for ≥10 hours, not worn for ≥5 hours and with at least 
20 steps. These strict criteria were a priori determined to prevent bias. For instance, if a 
participant wore the device for only 5 hours one day, unrepresentative data on the overall 
person’s PA would have been collected. The high dropout rate may have potentially biased 
the PA results, most likely an overestimation of the current PA level in IC patients.  Lack 
of motivation or misunderstanding the monitoring protocol could have led to incorrect 
use. A substantial number of participants said they had forgotten the end date of the mo-
nitoring period. In a few instances, participants fell asleep with the device still strapped 
to their waist. In our monitoring protocol, participants were asked to remove the device 
before sleeping to improve compliance. If the device was worn during night, that day 
was considered by definition ‘not correctly worn’. We are not sure if compliance could 
have been higher if participants wore the device constantly. In future studies, regular 
check-ups by phone calls could be relevant as a means to increase compliance and un-
derstanding of the monitoring protocol. For clinical practice one could consider a shorter 
amount of the monitoring period, considering results are summarized in an average daily 
PA level. However, accuracy of PA results of a shorter monitoring period should first be 
validated since these could vary.
We experienced only a few measurement failures with the tri-axial accelerometer. The 
Dynaport MoveMonitor can fail if the battery is not fully charged or if the device is worn 
backwards. The device indicates if it is fully charged, minimizing the change of human 
errors. However, in a handful of cases the device did not measure for 7 days because the 
investigators replaced the original SD-cards with new ones. The new SD-cards appeared 
to consume more battery energy than the original ones. Therefore the device could only 
measure for 5 or 6 days. Besides this error, we did not experience device malfunction. 
The investigators explicitly explained how to wear the device to minimize the change that 
participants wore the device backwards. This could be explained quite easy since the de-
vice is worn correct if one could read the word ‘McRoberts’ on the outside of the device. 
Therefore this error did not occur during any of the worn days. 
Another study limitation is the lack of an age-matched control group. Although 
groups were initially matched for age and sex, a significant difference in age was present 
between the IC and control group once the IC group drop out rate appeared high. Ho-
wever, a sensitivity analysis including healthy adults aged ≤ 60 years (n=14) revealed no 
significant difference in daily PA level in comparison to 13 other healthy adults aged > 
60 years (526 ± 160 METs×min vs. 471 ± 151 METs×min, p=0.37) although these groups 
may have been underpowered. 
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Conclusions
More than half of patients with intermittent claudication (IC) do not meet the 
minimum recommendations for physical activity (PA) and public health. Compared to 
healthy adults, they have a significantly lower daily PA level. PA differences are due to a 
IC subgroup with severe functional impairments. Because a low PA level is considered 
a strong predictor of mortality and functional decline, all health care workers should 
actively stimulate physical activities in IC. Future studies should assess the effects of 
treatment strategies including supervised exercise therapy on daily PA levels.
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Abstract
Objectives
Intermittent claudication (IC) is associated with a reduction in physical activity (PA) 
and a more rapid functional decline leading to a higher mortality rate compared to 
healthy individuals. Supervised exercise therapy (SET) is known to increase the wal-
king capacity of IC patients. However, it is unclear whether SET increases PA. The 
aim of this study was to investigate the effect of SET on PA levels and ambulatory 
activities in patients with IC.
Design & Methods
Newly diagnosed IC patients were requested to wear an activity monitor one week 
prior to and one week immediately following 3 months of SET. Primary outcome was 
the percentage of patients meeting the minimum recommendations of PA (ACSM/
AHA public health, ≥67 METs·min·day, in bouts of ≥10 min) at baseline and after 
3 months of SET. Additionally, daily PA level (metabolic equivalents, METs·min), 
duration of ambulatory activities, daily number of steps, pain free walking distance 
(PFWD), maximal walking distance (MWD) and SF-36 health surveys were compa-
red before and after SET.
Results
Data of 41 participants were available for analysis. A higher number of participants 
met the ACSM minimum recommendation for PA at the 3 months follow up (base-
line: 43%; 3 months: 63%, p= .003). Despite significant increases in PFWD (baseline: 
210m; 3 months: 390m, p=.001), MWD (baseline: 373m; 3 months: 555m, p=.002) 
and physical functioning score (SF-36) following SET, no increase in mean daily 
PA level was found (395 ± 220 vs. 411 ± 228 METs·min, p=.43). Furthermore, total 
number of steps and time spent in ambulatory activities did not change following 
SET.
Conclusions
Three months of SET for intermittent claudication leads to more patients meeting 
the ACSM/AHA public health minimum recommendations of PA. Assessment of 
PA may be incorporated as outcome parameter in future research comparing dif-
ferent treatment modalities for peripheral arterial disease.
Introduction
Most patients with intermittent claudication (IC) demonstrate a limited exercise per-
formance and have increased risks on cardio- and cerebrovascular events, reduced quali-
ty of life (QoL) and higher mortality rates.(1) Primary treatment of IC includes supervised 
exercise therapy (SET) as suggested by several international guidelines.(1-3) SET signifi-
cantly improves the maximal and pain-free walking distances and is cost-effective.(4-8) 
However, the question arises whether effectiveness of PAD treatment modalities should 
be evaluated on the basis of changes in walking capacity only. 
Individuals who are regularly physically active report better overall health, lower 
health care expenditures and fewer mobility limitations than their sedentary counter-
parts.(9,10) The American Heart Association (AHA) and the American College of Sports 
Medicine (ACSM) provide specific recommendations of various types of activity to sti-
mulate the elderly. Tailored recommendations are provided that apply to adults with 
clinically-significant chronic conditions or functional limitations that affect mobility and 
activity.(11) Guidelines suggest to engage in moderate-intensity aerobic exercise for a mi-
nimum of 30 minutes during five days a week, or a minimum of 20 minutes of vigorous-
intensity activity on three days each week, or some combination of the two.(11) Activities 
should be performed in bouts of at least 10 minutes. Intensity of effort is assessed in 
absolute terms by estimating the actual metabolic cost of a given activity and assigning 
intensity accordingly.(12) A metabolic equivalent (MET) is an estimate of oxygen con-
sumption at rest. A three-MET activity would be an activity that utilizes roughly three 
times the amount of resting energy expenditure. Accordingly, vigorous intensity activities 
(>6.0 METs) performed for a particular duration and frequency generate greater energy 
expenditure than moderate-intensity activities (3.0-6.0 METs) of the same duration and 
frequency. When combining the recommendations on moderate- and vigorous-intensity 
physical activity (PA), the daily minimum goal of physical activity (PA) should be in the 
range of 64-107 METs×min.(11)
Recent studies demonstrated that free-living daily PA levels in IC patients are lower 
compared to healthy controls(13-16). However, PA is scantly used as an outcome parameter 
in trials concerning IC treatment(15,17-21). It may be relevant to study the potential benefi-
cial effects of SET on PA level and exercise behaviour in IC patients. If PA levels improve 
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following SET, cardiovascular risk reduction and improved QoL may follow on the long 
term(22,23). Although SET has proven effective in improving walking distances(8,19), one can 
question whether an increased walking capacity is of benefit during the patient’s daily life 
activities. In other words, when an IC patient is able to walk further, this finding does not 
necessarily implicate that PA levels and/or exercise behavior are positively influenced. A 
potential goal of future PAD treatment should perhaps be aimed at increasing physical 
activity.
The aim of this study is to assess the effect of a SET program on PA and walking 
behavior in an IC population. In addition, we hypothesize that a SET induced increased 
walking distance would improve PA levels in IC patients.
Methods
The present study was executed between January 2013 and September 2013. The study 
was conducted following a previous study that was executed to quantify daily PA levels 
and energy expenditure in newly diagnosed IC patients.(16)
Patients were recruited from a population presenting with new onset manifestations 
of IC at outpatient departments of Vascular Surgery of the Catharina Hospital, Eind-
hoven and Maxima Medical Centre, Veldhoven/Eindhoven, The Netherlands. Following 
history taking and a physical examination, patients suspected of IC underwent an ankle-
brachial index (ABI) measurement using standard equipment. Patients with values below 
0.90 at rest or a drop in value of more than 0.15 after a standardised treadmill test (at 3.2 
km/hrs. and a 10% incline) were considered eligible. 
Exclusion criteria were serious cardiopulmonary limitations (NYHA class 3-4), cri-
tical limb ischemia or previous lower-limb amputation, use of walking aids, psychiatric 
instability or other serious comorbidity which possibly limited the patient’s walking abi-
lity. Patients who were treated with invasive revascularizations during follow up were 
excluded as well. Subjects that were willing to participate provided a written informed 
consent. All procedures described in this study were approved by the Medical Ethical 
Committee, Catharina Hospital, Eindhoven.
Study protocol
All participants received a detailed instruction on all specifics regarding proper hand-
ling and wearing of the DynaPort MoveMonitor (McRoberts BV, The Hague, the Nether-
lands) and were asked to wear the device correctly for 7 consecutive days. As the device is 
not waterproof, participants were instructed to remove the device when taking a shower 
or a bath. Participants were also asked to perform their normal daily activities during this 
week and not to wear the device during sleeping. 
A 3 months period of SET was commenced immediately after the first week monito-
ring period. Patients were referred to a local physical therapist, who was trained in pro-
viding SET according to the Royal Dutch Society for Physical Therapy guidelines and the 
Dutch ClaudicatioNet network quality standards(24). The educational program ensured 
that all patients received SET according to the guidelines of the Royal Dutch Society for 
Physical Therapy.(25) The physical therapist assessed a baseline and a 3 months pain-free 
walking distance (PFWD) and maximum walking distance (MWD) using a standardised 
graded treadmill protocol (walking at 3.2 kilometer per hour (km/h) with a 0% incline 
that increases by 2% every 2 minutes till a maximum of 10%).(26,27) Patients were tested 
for a maximum of 30 minutes (1600m). Evidence-based cardiovascular risk management 
including antiplatelet and statin therapy was standardly initiated, in case patients were 
not taking this medication already. After 3 months, SET outcome was discussed with the 
patient followed by a second 7-day period of wearing the DynaPort MoveMonitor.
Monitoring of physical activity and walking impairment
The DynaPort MoveMonitor, a tri-axial seismic accelerometer, was used to measure PA. 
The DynaPort MoveMonitor was placed in a belt that was strapped around the waist. It 
was positioned at the base of the lumbar column just cranial to the buttocks. This accele-
rometer was chosen because of an optimal correlation between indirect calorimetry and 
generated MET output whereas walking speed was correctly measured in a population 
with chronic obstructive pulmonary disease(28). Moreover, this activity monitor was re-
cently validated in an IC population(29). The device consists of a tri-orthogonal orientated 
piezo-capacitive acceleration sensor, a rechargeable battery and removable SD card to 
store the acceleration data. The raw acceleration data lend itself to a pattern recognition 
approach using logical algorithms (MoveMonitor analysis software, version 2.6) for the 
classification of postures (lying, sitting and standing) and motions (locomotion and shuf-
fling). General and specifics of the software were provided in several previously published 
articles(16,30-32).
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A Dutch validated version of the Walking Impairment Questionnaire (WIQ) and a 
36-item Short Form Health Survey version 2 (SF-36) were assessed at baseline and after 
the 3 months of SET treatment.(33-35)
Primary outcomes
• Percentage of participants meeting the ACSM lower limit recommendation for
 PA and public health (67 METs·min a day)
• Percentage of participants meeting the ACSM higher limit recommendation for 
 PA and public health (107 METs·min a day)
Secondary outcomes
• Daily PA level (measured in METs·min)
• Daily PA level performed in bouts of >10 minutes of moderate or vigorous 
 intensity (measured in METs·min)
• Mean time spent per day during different activities (in minutes; lying, standing,
 sitting, walking, shuffling, locomotion, not wearing the device) 
• Mean number of steps walked in one period and maximal number per day (top
 period of steps) 
• Activity per day  (in minutes; sedentary activity: intensity <1.5 METs; light: 1.5-3
 METs; moderate: 3-6 METs; vigorous: 6-9 METs)
• Change in SF-36 values 
Data Analysis
Data checks per patient for each study day were deemed necessary to assure proper use 
of the device. By definition, the device was ‘worn correctly’ during a day if it detected a 
minimum of 20 steps and if it was ‘worn’ ≥9 hours and if it was ‘not worn’ for ≥5 hours 
a day. Moreover, patients were arbitrarily excluded from analysis if the device was worn 
during less than 5 days, to filter out incorrect or unrepresentative data. Mean time that 
was spent per day was determined for each participant depending on the number of ‘cor-
rectly worn days’. Analysis was performed on patients with both a correct baseline and 
follow-up measurement.
Statistical analyses
All analyses were performed using IBM SPSS Statistics Version 21 (SPSS Inc., Chicago, 
IL, USA). Categorical variables are presented as frequencies with percentages. A Pearson 
Chi-Square test was used to identify differences for categorical variables. To obtain an 
impression of the distribution, values were analyzed for skewness and kurtosis. Nominal 
normally distributed variables are depicted as the mean ± standard deviation (SD), while 
non-normally distributed values are reported as median ± interquartile range (IQR). Sta-
tistical differences between the included and excluded study populations were analysed 
with an independent Students T-test, while differences between time periods were cal-
culated with a paired sample T-test or with Pearson correlation coefficients for conti-
nuous normal distributed variables. A Wilcoxon signed-rank test or Spearman’s rho were 
utilized for non-normal distributed continuous variables. A p-value <0.05 was used for 
statistical significance.
Results
Baseline characteristics
A total of 126 IC patients wore the device correctly at baseline and were considered eli-
gible for this study (figure 1). Analysis of the accelerometer data demonstrated that 17 
subjects did not wore the device correctly for ≥5 days at follow up. In six cases the internal 
memory card malfunctioned and data were not stored, another eight participants refused 
a follow up measurement and another 38 subjects were lost to follow up (36.5%). As a 
consequence, data of 57 participants could be used for analysis (45.2%), of which 10 pa-
tients received a vascular intervention during the study period and 6 did not receive SET 
due to inadequate health care insurance. The present study reflects the results obtained 
from 41 patients (35.3% of the total study population). Baseline characteristics regarding 
both the included and excluded study population are depicted in table 1.
ACSM recommendations in IC patients
A total of 18 participants achieved the lower limit of the ACSM recommendations (67 
METs×min a day) and 12 of them even met the ACSM upper limit (107 METs×min a day) 
as well at baseline line. The number of participants meeting the lower limit of the ACSM 
recommendations was significantly lower at baseline (n=18, 43%) compared to the num-
bers at 3 months of follow up (n=26, 63%, p=.003, figure 2). Of the initial 18 participants 
that achieved the lower limit of the ACSM recommendations at baseline, 16 achieved the 
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lower limit at follow up (figure 2) again, while the remaining other two did not. From the 
12 participants who achieved the higher limit of the ACSM recommendations at baseline 
(29%), eight achieved the higher limit again after 3 months (figure 2). In total 14 subjects 
met the ACSM higher limit (34%). 
Daily level of physical activity in IC patients
Mean daily PA level (in METs×min) was normally distributed. No significant difference 
in mean daily PA level was found after 3 months of SET (baseline: 395 ± 220 METs×min 
vs. 3 months: 411 ± 228 METs×min, p=.43; figure 3). Moreover, daily PA levels performed 
in bouts of >10 minutes were also not significantly different after 3 months (p=.13; figure 
3). No significant correlation coefficients were found between the change in mean daily 
PA (METs×min) or mean daily PA in bouts and the increase in MWD (Δmean daily PA 
vs. ΔMWD: r=.21, p=.19; Δmean daily PA in bouts vs. ΔMWD: r=.30, p=.06). 
Time consumption and intensity of various activities 
Table 2 depicts the time consumption and intensity of the various daily activities of IC 
patient. Data was non-normally distributed. No significant changes were found after 3 
months of SET. Analysis of the intensity levels did also not show any significant differen-
ces between baseline and 3-months values (table 2). However, the mean maximal number 
of consecutive steps (top period of steps), which was normally distributed, was signifi-
cantly higher after 3 months of SET (1914 ± 1473 vs. 2390 ± 1904, p<.05).
Walking distances and quality of life
PFWD, MWD and total WIQ score significantly improved following SET (table 3). Mo-
reover, quality of life as reflected by SF-36 scores showed a significant increase in the 
physical functioning (PF) and the bodily pain (BP) role (table 3). No significant correla-
tion was found between the increase in both QoL roles and an improvement in maximal 
walking distance (ΔPF vs. ΔMWD: r=-.07, p=.75; ΔBP vs. ΔMWD: r=.08, p=.73).
Table 1 Baseline characteristics
Total Study population (n=126)
Included patients 
(n=41)
Excluded patients 
(n=85)
P - value
Male (N - %) 20 (48.8%) 49 (57.6%) .45
Both legs symptomatic (N - %) 19 (46.3%) 38 (44.7%) .29
Age (years) (mean ± SD) 69 ± 11 68 ± 10 .42
BMI	(kg/m2) (mean ± SD) 27.4 ± 4.1w 26.7 ± 4.0 .37
Worst ABI in rest (mean ± SD) 0.61 ± 0.20 a 0.63 ± 0.19 d .50
Worst ABI after effort (mean ± SD) 0.43 ± 0.21 b 0.44 ± 0.22 e .85
Duplex right leg c
No lesions 6 (14.6%w) n/a
Aortoiliac 6 (14.6%) n/a
Femoropopliteal 12 (29.3%) n/a
Combination 5 (12.2%) n/a
Duplex left leg c
No lesions 10 (24.4%) n/a
Aortoiliac 4 (9.8%) n/a
Femoropopliteal 12 (29.3%) n/a
Combination 5 (12.2%) n/a
Pulmonary history (N - %) 9 (22.0%) 16 (18.8%) .81
Cardiac history (N - %) 10 (24.4%) 29 (34.1%) .33
Notes: a values based on 38 patients. b values based on 30 patients. c values based on 29 patients.  
 d values based on 82 patients. e	values	based	on	73	patients	n/a	=	(not	available)
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Baseline (n=41)
Median (IQR)
3 months (n=41)
Median (IQR)
P-value
Device worn correctly (days) 7 (6 – 7) 7 (6 - 7)
Time worn (min) 910 (880 – 1006) 932 (899 – 1043) .06 a
Lying (min) 139 (72 – 270) 182 (99 – 270) .27 a
Sitting (min) 462 (390 – 580) 512 (397 – 607) .24 a
Standing (min) 151 (108 – 221) 168 (123 – 209) .40 a
Walking (min) 64 (40 – 87) 61 (42 – 88) .87 a
Shuffling	(min) 20 (13 – 25) 17 (13 – 32) .70 a
Locomotion (min) 89 (61 – 116) 82 (60 – 125) .84 a
Not Worn (min) 529 (434 – 559) 509 (397 – 541) .11 a
Steps (mean ± SD) 5732 (3187) 5805 (3336) .43 b
Top period consecutive steps  
(mean ± SD) 1914 (1473) 2390 (1904) .03 
b
Light activity (min) 66 (50 – 91) 64 (51-91) .29 a
Moderate activity (min) 83 (59 – 107) 81 (58 – 106) .81 a
Vigorous activity (min) 1.3 (0.4 – 6.2) 0.9 (0.4 – 7.9) .97 a
Baseline
Median (IQR)
3 months
Median (IQR)
P-value
PFWD (m) b 210 (113 – 300) 390 (230 – 580) .001 a
MWD (m) c 373 (254 – 631) 637 (403 – 1045) <.001 a
WIQ total score d 0.33 (0.16 – 0.58) 0.54 (0.41 – 0.78) <.001 a
SF-36 d
physical functioning 36.0 (25.5 – 43.9) 38.1 (33.9 – 46.5) .002 a
physical role 42.2 (30.5 – 48.9) 39.8 (32.8 – 52.0) .12 a
bodily pain 41.4 (37.2 – 49.3) 46.1 (37.2 – 50.3) .04 a
general health 41.7 (36.8 – 49.3) 44.8 (38.2 – 51.8) .06 a
vitality 49.0 (43.5 – 61.5) 52.1 (45.8 – 60.7) .35 a
social role 45.9 (35.0 – 56.8) 51.4 (40.5 – 56.8) .11 a
emotional role 48.1 (40.3 – 55.9) 44.2 (36.0 – 55.9) .34 a
mental health 52.8 (44.0 – 61.3) 55.6 (42.3 – 58.5) .85 a
Table 2 Mean daily activities and duration in different intensity levels at baseline and at 
 three months follow up
Notes:  a	Wilcoxon	signed	rank	test,	b	paired	T-test.	Light	activity	=	activity	with	an	intensity	of	1.5-3	METs,	
	 Moderate	activity	=	activity	with	an	intensity	of	3-6	METs,	Vigorous	activity	=	activity	with	an	intensity		
 of 6-9 METs.
Table 3 Quality of Life and walking distances at baseline and at three months follow up
Notes: aWilcoxon signed rank test. bvalues based on 34 patients. cvalues based on 40 patients.  
 dvalues based on 39 patients. 
Figure 1 Flowchart of study population
 
 
Eligible patients with a correct
baseline measurement
(n=126)
Eligible patients for analysis
(n=57)
Included patients for analysis
(n=41)
Exclusion (n=69)
• Not correct worn follow up measurement (n=17)
• refused a follow-up measurement (n=8)
• loss to follow up (n=38)
• SD card failure (n=6)
Not a solely SET regimen
• SET plus vascular surgery (n=10)
• “go home and walk advice” (n=6)
Note: Correct worn: “the device was ‘worn correctly’ during a day if it detected a minimum of 20 steps and  
	 if	it	was	‘worn’	≥9	hours	and	if	it	was	‘not	worn’	for	≥5	hours	a	day.”
Figure 2 Adherence to ASCM minimum recommendation for physical activity and public health  
 (67 METs·min a day) at baseline and at 3 months follow up 
Note: * indicates	level	of	significance	<0.05
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Discussion
In line with the upcoming interest in studying potential associations between daily PA 
and their impact on cardiovascular risk reduction and mortality(36-42), this study assesses 
the effect of SET on proportions of IC patients meeting the ACSM lower and higher limit 
recommendation for PA and public health. Several studies registered activity levels in 
IC patients.(15,17-21) However, this parameter was never considered as a primary outcome 
value. McDermott et al. showed in a 7-day measurement model that IC patients signifi-
cantly improved their PA levels (in activity units) after 6 months of home-based exercise.
(21) These findings might in part be confirmed by the present results. Although our study 
was based on a shorter follow up period and based on supervised therapy, SET increased 
the percentage of IC patients achieving the lower and higher limit of daily PA level as 
recommended in the international ACSM guideline(11). However, firm conclusions can-
not be drawn, since some patients did show a decline in PA level and mean values for 
ambulatory activities (e.g. walking time, total number of steps) were not influenced after 
a period of SET. Probably large variations in activities per patient (duration as well as in-
tensity) and between patients in combination with our relatively small study population 
could have caused this contradiction. Therefore further research is necessary to optimize 
the determination of PA levels in patients suffering from IC. However from our results 
it may be argued that a 3-month SET program may have beneficial effects on increasing 
daily PA in an IC population. 
Figure 3 Mean daily physical activity level at baseline and at 3 months follow up
Note: * Data was normally distributed and analysed with a paired T-test.
It was hypothesized that an increased walking capacity would result in an improved 
PA level of IC patients. Although both the percentage of patients meeting the ACSM 
limits and walking capacity significantly improved after 3 months of SET, no significant 
correlation between the change in PA levels and the increase in walking distance was 
found. Therefore one may argue that components of a SET program other than an incre-
ased walking capacity influence daily PA. Our findings might suggest that solely focusing 
on improvement of walking capacity has a limited value in optimizing SET treatment 
efficacy. It appears that patients who are able to walk further (because of a decrease in IC 
symptoms), will not use this capacity to walk more often, longer or with probably more 
intensity in daily life. 
The effect of SET on QoL is still subject to debate.(8) A recently published meta-analy-
sis found a positive trend in improved QoL after three months of SET, although only the 
SF-36 “general health” role appeared significantly increased.(8) In addition, McDermott et 
al. found no group differences in changes in the SF-12 PCS or MCS subscales.(21) In con-
trast, we found a significant increase in both the physical functioning and the bodily pain 
role after three months of SET. Although patients showed an increased walking capacity, 
no significant correlation in the change of SF-36 values was found. This finding was re-
cently confirmed by others reporting that the improvement in self-efficacy, satisfaction 
with functioning, pain acceptance and social functioning after six months of home-based 
walking exercise compared to a non-exercising control group was independent of wal-
king performance.(43) In combination with our finding that walking capacity might be of 
diminished value, a shift in SET treatment paradigm seems necessary. Future research 
should therefore focus on the optimization of SET programs other than increasing wal-
king capacity alone (intrinsic motivation, life-style, patient satisfaction and expectations, 
social functioning, etc.).
Unfortunately a large number of participants were lost to follow up which may have 
potentially resulted in a selection bias. However, this is probably not the case as any dif-
ferences regarding baseline characteristics between the study group and excluded pa-
tients were found. Furthermore both study groups were a representative reflection of the 
general PAD population encountered in a vascular outdoor clinic. An important reason 
for this substantial loss to follow up is the fact that 56 of the 126 included patients were 
recruited from a previous performed study.(16) Only 23 of these 56 patients were eligible 
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for inclusion, because in the other patients the 3 months follow up period was already 
expired. Furthermore, introducing the Dynaport MoveMonitor from a research setting to 
daily practice in our patient outdoor clinic may boost wear compliance, as was observed 
in comparable research concerning COPD patients.44 Unfortunately, a reliable sub-ana-
lysis between revascularization and SET treatment could not be performed as only 16 
participants did receive such a treatment. Future research is needed to identify the effect 
of different IC treatment modalities on daily PA levels and ambulatory activities.
Conclusion
A 3-month SET program increases the number of patients achieving the ACSM/AHA 
public health minimum recommendations for physical activity (PA). The general focus 
of increasing solely walking capacity seems ancillary to other elements of supervision. 
Further research is needed to determine the optimal content of a SET program. In con-
cert with the interest in factors such as sedentary activities and cardiovascular event risks, 
exercise behavior and PA might be included as outcome parameter in future PAD re-
search and eventually clinical practice.
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General discussion & Summary
Peripheral arterial disease (PAD) is an expression of systemic atherosclerosis. Plaque 
formation causes progressive narrowing and hardening of the arteries. The manifestation 
of PAD is diverse. The vast majority of individuals are asymptomatic whereas only a small 
portion of patients develops tissue loss that necessitates amputation of the affected limb. 
Globally, 202 million people are affected by PAD. The disease is found in 19% of the 
Dutch population >55 years.(1,2) Between 2000 and 2010, the number of patients with 
PAD has increased by nearly a quarter in first, second and third world countries1. In view 
of the association of PAD with loss of mobility, functional decline and cardiovascular 
events, this dramatic increase represents a major public health challenge. Recently, a call 
for governments, nongovernmental organizations and the private sector was made to ad-
dress the social and economic consequences of PAD and to assess the best strategies for 
optimum treatment and prevention of this disease.(1)
Most PAD patients suffer from intermittent claudication (IC).(3) IC is defined as mus-
cle discomfort in the lower limb reproducibly evoked by exercise and relieved by <10 mi-
nutes rest.(3) Most patients with IC are physically impaired. Therefore, treatment goals are 
to relieve symptoms and to improve exercise performance and daily functional abilities. 
PART I – Towards a stepped care approach in intermittent 
claudication
Contemporary guidelines
A number of international guidelines provide recommendations for diagnosis and ma-
nagement of patients with PAD.(3-5) IC patients are at risk for cardiovascular events and 
thus require intensive risk factor modification. Levels of blood pressure, glucose and cho-
lesterol should be optimized. Attention should be paid to smoking cessation as nicotine 
use is the most important modifiable vascular risk factor. Antiplatelet therapy and statins 
are indicated for all IC patients as a means to reduce the risk of cardiovascular events.(6)
To relieve PAD related symptoms, a supervised exercise therapy regimen (SET) is 
advised as an initial treatment modality in these international guidelines.(3-5) Several stu-
dies have demonstrated that some level of supervision is necessary to optimize results. 
Conversely, general and unstructured exercise recommendations that are haphazardly 
provided by a physician do not result in any clinical benefit.(7-10) 
An update
SET is effective as a treatment for IC.(7-10) In chapter 2 a systematic meta-analysis was per-
formed confirming that SET improves maximum treadmill walking distance compared 
to non-supervised exercise therapy regimens. Compared to the 2006 edition,(7) which 
revealed a significant overall effect size of 0.58, an increase to 0.69 was found, correspon-
ding with an approximately 180 meters increase in walking distance favoring the super-
vised group. SET was also beneficial when maximum and pain-free walking distances at 
12 months were considered. However, a significant effect on quality of life parameters as 
evaluated using a SF-36 questionnaire was not found.
A stepped care approach
Supported by this body of evidence, by international guidelines and by the Hippocratic 
oath adagium ‘primum non nocere’, SET should be offered to all IC patients as a first-
choice treatment option.(3-5) Invasive means of limb revascularization, either minimal-
ly invasive (percutaneous transluminal angioplasty, PTA) or by means of conventional 
‘open’ vascular surgery, should only be considered if a patient fails to respond to this 
conservative approach. This so-called stepped care model (SCM) is illustrated in figure 1.
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In chapter 3 it is reported that in 2009 only 14% of the patients were treated with a 
SCM, while 28% of the patients primarily received a revascularization, of which 51% con-
cerned aortoiliac lesions. More than half (58%) were assumed to have received a proven 
inferior non-supervised walking advice (chapter 2). Ambiguities in the TASC II guide-
line may be responsible for a too liberal use of invasive procedures in patients with IC 
due to aortoiliac lesions.(3) The role of invasive interventions as primary treatment for 
this type of lesion is unfortunately still subject of debate in current daily practice. The 
CLEVER trial demonstrated that SET resulted in a superior treadmill walking distance 
after 6 months compared to PTA with stent revascularization in aortoiliac disease, but a 
non-significant greater improvement of disease-specific quality of life in favor of PTA.(11) 
The question that may be asked is: Why do most patients do not receive SET at all? Causes 
are multifactorial and depend on the physician who should prescribe SET as a first line 
treatment, on the patient who should be willing to comply with SET as a first line treat-
ment, and on the health insurer who should reimburse SET.
Reimbursement issues versus costs
Unfortunately, there is no adequate reimbursement policy for IC worldwide.(12,13) Nation-
wide implementation of SET programs was thought to require a substantial investment 
in most countries.(14) Although several cost-effectiveness analyses were performed sup-
porting a SET first treatment strategy(14-19), no study investigated the overall economic 
consequences of a nationwide SCM implementation.
In chapter 3 a cost-analysis is performed ‘as if a SCM (figure 1) was implemented’ in 
the Dutch healthcare system. Costs of IC treatment were calculated and compared to es-
timated costs associated with a theoretical increase of nationwide SCM implementation. 
Invoice data of all patients with IC in 2009 were obtained from a Dutch health insurance 
company (3.4 million members). Patients were divided into three groups based on initial 
treatment as followed after diagnosis (t0). The (first) SET group received SET initiated at 
any time between 12 months before and up to 3 months after t0, which was considered as 
Stepped Care. The (second) intervention group (INT) underwent endovascular or open 
revascularization between t0 and t+3months. The third group (REST) received neither SET 
nor an intervention. All peripheral arterial disease related invoices were recorded during 
2 years, and average costs per patient were calculated. Savings following use of a SCM 
were calculated for 3 scenarios. These scenarios were based on two critical success factors 
(the surgeons’ compliance (willingness) to refer each IC patient to SET and the patient’s 
motivation to participate in a SET program). 
Despite the fact that, according to contemporary international guidelines, all patients 
with IC initially should be referred for SET(3-5), this ratio was hypothetically set to 80% 
(best), 50% (moderate) and 30% (worst) based on reimbursement issues, appreciation of 
SET by vascular surgeons and preference (although evidence to do so is lacking) for a re-
vascularization in certain cases. The patient’s motivation to participate in a SET program, 
which largely depends on level of reimbursement as well as a thorough understanding of 
the benefits of a SET program in comparison to an invasive intervention, was set to 80% 
or 25%. In total, three potential scenarios were considered: best (80%-80%), moderate 
(50%-80%) and worst case (30%-25%).
The percentage of patients who received a SCM in 2009 was 14.1%, while 27.5% and 
58.3% were treated with invasive revascularization, or neither of both, respectively. Wit-
hin two years from t0, invasive revascularization in the SET group was performed in 45 
patients (6.4%). Additional interventions (primary at other location and/or re-interven-
tions) were performed in 480 INT patients (35.2%). Some 431 REST patients received 
additional SET (n=299, 10.3%) or an intervention (n=132, 4.5%). Mean total IC related 
Figure 1 Schematic overview of the Stepped Care Model
Notes: SET: Supervised exercise therapy
 CVRM: Cardiovascular Risk Management
 CNet: ClaudicatioNet
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costs per patient were €2191, €9851 and €824 for SET, INT and REST, respectively. Based 
on a hypothetical worst, moderate, and best case scenario, some 3.8, 20.6 or 33.0 million 
euros would have been saved per year if SCM was implemented in the Dutch health care 
system.
A worldwide extrapolation: Savings up to 1 billion €’s?
Despite limitations inherent to its retrospective character, this cost-analysis study added 
an important finding to the already existing body of solid evidence supporting SET as 
first line treatment for patients with IC. Extrapolation of these results (based on reported 
costs for SET and invasive interventions in the rest of Europe and the USA, having a low 
penetration of (community-based) supervised exercise programs and thus a low thres-
hold for invasive vascular interventions) suggests that savings of around 1 billion euro’s 
may be achieved. 
Are costs really the problem?
Despite the finding that implementation of a SCM is beneficial concerning costs for heal-
thcare insurers (a potential increase of quality of care at lower costs), it may seem that 
patients as well as their physicians are reluctant to embrace a SCM strategy. A significant 
number of claudicants is after a ‘quick fix’ of their problem. Therefore, they are not willing 
to adhere to a lengthy exercise program. They rather prefer a ‘magic polypill’ or a swift in-
tervention. By doing so, the burden that is placed on their personal life is minimal. With 
a SCM, patients are obliged to make a concerted lifetime effort, to change their life-style 
and to increase their ambulatory activities.(20) This is generally not what they expected 
when consulting their physician. Moreover, it’s hard to comply with, as they were typi-
cally sedentary for much or all of their lives.(21)
Another possible explanation of the unpopularity of SET is put forward by the hypo-
thesis that some physicians do not prefer SET.(22,23) Vascular surgeons and interventional 
radiologists are remunerated for the execution of interventions. They opt for these inva-
sive treatments because they are convinced that they optimally serve their patients, they 
like to perform these interventions whereas their skills have to be trained or improved.
(22) The more complex and ‘avant garde’ an intervention is, the better the clinician’s kudos 
within the hospital and at conferences.(22) These sentiments are obviously augmented by 
the medical industry exerting aggressive promotion of new invasive techniques. In con-
trast, SET lacks promotion(16,22). 
Beneficial side effects of a mandatory three-month trial period  
of SET
Above-mentioned statements possibly contributed to our low 14% SCM implementation 
ratio (chapter 3). However, apart from decreasing costs, the SET component of a SCM 
may reduce cardiovascular mortality and morbidity as collateral beneficial side effects.(24) 
Moreover, starting with SET may provide awareness of important functional restrictions 
in daily life other than caused by IC (e.g. COPD, congestive heart failure, osteoarthritis, 
spinal stenosis, equilibrium disorders). As a benefit, SET as a systemic treatment moda-
lity treats both legs. So by following a SCM strategy, potentially futile vascular interven-
tions in polymorbid patients who are limited by more than IC alone may be prevented. 
Implementing a SCM approach, more or less stimulating patients and physicians to try 
‘SET first’, preserving ‘invasive treatment next’ for those not responding to SET, suits well 
in a world with rapidly rising health care system costs(25).
Is SET safe?
A frequently used argument not to refer patients for SET is the matter of safety.(23) Some 
fear the onset of cardiovascular events that may possibly occur during exercise in a po-
pulation with known cerebral and coronary artery disease.(26,27) In a nationwide survey 
among Dutch vascular surgeons, approximately 70% were convinced that coexisting car-
diopulmonary comorbidity and/or aorta–iliac stenosis or occlusion were relative contra-
indications for SET participation.(23) In chapter 4, SET related complications in patients 
with IC were systematically studied in a meta-analysis. A total of 74 articles representing 
82,725 hours of training in 2,876 IC patients met inclusion criteria. Eight adverse events 
were reported, six of cardiac and two of non-cardiac origin, resulting in an all-cause com-
plication rate of 1 per 10,340 patient-hours. It was concluded that SET could safely be 
prescribed to all patients with IC as an exceedingly low all-cause complication rate is 
found during SET. Furthermore, routine cardiac screening prior to commencing SET is 
not advised.
How to increase a Stepped Care approach nationwide? 
It may seem that physicians, healthcare insurers as well as patients do not like SET(22). As 
a consequence, SET is seriously underused as a therapeutic tool for IC in current clini-
cal practice.(12,13) Some also hypothesized a supposed shortage of supervised settings to 
which patients can be referred to, or the necessity for patients to travel to a SET facility 
as potential causes for this underutilization.(12,13) To overcome these potential blockades, 
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a community-based SET program was instigated(28) that appeared effective after 3 and 6 
months.(29) Based on these results, a nationwide community based SET network was initi-
ated providing a 100% SET availability in the Netherlands.(12,30) In chapter 5, this network, 
based on the World Health Organization chronic care framework, is presented in com-
bination with the introduction of innovative technologies to simulate SCM implementa-
tion. This concept termed ClaudicatioNet was launched in 2011 in the Netherlands as a 
means to tackle some of earlier described shortcomings in IC treatment and to stimulate 
cohesion and collaboration between stakeholders.(30) The overall goal of ClaudicatioNet 
is to stimulate quality and transparency of IC treatment by optimizing multidisciplinary 
healthcare chains on a national level. In this model, all patients suffering from IC are 
initially subjected to an extensive community-based SET program performed by a qua-
lified and trained physiotherapist for at least 2-3 months before an invasive procedure 
is proposed (SCM)(30). SET is improved by stimulating both a theoretical and practical 
knowledge base. eHealth and mHealth technologies are used to create insights of pro-
vided care, to enhance quality control management, to facilitate patient empowerment 
and to stimulate life-style change. It is likely and subject of continuous research that the 
ClaudicatioNet concept will create a more efficient and cost effective management of IC. 
Conclusions
The incidence of intermittent claudication (IC) is increasing worldwide whereas health 
care costs are progressively unaffordable (from 13% of national income in 2012 to a cal-
culated 31% in 2040 in The Netherlands)(25). Therefore, potential novel strategies for IC 
prevention and optimum treatment are required.
Current guidelines advocate the use of SET for IC(3-5), as this tool is superior compa-
red to a non-supervised exercise regimen (chapter 2). Moreover, SET is safe (chapter 4), 
possibly even more effective, durable and less harmful than a revascularization (11,17,31-38), 
and certainly less expensive (chapter 3). At present, there is a nationwide availability in 
the Netherlands (chapter 5). However, a contradictory situation concerning the initial 
treatment of IC patients in the Netherlands is at hand. Despite the high availability of 
SET programs, a low referral rate of 14% was found (chapter 3). Although further re-
search would be helpful (and is certainly required), the main blockage of adopting SET 
is apparently not a lack of evidence (other areas of vascular surgery practice have enthu-
siastically embraced other treatment modalities despite a much lower level of scientific 
justification).(22) The patient’s and doctor’s unwillingness and misconceptions to partici-
pate in combination with the anxiety among healthcare insurers all seem to contribute 
SET underutilization and unnecessary health expenditure. The introduction of a Stepped 
Care Model with a mandatory three-months trial period of SET according to the Claudi-
catioNet quality standards might reduce this mismatch and could be beneficial for all sta-
keholders. It must be appreciated that politicians, health care insurers, physicians as well 
as patients should all head in the same direction in order to optimize the implementation 
of this approach. Quality of care is thus increased whereas financial profit is gained. The 
overall consequence of this approach on the Dutch as well as European and USA society 
should be subject of future research.
PART II – Towards new outcome measures in intermittent 
claudication
Diagnosing IC, are there any alternatives around?
Noninvasive diagnostic vascular examinations are often used as adjunctive tools to con-
firm the clinical diagnosis IC or to screen patients who have risk factors for PAD. Cal-
culation of the ankle-brachial index (ABI) is a relatively simple and inexpensive method 
to confirm a suspicion of peripheral arterial disease.(26) A resting ABI measurement with 
additional exercise testing using a standard treadmill test is a simple, inexpensive and 
effective noninvasive diagnostic method for IC with a high sensitivity (79-95%) and spe-
cificity (95-100%).(39) A walking test may seem an obvious choice for eliciting symptoms 
of IC, because an IC patient typically presents with impaired walking rather than for 
example impaired cycling. However, some patients are not able to adequately perform 
treadmill testing, occasionally due to fear (of falling) or due to orthopedic or neurological 
causes precluding walking on a treadmill. Moreover, orthopedic/neurological diseases 
may mimic a clear IC diagnosis as a similar pattern of symptoms may present with these 
disorders during walking. 
Cycling is a non-weight bearing form of exercise, relatively non-moving and possibly 
better tolerated and more discriminating in some of these IC patients. In chapter 6, the 
correlation in ABI values obtained after treadmill testing and bicycle testing in IC patients 
was determined. In a validation study, newly diagnosed IC patients (Rutherford 1-3) un-
derwent a standard treadmill test and two bicycle protocols, one with a continuous re-
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sistance submaximal character and a second with an incremental ramp form, having a 
maximal character. ABI of both legs were obtained prior to and twice after each of these 
three different exercise tests. 
It was concluded that bicycle exercise testing is a valid alternative tool in diagnosing 
patients with IC. Bicycle testing confers additional advantages. The tool is a non-weight 
bearing and non-moving exercise object whereas a cardiovascular screening program can 
also be incorporated. Patients suspected of IC who have contraindications for treadmill 
testing can be accurately diagnosed using a bicycle-test. Submaximal testing is preferred 
to maximal testing because of optimal sensitivity and specificity characteristics whereas 
the risk on (cardiovascular) complications is lowest. 
Contemporary determination of IC treatment effectiveness 
Current IC treatment strategies, described in international guidelines(3-5), are mainly 
based on trials using the limitation in walking distance as primary outcome value. Howe-
ver, the value of various walking distance assessments is disputed. For instance, a patient’s 
estimation of walking distance does not properly reflect objectively measured daily life 
walking distances.(40-43) A disease specific questionnaire such as the Walking Impairment 
Questionnaire (WIQ) may quantify walking impairments in IC patients better although 
correlations with walking distances appeared weak.(41) Standardized treadmill tests are 
widely used as an objective assessment of walking distances.(3-5) However, there is a sub-
stantial variability in treadmill protocols (chapter 2) whereas a relatively artificial mea-
sure of walking capacity is tested.(44) In chapter 7, results of walking distances in a group 
of IC patients using four different tools (a graded and a non-graded treadmill protocol, 
patient estimations and outside walking) that are frequently used by physical therapists 
in the assessment of IC severity are compared in a single model.
In chapter 7 it is illustrated that walking speed is of importance in the determination 
of walking capacity in an IC population. But above all an important piece of evidence is 
added to the discussion whether treadmill testing should be used as primary outcome 
measurement to determine treatment effects in future PAD trials. Researchers should 
realize that the frequently used MWD as primary outcome measurement demonstrates 
a substantial variability. A single MWD assessment may not be a proper reflection of 
walking impairment in IC patients and may certainly not correspond with (daily life) out-
side walking. Furthermore, self-reported walking capacity appeared a poor reflection of 
objectively measured MWD.(40-42,45) Moreover, the value of both assessments is debatable 
as these parameters merely provide insight into walking capacity, a parameter that not ne-
cessarily corresponds with patient-perceived disability.(41,46) Future research should there-
fore focus on patient-reported outcomes of perceived disability and burden of disease, 
as both can be of more importance than a determination of walking capacity. If walking 
(exercise) capacity is monitored, it should be measured over prolonged periods of time to 
provide a more reliable reflection of a patients’ walking impairment. A 6-minute walking 
test, a shuttle walking-test or GPS-based accelerometers (physical activity monitors) may 
be better alternatives to treadmill testing. 
Physical activity as an alternative outcome measure in IC
The fact that treadmill test results and ambulatory functions do show inconsistencies im-
plies that an increased walking capacity does not automatically change a patients’ exercise 
behaviour.(41,44) Others have previously suggested that changes in treadmill test results 
do not properly reflect symptom relief after revascularization interventions for claudica-
tion.(47) A call was made for future studies to focus on quality of life parameters or other 
disease-specific functional outcomes to determine the effect of IC treatment modalities 
(chapter 2&7).(20,43) Moreover, in line with the upcoming interest in studying potential 
associations between daily physical activity (PA) and impact on cardiovascular risk re-
duction and mortality(48-54), it may be more relevant to include PA as outcome measure 
in future IC research. IC is closely associated with cardiovascular and cerebrovascular 
disease,(3,55,56) and improved levels of PA might result in cardiovascular event risk reduc-
tion on the long term.(57,58) 
Nowadays, PA levels can be obtained with activity monitors. Tri-axial accelerometers 
measure accelerations in three dimensions that can be converted into intensities and me-
tabolic equivalents (METs) enabling a quantification of overall PA. A MET is an estimate 
of oxygen consumption at rest. A three-MET activity would be an activity that utilizes 
roughly three times the amount of resting energy expenditure. When combining the re-
commendations on moderate- and vigorous-intensity physical activity, the daily mini-
mum goal of PA should be in the range of 64-107 METs·min.(59) 
The Dynaport MoveMonitor is an activity monitor that measures PA in METs, is ea-
sily applicable in a daily life setting and is optimized for clinical research assessments. 
The MoveMonitor was previously validated in an elderly population60 as well as for Par-
kinsons disease(61,62) and COPD(63-65). In chapter 8, the MoveMonitor is validated in an IC 
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population in a near real-life setting. It was concluded that the MoveMonitor provides 
accurate information on a diverse set of postures, daily activities and number of steps in 
IC patients. This tool is useful to assess the role of physical activity as a novel clinically 
relevant outcome parameter in IC.
Physical activity levels of claudicants versus healthy individuals
Compared to healthy adults, IC patients are burdened with a low health-related quality of 
life and functional impairment during daily activities.(66,67) Individuals who are regularly 
physically active report better overall health, lower health care expenditures and fewer 
mobility limitations than their sedentary counterparts.(68,69) The American Heart Associ-
ation (AHA) and the American College of Sports Medicine (ACSM) provide specific re-
commendations of various types of activity to stimulate the elderly. Tailored recommen-
dations are suggested that apply to adults with clinically-significant chronic conditions 
or functional limitations that affect mobility and activity.(59) In chapter 9, we quantified 
daily PA level and energy expenditure of newly diagnosed patients with IC and healthy 
controls. In conclusion, more than half of the patients with IC do not meet recommended 
standards of PA. Considering the serious health risks associated with low PA levels, these 
findings underscore the need for more awareness to improve physical exercise in patients 
with IC.
The impact of SET on physical activity level in IC patients.
Since SET is the first choice option in the treatment of IC(3-5) and as it is the cornerstone 
of a SCM, it may be relevant to study the potential beneficial effects of SET on PA level 
and exercise behaviour in IC patients. Moreover, SET offers patients at least 25 full hours 
of counseling with a specialized physiotherapist trained in motivation interviewing and 
life-style change. We do know that SET significantly improves the maximal and pain-free 
walking distance in IC (chapter 2), SET possibly leads to significant savings in our health-
care system (chapter 3) and that SET is proven to be cost-effective based on the change in 
walking distance.(14-19) However, the question arises whether effectiveness of IC treatment 
modalities should be evaluated on the basis of changes in walking capacity only (chapter 
2&7&8). In chapter 9 it was demonstrated that free-living daily PA levels in IC patients 
are lower compared to healthy controls.(70-73) Despite these findings, PA is scantly used 
as an outcome parameter in trials concerning IC treatment, a fact that was previously 
reported by other researchers in this field.(9,72,74-77) If PA levels improve following SET, 
cardiovascular risk reduction and improved Health related Quality of Life (HrQoL) may 
follow on the long term.(57,58) Therefore, the effect of a SET program on PA, HrQoL and 
walking behavior in an IC population was assessed in chapter 10. We hypothesized that 
a SET induced increased walking distance would also improve PA levels in IC patients. A 
total of 41 newly diagnosed IC patients were requested to wear an activity monitor one 
week prior to and one week immediately following 3 months of SET. 
A 3-month SET program was found to increase the number of patients achieving the 
ACSM/AHA public health minimum recommendations for physical activity (baseline: 
43%; 3 months: 63%, p= .003). However, firm conclusions could not be drawn, since 
some patients did show a decline in PA level or mean values for ambulatory activities 
after a period of SET. Probably large variations in activities per patient (duration as well 
as intensity) as well as between patients could have caused this contradiction. Moreover, a 
relatively small population was studied. Further research with larger populations is neces-
sary to study PA levels in patients suffering from IC. 
Future perspectives
It seems that solely focusing on exercise capacity such as maximal walking distance or 
time in the determination of effectiveness of IC treatment strategies seems insufficient. In 
chapter 8&9 it was demonstrated that PA is correctly measured with an activity monitor 
whereas IC patients show less activity levels as advised in the international guidelines 
compared to healthy adults. Increasing PA levels in an IC population may have beneficial 
effects. SET seems promising in achieving to do so (chapter 10). Surprisingly, no signi-
ficant correlation between the change in PA levels and the increase in walking distance 
was found (chapter 10). Therefore one may argue that components of a SET program 
other than an increased walking capacity do influence daily PA. It appears that patients 
who are able to walk further (because of a decrease in IC symptoms), will not use this 
capacity to walk more often, longer or with probably more intensity in daily life. In ad-
dition, no significant correlation between the increase in walking capacity and the change 
of SF-36 values was found (chapter 10). This finding was recently confirmed by others.(78) 
They reported that the improvement in self-efficacy, satisfaction with functioning, pain 
acceptance and social functioning after six months of home-based walking exercise com-
pared to a non-exercising control group was independent of walking performance. In 
combination with our finding that walking capacity might be of diminished value, a shift 
in both SET treatment and primary research outcomes seems necessary. Nordanstig et al. 
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were one of the first to use HrQoL as primary outcome in the recently published IRONIC 
(Invasive Revascularization or Not in IntermittentClaudication) trial.(79) Apparently the 
call for and use of patient-centered outcomes is beginning to proliferate in medicine.(80) A 
patient’s assessment of how quality of life is affected by both the disease and its treatment 
is very important. Future research should therefore primarily focus on the change in Hr-
Qol and the reliable assessment of (disease-specific) HrQoL.
What other directions should future research take? SET programs require optimiza-
tion. Factors such as intrinsic motivation, life-style change, patient satisfaction and ex-
pectations and social functioning should be subject of research other than the optimiza-
tion of increasing walking capacity alone. We should concentrate on changing a patients’ 
exercise behavior in daily life (life-style change) by tailoring SET to a patients needs 
(shared-decision making). Expectations of an IC patient should be leading in treatment. 
Moreover, a SET physiotherapist should address the change of a patients’ walking pattern 
and combine different modes of exercise.(81) One may also consider the effect of initiating 
exercise programs in a home-based environment, thereby diminishing the amount of 
labour-intensive supervision.(82,83) Two recent published trials and a meta-analysis revea-
led promising results regarding the effect of such an approach.(75,77,78,84) Future research 
should also be aimed at the optimal mixture of supervised and home-based programs in 
combination with evolving eHealth and mHealth technologies (activity monitors, smart-
phones, apps; chapter 5). This endeavor is likely to result in an optimal treatment strategy, 
both from a patient’s perspective as well as from a cost-effectiveness perspective.
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Introductie
Perifeer arterieel vaatlijden (PAV) wordt veroorzaakt door atherosclerose (slagader-
verkalking). Het symptomenspectrum van PAV is sterk heterogeen en varieert van ziekte 
zonder klachten tot weefselversterf (gangreen). Claudicatio intermittens is een veel voor-
komend symptoom van PAV en betekent letterlijk ‘intermitterend hinken’. Claudicatio 
treedt op bij het stadium van PAV waarin patiënten pijn hebben bij het lopen die nood-
zaakt tot stoppen. Waar in rust de zuurstofvoorziening van de beenspieren nog volstaat, 
kan bij lopen aan de toegenomen zuurstofbehoefte onvoldoende worden voldaan. Na 
een stuk lopen moeten ‘claudicanten’ stoppen omdat zij pijn ervaren. Omdat claudicatio 
niet alleen de actieradius beperkt, maar ook de mens in zijn totale functioneren belem-
mert, gaan patiënten deze klachten maskeren, bijvoorbeeld door tijdens het gedwongen 
stilstaan net te doen of een etalage wordt bekeken. In de volksmond wordt bij claudicatio 
intermittens gesproken van ‘etalagebenen’. De veroorzakende atherosclerose komt uitein-
delijk bij alle mensen voor maar meer naarmate men ouder wordt. Een aantal factoren 
versnelt dit proces; roken en een ongezonde leefstijl zijn de grootste boosdoeners. 
In Nederlands populatieonderzoek onder 55-plussers, werd de prevalentie van PAV 
geschat op 19,1%.(1) Voor de Nederlandse situatie wordt uitgegaan van 800.000 tot een 
miljoen mensen met PAV. Per jaar komen er 25.000 nieuwe CI patiënten bij.(2) Bij pa-
tiënten met PAV is de levensverwachting ongeveer tien jaar verkort. Dit wordt met name 
veroorzaakt door sterfte aan andere hart- en vaatziekten dan perifeer arterieel vaatlijden, 
allen veroorzaakt door atherosclerose. (3-5)
De behandeling van CI rust op twee pijlers. De eerste pijler is cardiovasculair risi-
comanagement, waarmee alle acties worden bedoeld die het genoemde verhoogde ri-
sico op vroegtijdig overlijden of ernstige invaliditeit verkleinen. Dat wil zeggen, leefstijl 
aanpassingen als stoppen met roken, gezonde(re) voeding, meer bewegen. Maar ook 
medicamenteuze behandeling zoals met een plaatjesremmer, een cholesterolverlager, 
bloeddrukverlager(s) en adequate regulatie van eventueel aanwezige diabetes mellitus. 
De tweede pijler is een symptomatische behandeling gericht op vermindering van de 
voornaamste klacht, het slechte lopen. Hierbij kan gekozen worden voor een conservatie-
ve of een invasieve behandeling, of voor een combinatie van beiden. Onder conservatieve 
behandeling (looptherapie) verstaan we alle acties gericht op het toe laten nemen van de 
loopafstand, de ervaren mobiliteit, de mate van onafhankelijkheid en de aanwezige be-
invloedbare slechte leefstijlfactoren. Onder looptherapie  worden verschillende vormen 
verstaan.(6) Bij ‘niet-gesuperviseerde’ looptherapie wordt de patiënt (passief) gewezen op 
het feit dat hij meer moet bewegen, soms wordt een folder meegeven. Bij ‘gesuperviseer-
de’  looptherapie (GLT) wordt de patiënt meerdere malen per week (actief) begeleid door 
een getrainde vaatverpleegkundige of fysiotherapeut. Daarnaast bestaat een zo genoemde 
‘home-based’-variant, waarbij de patiënt zonder direct contact wordt begeleid. Te den-
ken valt dan aan logboeken, telefonisch contact of het gebruik van web-based applicaties 
(apps of (video)-chats). Invasieve behandelingen zijn onder te verdelen in minimaal in-
vasieve, ook wel endovasculaire procedures (PTA, percutane transluminale angioplasty, 
‘dotteren’ in de volksmond) en conventionele ‘open’ vaatchirurgische ingrepen.
PART I – Op weg naar stepped care in de behandeling  
van claudicatio intermittens
Wat is nu de optimale behandelingsstrategie voor een  
patiënt met CI? 
In hoofdstuk 2 wordt in een update van een Cochrane meta-analyse uit 2006 de effecten 
van gesuperviseerde versus niet-gesuperviseerde looptherapie op de loopafstand en kwa-
liteit van leven geëvalueerd bij patiënten met PAV.7 In de meta-analyse werden 14 studies 
geïncludeerd met in totaal ruim 1000 patiënten. De follow-up van de studies varieerde 
van 6 weken tot 12 maanden. GLT toonde significante en klinische relevante verschillen 
tot 180 meter in verbetering van de maximale loopafstand vergeleken met niet-gesuper-
viseerde looptherapie. Verschillen in kwaliteit van leven konden niet worden aangetoond 
tussen beide therapieën, wellicht omdat een beperkt aantal studies (50%) kwaliteit van 
leven hadden geregistreerd. Onze analyse laat zien dat het effect van GLT groter is dan 
werd aangenomen in de review uit 2006.  Bovendien kan geconcludeerd worden dat meer 
onderzoek nodig is om de effecten van een toegenomen loopafstand op de kwaliteit van 
leven aan te tonen. Hierbij valt ook te denken aan de introductie van nieuwe, meer ziekte-
gespecifieerde uitkomstmaten. 
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Een “stepped care” behandeling
In hoofdstuk 3 wordt een innovatieve landelijke strategie geïntroduceerd om de be-
handeling van claudicatio intermittens te optimaliseren.(2,8) In dit zogenoemde “stepped 
care” of wel “getrapte behandeling”- model ontvangen patiënten een behandeling, die 
niet zwaarder (risicodragend) is dan noodzakelijk. Het model is gebaseerd op vigerende 
richtlijnen(9-11), de meest recente literatuur en het eeuwenoude adagium ‘primum non 
nocere’ (‘first do no harm’). Samenvattend houdt het een ‘verplichte’ start in met ten-
minste 3 maanden GLT (figuur 1, hoofdstuk 11). Tijdens dit traject wordt veel aandacht 
besteed aan het beïnvloeden van aanwezige risicofactoren voor hart- en vaatziekten. Pas 
bij falen van dit traject, in de zin van een discrepantie tussen gewenste en bereikte loop-
afstand, wordt nadere diagnostiek gedaan en gekeken of een endovasculaire behandeling 
kan worden aangeboden.
Uit declaratiedata uit het jaar 2009 van een grote Nederlands zorgverzekeraar bleek 
dat slechts 14% van de PAV patiënten in Nederland werd behandeld volgens het step-
ped care model (hoofdstuk 3). De overige 28% werd direct een interventie aangeboden 
en 58% kreeg  een niet nader gespecificeerd loopadvies (hoofdstuk 2). In de internatio-
nale literatuur wordt het niet beschikbaar zijn van GLT programma’s vaak als argument 
gebruikt om patiënten dan maar te behandelen met een PTA dan wel een loopadvies. 
Ondanks dat in Nederland een landelijk dekkend netwerk voor GLT beschikbaar is, werd 
in 2009 ook in Nederland niet volgens deze internationale richtlijnen gewerkt.(9-11) De 
oorzaak hiervan is multifactorieel; sommige vaatchirurgen behandelen (al dan niet speci-
fieke categorieën patiënten) primair met een PTA.(12) Daarnaast blijkt GLT vaak niet (vol-
ledig) vergoed te worden. Dit in tegenstelling tot een invasieve behandeling, die wel tot 
de basiszorg wordt gerekend. Onder druk van steeds nieuwe en dokters- aansprekende 
invasieve behandelmogelijkheden en de ongefundeerde aanname van patiënten en soms 
zelfs behandelaars dat CI eenvoudig en doeltreffend primair invasief behandeld kan wor-
den, wordt de drempel tot primaire invasieve behandeling van CI verlaagd.
Vergoeding versus kosten
In de budget-impact-analyse van hoofdstuk 3 wordt het “stepped care model” toegepast. 
Drie hypothetische scenario’s werden doorlopen. Deze 30-50-80 procent scenario’s wer-
den gebaseerd op verwijsgedrag en vergoeding (compliance). Het best-case scenario be-
stond zo uit de situatie waarin  80% van de patiënten met CI werd  verwezen, gevolgd 
door 80% compliance (vergoeding en continuering van een traject GLT). Patiënten wer-
den op basis van hun initiële behandeling (2009) na tijdstip van diagnose (t0) ingedeeld 
in drie groepen. De GLT groep kreeg gesuperviseerde looptraining in de 12 maanden 
voor t0 of 3 maanden na t0. De interventie groep (INT) kreeg een endovasculaire of open 
revascularisatie tussen t0 en t3mnd. De derde groep (REST) kreeg noch GLT noch een in-
terventie in de eerste drie maanden. Alle PAV gerelateerde facturen werden geanalyseerd 
gedurende 2 jaar na t0. Daaruit werden de gemiddelde kosten per patiënt per groep be-
rekend. Implementatie van het stepped care model werd berekend voor drie scenario’s 
(worst-, moderate, best-case). 
Er werden 4954 patiënten geïncludeerd. Initiële behandeling was GLT (n=701, 14.1%), 
INT (n=1363, 27.5%) of REST (n=2890, 58.3%). Een invasieve behandeling werd bij 45 
patiënten (n=6.4%) in de GLT groep in tweede instantie alsnog aangeboden en bij 480 
patiënten in de INT groep (35.1%). Van de REST groep kregen 431 patiënten alsnog een 
aanvullende behandeling (GLT: n=299, 10.3%) en/of een revascularisatie (n=132, 4.5%). 
De gemiddelde kosten voor de groepen waren €2191, €9851 en €824 voor respectievelijk 
de GLT, INT en REST groep. Afhankelijk van het gekozen scenario (worst-moderate-
best) werd bij implementatie van een stepped care model in de Nederlandse situatie een 
jaarlijks besparing potentieel  van 3.8, 20.6, of 33.0 miljoen euro berekend. 
De resultaten van deze studie bevestigen eerder gepubliceerde directe kosteneffec-
tiviteit vergelijkingen tussen GLT en invasieve interventies.(13-16) Implementatie van een 
stepped care model bij de behandeling van patiënten met claudicatio intermittens leidt tot 
significante kostenbesparingen. Een reductie van interventie geassocieerde mortaliteit en 
morbiditeit in deze patiëntenpopulatie is te verwachten. Het aantal interventies en het 
aantal daarmee geassocieerde complicaties kent immers een lineair verband. Alhoewel 
dit laatste niet onderzocht is in dit proefschrift, tonen anderen deze effecten wel aan.(17) 
Ongekende voordelen van een stepped care aanpak
Naast een verschil in kosten, brengt een stepped care aanpak ten opzichte van een direct 
invasief alternatief meer voordelen met zich mee. Zo wordt bij stepped care niet alleen 
het aangedane been getraind, maar ook het op dat moment (mogelijk) geen klachten 
gevende, andere been. Dat geldt ook voor het tegelijk (mee) trainen van hart en longen 
(de cardiopulmonale conditie), hetgeen weer een positief effect heeft op de overleving 
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en het verlagen van het risico op cardiovasculaire events.(17) Effecten die weliswaar niet 
werden aangetoond in dit proefschrift, maar kunnen worden afgeleid uit onderzoek naar 
interventies gedaan door anderen.(18-20)
Een tot op heden nauwelijks onderkend en daardoor onbenut voordeel is dat een 
gesuperviseerd traject met ongeveer 20-25 ‘contacturen’ gepaard gaat. In deze tijd kan 
een daartoe speciaal opgeleide en getrainde claudicatio-therapeut patiënten begeleiden 
bij leefstijlaanpassingen als stoppen met roken, het belang van medicatie compliance, 
een gezond dieet en meer bewegen naast de looptraining.(19) Samen trainen en lotgeno-
tencontact kunnen ook worden gestimuleerd door deze getrainde behandelaar. Super-
visie wordt daarmee supervisie ‘plus’, of ook wel een “ClaudicatioNet traject” genoemd 
(hoofdstuk 5). Daar waar bij een ‘PTA-eerst’ behandeling weliswaar een sneller effect kan 
worden bereikt betreffende de loopcapaciteit, wordt een patiënt de kans ontnomen om 
deze minstens zo belangrijke voordelen te benutten. 
GLT kent nog een voordeel. Wanneer wordt overgegaan tot een primair invasieve 
behandeling is dit gebaseerd op de klacht van de patiënt (de anamnese), het verrichte 
lichamelijk onderzoek en aanvullende, beeldvormende diagnostiek. De klachten van de 
patiënt worden in dit diagnostisch proces gerelateerd aan de bevindingen bij beeldvor-
mende diagnostiek. In een dergelijk, decennia bestaand deductief proces was tot recent 
geen ruimte voor het proefondervindelijk signaleren van limiterende klachten die niet 
veroorzaakt worden door PAV. De zo bij een PAV patiënt eveneens aanwezige en mis-
schien wel oorzakelijk limiterende klachten, bijvoorbeeld van het bewegingsapparaat, 
van cardiopulmonale of van neurogene oorzaak, blijven zo onontdekt. Dit is belangrijke 
informatie die idealiter moet worden onderzocht voordat de optie van een invasieve be-
handeling wordt overwogen. Een fysiotherapeut komt hier in de eerste GLT behandelin-
gen proefondervindelijk achter, om zo zijn therapie aan te passen.
Is GLT veilig?
In hoofdstuk 4 van dit proefschrift concluderen wij dat GLT veilig is en kan worden 
voorgeschreven aan alle patiënten met CI. In een systematische review van 74 artike-
len worden op een totaal van 82.725 trainingsuren van 2.876 patiënten, 8 adverse events 
gerapporteerd. Hiervan bleken 6 cardiovasculair gerelateerd.. Uiteindelijk wordt zo een 
complicatie-ratio van 1 op de 10.340 GLT trainingsuren gevonden. Dit lage getal moet 
worden afgezet tegen het risico op een myocardinfarct of een significante beroerte na een 
endovasculaire (infra-inguinale) behandeling (respectievelijk een totaal van 0.7%).(21,22) 
Ondanks dat dit relatief lage complicatie percentages zijn, moeten deze wel gerelateerd 
worden in het licht van de grote hoeveelheden interventies wereldwijd. Zo laten wij in 
hoofdstuk 3 zien dat er ongeveer 25.000 nieuwe claudicanten per jaar bij komen. 
De landelijke implementatie van het stepped care model
De vraag voor de komende jaren luidt dan ook; ‘hoe krijgen wij alle neuzen dezelfde 
kant op?’. Hoe kunnen wij de behandeling van patiënten met claudicatio intermittens via 
het stepped care model verhogen? Een belangrijke aanzet daartoe werd gedaan in 2011 
met de oprichting van ClaudicatioNet.(23) De stichting ClaudicatioNet beoogd het cre-
eren van een zorgmodel waarin evidence-based zorg geleverd wordt aan een geïnfor-
meerde en actief participerende centraal staande PAV patiënt. ClaudicatioNet faciliteert 
daarmee in feite een geïntegreerd zorgnetwerk dat patiënten en behandelaars (bijv. vaat-
chirurgen, huisartsen, fysiotherapeuten) met elkaar in contact brengt. De stepped care 
aanpak wordt hiermee geïmplementeerd in het Nederlandse zorgsysteem. Transparante, 
kwalitatief hoogwaardige, wetenschappelijk bewezen  en doelmatige zorg voor alle pa-
tiënten met PAV creëren, is het doel. De stichting beschikt over een landelijk dekkend 
netwerk van geschoolde fysio- en oefentherapeuten die een driejarig specialisatietraject 
doorlopen.(23) Met eHealth- (en in de nabije toekomst ook mHealth) wordt inzicht ver-
kregen in de kwaliteit van geleverde zorg. Niet alleen de patiënt krijgt op deze wijze feed-
back over zijn of haar vorderingen, maar ook de therapeut en verwijzer kunnen worden 
‘gebenchmarkt’ met hun ‘peers’. In hoofdstuk 5 worden enkele van deze processen en 
diensten beschreven. 
Conclusie
De incidentie van het aantal patiënten met PAV zal de komende jaren stijgen.(24) De com-
binatie van frequenter voorkomen, een hoge kans op een fatale of invaliderende vascu-
laire gebeurtenis (hart- en/of herseninfarct), en een steeds duurder wordende behande-
ling, maakt dat PAV ondertussen een belangrijk gezondheidszorg probleem is geworden. 
Zeker in het licht van de verwachting dat de nationale zorgkosten exponentieel zullen 
stijgen (13% van 2012 bruto nationaal product naar 30% in 2040).(25) Huidige richtlijnen 
adviseren GLT boven niet-GLT of een interventie als primaire behandeling voor claudi-
catio (hoofdstuk 2).(9-11) Bovendien is GLT veilig (hoofdstuk 4) duurzamer, goedkoper, 
gaat het gepaard met minder complicaties en is zeer waarschijnlijk effectiever vergeleken 
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met een invasieve ingreep (hoofdstuk 3).(15,26-34) Alhoewel meer onderzoek naar de effec-
tiviteit van gesuperviseerde looptraining binnen het stepped care model noodzakelijk is, is 
landelijk gereguleerde implementatie van het concept niet te berusten op een gebrek aan 
literatuur. Zeker als men een vergelijking maakt naar de toepassing van andere behande-
lingen in de vaatchirurgie, die al snel omarmt worden bij een lager level of evidence. De 
ongefundeerde aanname van patiënten en verwijzers en daarmee ook de verzekeraar dat 
CI eenvoudig en doeltreffend primair invasief behandeld kan worden, lijkt de oorzaak 
te zijn voor het lage aantal verwijzingen naar GLT. De introductie van het stepped care 
model met een verplichte 3 maandelijkse periode GLT volgens het ClaudicatioNet prin-
cipe zal er dan ook voor zorgen dat de huidige richtlijnen in praktijk worden gebracht. 
Betrokken partijen zullen de handen ineen moeten slaan om de zorg voor de patiënt met 
etalagebenen in de komende jaren te optimaliseren. Deze thesis kan dienen als opmaat 
hiervoor en is een duidelijke handreiking naar betrokken stakeholders.
PART II – op weg naar nieuwe uitkomstparameters bij  
claudicatio intermittens
Diagnosticeren van claudicatio, kan het ook anders?
Verlaagde enkel–arm index (EAI) waarden in rust (<0.9, normaal >1.0) of na inspanning 
op een loopband (Δ >0.15) worden gehanteerd om PAV aan te tonen. Echter, sommige 
patiënten die verwezen worden voor een diagnostische loopbandtest kunnen deze niet 
ondergaan door ernstige co-morbiditeit of angst voor lopen op de loopband. Vaak kun-
nen deze patiënten wel fietsen. In hoofdstuk 6 werd een fietstest gevalideerd om claudi-
catio intermittens te diagnosticeren. In een prospectieve validatiestudie ondergingen 32 
patiënten met bewezen PAV een standaard conventionele looptest en twee verschillende 
fietsprotocollen, een submaximale fietstest en een maximale fietstest. EAI waarden werd 
geregistreerd in rust en tweemaal na iedere inspanningstest. Controledata werd verkre-
gen bij 13 individuen zonder PAV. Er werd geconcludeerd dat zowel een submaximale als 
een maximale fietstest bruikbare methoden zijn om PAV aan te tonen en kunnen worden 
gebruikt bij personen die een conventionele looptest niet kunnen ondergaan. Een sub-
maximale fietstest lijkt superieur aan een maximale fietstest. Bovendien lijkt een fietstest 
voordelen te bieden ten opzichte van een conventionele looptest. Fietsen op een ergome-
ter is gewichts-onafhankelijk (geen belasting voor de gewrichten) en is een “non-moving” 
oefening (dus goed bruikbaar voor patiënten met evenwichtsproblemen). Tevens bestaat 
de mogelijkheid de fietstest te combineren met een screening op cardiovasculaire patho-
logie.  
Effectiviteitsmeting bij de behandeling van  
claudicatio intermittens
Belangrijk onderdeel in de evaluatie van wetenschappelijk onderzoek, maar ook in het 
toepassen van de fysiotherapeutische behandeling bij claudicatio, is het toepassen van 
betrouwbare en valide meetinstrumenten. De meest gebruikte uitkomstmaat in onder-
zoek naar PAV is op dit moment de maximale of pijnvrije loopafstand of -tijd. De waarde 
van deze uitkomstmaat staat echter ter discussie. Het uitvragen van de loopafstand blijkt 
geen objectieve maat te zijn voor de daadwerkelijk gelopen afstand in het dagelijks le-
ven.(35-38) Specifieke vragenlijsten, zoals de Walking Impairment Questionnaire (WIQ) 
lijken beter te functioneren, maar ook hier blijven de correlaties met de daadwerkelijk 
gelopen afstand zwak.(36) Loopbanden worden daarom veelal gebruikt om de afstand ob-
jectief te bepalen.(9-11) Echter, er blijkt een grote verscheidenheid aan loopbandprotocol-
len te bestaan (hoofdstuk 2). Daarnaast wordt de meting niet verricht in het dagelijks 
leven maar in een voor de patiënt onnatuurlijke omgeving.(39) In hoofdstuk 7 wordt de 
overeenkomst bepaald tussen de daadwerkelijk buiten gelopen loopafstand, de bij twee 
loopbandprotocollen gemeten loopafstand en de door de patiënt geschatte loopafstand. 
Er werd geconcludeerd dat patiënten met claudicatio intermittens hun maximale loopaf-
stand overschatten, en dat deze verschillen mogelijk verklaard kunnen worden door een 
verschil in loopsnelheid. Echter, het belangrijkste is dat bevestigd wordt dat een resultaat 
van een loopbandtest mogelijk geen betrouwbare uitkomstmaat geeft. Zeker niet in on-
derzoek wat gericht is op het vaststellen van behandelingseffecten voor PAV. Bovendien 
geeft de loopafstand alleen inzicht in de mate van fysieke capaciteit. Het verhogen van 
deze capaciteit impliceert niet vanzelfsprekend dat de patiënt ook meer gaat bewegen 
(= activiteit). Daarbij is de toename in kwaliteit van leven niet per definitie gecorreleerd 
aan de toename van de loopcapaciteit (hoofdstuk 7).  Al deze methodologische beperkin-
gen leiden tot een lagere validiteit van deze uitkomstmaat dan gewenst. Een alternatieve 
maat, waarbij over langdurige tijd de activiteit van een claudicant gemeten kan worden, 
zou uitkomst kunnen bieden.
Algemene discussie & Samenvatting
251
12
Innovative strategies for intermittent claudication 
250
12
Fysieke activiteit als alternatieve uitkomstmaat in CI
We zien dus verschillen tussen loopbandresultaten en het dagelijkse beweeggedrag van 
patiënten. Een toegenomen loopcapaciteit betekent niet automatisch dat een patiënt ook 
meer gaat bewegen.(36,39) Anderen lieten eerder zien dat ook het effect van een revascula-
risatie op claudicatio-symptomen niet terug te zien is op loopbandresultaten.(40) Onder-
zoekers laten daarom regelmatig doorschemeren dat de nadruk in toekomstig onderzoek 
meer moet liggen op “kwaliteit van leven”- parameters en ziekte-specifieke vragenlijsten 
om zodoende het effect van CI behandelingen beter te kunnen vergelijken (hoofdstuk 
2&7).(38,41) Bovendien is maatschappelijk gezien ook meer interesse in dagelijkse fysieke 
activiteit en het gevolg daarvan op het verlagen van de cardiovasculaire morbiditeit en 
mortaliteit.(42-48) Een logisch vervolg is dan ook om fysieke activiteit als uitkomstwaar-
de te bestuderen in PAV onderzoek. Men weet dat CI nauw gerelateerd is aan hart en 
vaatziekten(11,49,50), een verhoging van de mate van fysieke activiteit kan daarom resulte-
ren in een verlaging op het krijgen van een van deze ziekten of een hieraan gerelateerde 
aandoening.(51,52 )
Tegenwoordig kan fysieke activiteit vastgelegd worden met behulp van activiteitmoni-
tors. Tri-axiale accelerometers meten acceleratie in drie dimensies en het resultaat daar-
van kan geconverteerd worden in intensiteiten en metabolische equivalenten (METs). 
Hierdoor kan men fysieke activiteiten kwantificeren. De MET-waarde ofwel het meta-
bool equivalent is een meeteenheid binnen de fysiologie voor de hoeveelheid energie die 
een bepaalde fysieke inspanning kost ten opzichte van de hoeveelheid benodigde energie 
in rust. Eén MET komt overeen met de ruststofwisseling ofwel basaalstofwisseling, de 
hoeveelheid energie die verbruikt wordt tijdens stilzitten. Volgens de huidige richtlijnen 
wordt een minimum van dagelijks 64-107 METs·min geadviseerd.(53)
De Dynaport MoveMonitor is een activiteitenmonitor die fysieke activiteit uitdrukt 
in METs, makkelijk is in het dagelijks gebruik en geoptimaliseerd is voor klinisch on-
derzoek. Hoewel de MoveMonitor reeds is gevalideerd in diverse patiëntengroepen(54-59), 
ontbrak een validatiestudie in een studiepopulatie met claudicanten in een niet-klinische 
onderzoek setting. In hoofdstuk 8 wordt geconcludeerd dat de MoveMonitor accurate 
informatie verschaft over diverse houdingen, dagelijkse activiteiten en het aantal stap-
pen. Het apparaat wordt als bruikbaar beschouwd bij het bepalen van fysieke activiteit 
en levert innovatieve klinisch relevante uitkomstgegevens voor onderzoek naar dit ziek-
tebeeld.
Fysieke activiteit van claudicanten ten opzichte van gezonde 
proefpersonen
Ten opzichte van gezonde volwassenen, hebben patienten met CI een lagere kwaliteit 
van leven en functioneren zij bij dagelijkse activiteiten slechter.(60,61) Verder weten we dat 
personen die regelmatig fysiek actief zijn, vaak een betere gezondheid hebben met la-
gere zorgkosten en dat zij minder invaliditeit vertonen ten opzichte van personen die 
voornamelijk een zittend leven leiden.(62,63) De Amerikaanse Hartstichting (AHA) en het 
Amerikaanse College van Sportgeneeskunde (ACSM) hebben richtlijnen opgesteld waar-
aan ouderen minimaal zouden moeten voldoen. Deze aanbevelingen zijn aangepast voor 
patienten met chronische aandoeningen.(53) In hoofdstuk 9 wordt de dagelijkse fysieke 
activiteit van patiënten met CI vergeleken met gezonden proefpersonen. Tevens worden 
de resultaten vergeleken met de hierboven genoemde aanbevelingen. Het bleek dat meer 
dan de helft van de CI patiënten niet voldoen aan de eisen zoals gesteld door de AHA. 
Deze resultaten in acht nemend, met daarbij de verhoogde risico’s op hart- en vaatziekten 
in deze populatie, doen ons concluderen dat het belangrijk is om fysieke activiteit te sti-
muleren. Deze bevindingen moeten leiden tot meer awareness voor deze uitkomstpara-
meter in zowel onderzoek als bij verwijzer en behandelaar. Het is essentieel om de fysieke 
activiteit in het dagelijks leven van patiënten met CI te verhogen.
De impact van GLT op fysieke activiteit
GLT is de belangrijkste pijler binnen het stepped care model (hoofdstuk 3).(9-11) De 20-25 
‘contacturen’ van een speciaal opgeleide en getrainde therapeut die beschikbaar komen 
bij GLT, kunnen uitstekend ingezet worden om patiënten te begeleiden. Leefstijlaanpas-
singen als stoppen met roken, het belang van medicatie compliance, een gezond dieet en 
meer bewegen naast de looptraining zijn belangrijke speerpunten. PAV patiënten blijken 
een forse reductie in dagelijkse fysieke activiteit te hebben (hoofdstuk 9), wat geassoci-
eerd is met een verhoogde mortaliteit.(51,52) Ondanks dat GLT de loopcapaciteit verhoogt, 
is het effect van deze therapie op de fysieke activiteit bij personen met PAV onbekend. In 
hoofdstuk 10 wordt onderzocht of GLT een positief effect heeft op zowel fysieke activiteit 
als dagelijkse activiteiten (gedrag) en kwaliteit van leven bij patiënten met PAV.
Nieuw gediagnosticeerde CI patiënten werden gevraagd om een activiteitenmonitor 
(Dynaport MoveMonitor) te dragen gedurende één week voor de start van de GLT, en na 
een periode van 3 maanden GLT. De primaire uitkomstmaat was de toename in patiënten 
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die voldeden aan de minimum eis voor fysieke activiteit zoals voorgesteld door ACSM 
(≥67 METs·min·dag, in perioden van ≥10 min). Data van 41 patiënten waren bruikbaar 
voor analyse. Na 3 maanden GLT bleek een significant hoger percentage patiënten te vol-
doen aan de genoemde ACSM minimum eisen (baseline: 43%; 3 maanden: 63%, p=.003). 
Echter, harde conclusies konden niet getrokken worden, omdat sommige patiënten juist 
een afname lieten zien in zowel fysieke activiteit (in METs·min·dag) als in hun gemid-
delde waarden met betrekking tot dagelijkse activiteiten. Waarschijnlijk heeft zowel een 
grote variatie in activiteiten van een patiënt (zowel duur als intensiteit) als een grote vari-
atie tussen patiënten deze tegenstelling veroorzaakt. Bovendien is slechts een relatieve 
kleine studiepopulatie gebruikt. Vervolgonderzoek met een grotere studiepopulatie is 
noodzakelijk om de effecten van diverse behandelingsopties op de fysieke activiteit van 
patiënten met CI te bestuderen. 
Toekomstperspectieven
Het lijkt er op dat het puur en alleen focussen op de loopcapaciteit, zoals maximale loop-
afstand of –tijd, inefficiënt is bij het bepalen van de effectiviteit van CI behandelingen. 
In hoofdstuk 8 werd aangetoond dat fysieke activiteit correct gemeten werd met een ac-
tiviteitenmonitor. Daarnaast lieten wij zien dat CI patiënten minder actief waren dan 
geadviseerd wordt in de internationale richtlijnen en ook ten opzichte van gezonde proef-
personen (hoofdstuk 9). 
Het verhogen van de fysieke activiteit in patiënten met CI heeft een gunstig effect 
op de verlaging van hart- en vaatziekten.(51,52) GLT lijkt veelbelovend om dit te bewerk-
stelligen (hoofdstuk 10). Verrassend genoeg werd geen significante correlatie gevonden 
tussen de verandering in fysieke activiteit en de toename in loopafstand (hoofdstuk 10). 
Men zou op basis hiervan kunnen beargumenteren dat andere componenten van loop-
training, anders dan de toename van de loopafstand, van invloed is op de fysieke acti-
viteit. Het lijkt of patiënten die in staat zijn verder te wandelen (door een afname in CI 
symptomen) deze capaciteit niet gebruiken in hun dagelijks leven om ook daadwerkelijk 
vaker, langer of meer intensief te lopen. Bovendien werd geen significante correlatie ge-
vonden tussen de toename in loopcapaciteit en de verandering van kwaliteit van leven 
(hoofdstuk 10). Deze bevinding werd recentelijk ook bevestigd door anderen.(64) Zij be-
schreven dat de vooruitgang in zelfredzaamheid, tevredenheid in het functioneren, pijn-
tolerantie en sociaal functioneren na zes maanden home-based looptraining los staat van 
de loopcapaciteit. In combinatie met onze bevindingen dat de loopcapaciteit niet corre-
leert met fysieke activiteit leidt tot het inzicht dat een verschuiving dient plaats te vinden 
in het doel van het fysiotherapeutisch behandelen. Maar ook in het stellen van de pri-
maire uitkomstmaten in medisch wetenschappelijk onderzoek. Gelukkig zien we dit laat-
ste steeds vaker gebeuren, zo waren Nordanstig et al. een van de eersten die gezondheid 
gerelateerde kwaliteit van leven als primaire uitkomstmaat gebruikten in hun recentelijk 
gepubliceerde IRONIC (Invasive Revascularization or Not in IntermittentClaudication) 
trial.(65) Toekomstig CI onderzoek zal zich daarom primair moeten richten op de veran-
dering van  kwaliteit van leven en de betrouwbare beoordeling hiervan. 
En verder? GLT programma’s van de toekomst vereisen verdere optimalisatie. Niet al-
leen zou de focus van onderzoek moeten liggen op de toename van loopcapaciteit, maar 
ook factoren zoals intrinsieke motivatie, life-style veranderingen, de verwachtingen en de 
tevredenheid van de patiënt en zijn sociaal functioneren. Wij zouden ons moeten richten 
op het veranderen van het beweeggedrag van de patiënt in zijn dagelijkse leven door het 
GLT programma toe te spitsen op de specifieke patiëntbehoefte. De verwachtingen van 
de CI patiënt zou leidend moeten zijn tijdens de behandeling. Daarnaast dient de fysio-
therapeut zich te concentreren op het looppatroon en het combineren van verschillende 
manieren van training.(67) Een optimale mix van supervisie met home-based training, 
waarbij eHealth en mHealth technologieën worden ingezet, zouden hier tot een verdere 
optimalisatieslag kunnen leiden (hoofdstuk 5). Het betrouwbaar kunnen vaststellen van 
het effect van diverse therapieën en behandelingsstrategieën in de behandeling van PAV 
(zoals de stepped care aanpak), zullen er uiteindelijk voor zorgen dat de PAV patiënt hier-
van zal profiteren. 
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Introductie 
Perifeer arterieel vaatlijden (PAV) is de verzamelnaam voor slagaderlijke vaatziekten in 
het lichaam, de hart- en hersenvaten uitgezonderd. PAV is een uitingsvorm van athero-
sclerose, in de volksmond abusievelijk aderverkalking genoemd, terwijl slagaderverkal-
king wordt bedoeld. Claudicatio intermittens is een veel voorkomend symptoom bij PAV 
en betekent letterlijk ‘intermitterend hinken’. Claudicatio treedt op bij het stadium van 
PAV waarin patiënten pijn hebben bij het lopen, hetgeen noodzaakt tot stoppen. Waar in 
rust de zuurstofvoorziening van de beenspieren volstaat, wordt bij lopen aan de toege-
nomen zuurstofbehoefte onvoldoende voldaan. Na een bepaalde afstand lopen moeten 
‘claudicanten’ stoppen omdat zij pijn ervaren. Omdat dit noodgedwongen pauzeren niet 
alleen de actieradius beperkt, maar ook als mens ongemakkelijk wordt ervaren, gaan pa-
tiënten deze klachten maskeren, bijvoorbeeld door net te doen of een etalage wordt beke-
ken tijdens het gedwongen stilstaan. In de volksmond wordt bij claudicatio intermittens 
daarom gesproken van ‘etalagebenen’.
PAV komt wereldwijd voor bij ruim 200 miljoen mensen.(1) De afgelopen 10 jaar is 
het aantal patiënten met PAV wereldwijd met bijna een kwart gestegen, zowel in hoge- als 
ook in lage inkomenslanden.(1) De combinatie van frequenter voorkomen, de hogere kans 
op een geassocieerde fatale of invaliderende vasculaire gebeurtenis (hart- en/of hersen-
infarct) en de aanzienlijke kostenstijging die gepaard gaat met de behandeling, maakt dat 
PAV ondertussen een belangrijk gezondheidszorg probleem is geworden. Zeker in het 
licht van de verwachting dat de nationale zorgkosten exponentieel zullen stijgen (13% 
van 2012 bruto nationaal product naar 30% in 2040)(2) en de behandeling van PAV hier 
fors aan zal bijdragen. Onlangs werd een oproep gedaan aan overheden, relevante orga-
nisaties en de private sector om met een oplossing te komen voor de maatschappelijke en 
economische consequenties van PAV.(1)
Stepped care
In het eerste deel van dit proefschrift wordt een innovatieve strategie geïntroduceerd om 
de behandeling van claudicatio intermittens te optimaliseren.(3,4) Deze “stepped care ap-
proach” of wel “getrapte behandeling” levert naast economische ook maatschappelijke 
voordelen op in de vorm van minder sterfte en morbiditeit, meer aandacht voor cardio-
vasculair risico management en daarmee een betere kwaliteit van zorg voor deze groep 
patiënten en mogelijk langere overleving. In dit model ontvangen patiënten een behan-
deling die niet zwaarder (risicodragend) is dan noodzakelijk. Het model is gebaseerd op 
de vigerende richtlijnen(5-7), meest recente literatuur en het eeuwenoude adagium ‘pri-
mum non nocere’ (‘first do no harm’). Samenvattend houdt het een ‘verplichte’ start met 
minimaal 3 maanden Gesuperviseerde Looptherapie (GLT) in. Tijdens dit traject wordt 
veel aandacht besteed aan het beïnvloeden van aanwezige risicofactoren voor hart- en 
vaatziekten. Pas bij falen van dit traject, in de zin van een discrepantie tussen gewenste 
en bereikte loopafstand wordt nadere diagnostiek verricht en beoordeeld of een endovas-
culaire behandeling kan worden aangeboden. 
33 miljoen besparing
In dit proefschrift worden, in een budget impact analyse (BIA) op basis van tweede lijn 
declaratie gegevens bij een grote Nederlandse zorgverzekeraar, de kosten van deze aanpak 
vergeleken met een initiële endovasculaire procedure en niet-gesuperviseerde loopthera-
pie.(4) De in twee jaar gegenereerde gemiddelde kosten van een interventietraject bleken 
vijf maal hoger dan bij de “stepped care approach”. Om het effect van volledige landelijke 
implementatie van dit model te concretiseren is gewerkt met drie scenario’s. Deze zijn ge-
baseerd op twee essentiële factoren die momenteel als belemmerend worden ervaren om 
het stepped care model in praktijk te brengen. In het 80-80% scenario, wordt veronder-
steld dat in 2018 80% van alle patiënten primair naar een traject GLT wordt verwezen en 
in 80% van deze gevallen de patiënt voldoende verzekerd is om deze behandeling daad-
werkelijk te ondergaan. De verwijzingen komen vanuit de tweede lijn tot stand als andere 
belemmerende factoren worden weggenomen. Een onvoldoende verzekerde patiënt die 
zelf een aanvullende bijdrage niet wil of kan dragen zal kiezen voor een veel duurdere 
maar voor hemzelf ‘gratis’ interventie. Op basis van dit scenario zou in Nederland een 
jaarlijkse besparing van €33 miljoen euro gerealiseerd kunnen worden. Een besparing die 
hand in hand gaat met betere, veiligere zorg!
Duurzaam, kwalitatief beter en goedkoper, kan dat? 
Ja, althans zo blijkt uit onze analyse. Waarin belangrijke aanvullende voordelen van GLT 
niet werden meegerekend. Voordelen die bij een initiële behandeling met een revascula-
risatie niet optreden. Zo wordt bij GLT (en daarmee stepped care) niet alleen het aange-
dane been getraind, maar ook het op dat moment (mogelijk nog) geen klachten gevende, 
andere been. Dat geldt ook voor het gelijktijdig mee trainen van hart en longen (de car-
diopulmonale conditie), hetgeen weer een positief effect kan hebben op de overleving 
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en het verlagen van het risico op cardiovasculaire events.(8) Effecten die weliswaar niet 
werden onderzocht, laat staan aangetoond in dit proefschrift, maar die kunnen worden 
afgeleid uit onderzoek naar psychologische interventies zoals verricht door anderen.(9-11) 
Een interventie bestaande uit motiverende gespreksvoering van slechts twee sessies laat 
het loopgedrag verbeteren, een effect dat zelfs voor minimaal twee jaar stand houdt.(12)
 
Een tot op heden nauwelijks onderkend en daardoor niet benut voordeel is dat bij een 
gesuperviseerd traject ongeveer 20-25 ‘contacturen’ beschikbaar komen. In deze tijd kan 
een daartoe speciaal opgeleide en getrainde claudicatio-therapeut patiënten begeleiden 
bij leefstijlaanpassingen als stoppen met roken, het belang van medicatie compliance, een 
gezond dieet en meer bewegen naast de looptraining.(10) Samen trainen en lotgenoten-
contact kunnen ook worden gestimuleerd door deze getrainde behandelaar. Supervisie 
wordt daarmee supervisie ‘plus’, of ook wel “ClaudicatioNet traject” genoemd. Daar waar 
bij een ‘PTA (‘Dotter’)-eerst’ behandeling weliswaar mogelijk een sneller effect kan wor-
den bereikt betreffende de loopcapaciteit, wordt een patiënt de kans ontnomen om deze 
minstens zo belangrijke voordelen te benutten. 
GLT kent nog een voordeel, een ander aspect wat invasief ingestelde behandelaars 
zich mogelijk onvoldoende realiseren. Bij een primair invasieve behandeling wordt de 
klacht van de patiënt op basis van de anamnese gerelateerd aan de vasculaire afwijking. 
De patiënt wordt zo de kans ontnomen op het proefondervindelijk signaleren van limi-
terende klachten die niet veroorzaakt worden door PAV. De eveneens aanwezige limite-
rende klachten, bijvoorbeeld van het bewegingsapparaat of van neurogene oorzaak, kun-
nen zo onontdekt blijven bij een PAV patiënt. Maar ook het feit dat een patiënt mogelijk 
door kortademigheid wordt beperkt en niet door de aanwezige pijn in het been. Dit is 
belangrijke informatie die idealiter moet worden onderzocht voordat de optie van een 
invasieve behandeling wordt overwogen. Een binnen ClaudicatioNet werkzame fysiothe-
rapeut komt hier in de eerste behandelingen proefondervindelijk achter. In voorkomende 
gevallen kan hier specifieke training op worden geïnitieerd (er bestaan gevalideerde pro-
gramma’s voor COPD, hartfalen, artrose, etc.). De algehele conditie, COPD, pijn op de 
borst, neurogene klachten, een  versleten heup of knie worden echt niet beter van een 
vasculaire interventie!(12) 
Toch wordt in de dagelijkse praktijk als eerste behandelingsoptie nog (te) vaak voor 
een invasieve behandeling gekozen. In dit proefschrift wordt aangetoond dat van de bijna 
5000 keer dat in 2009 de ‘DBC claudicatio intermittens’ door een chirurg werd geopend, 
in een derde van de gevallen primair werd gekozen voor een invasieve interventie.(4) 
Slechts bij 14% werd eerst gekozen voor GLT en daarmee ‘stepped care’. Opvallend is ver-
volgens dat in deze laatste groep in 6.4% van de gevallen, tijdens de twee jaar follow-up 
periode, alsnog werd gekozen voor een vasculaire interventie. Terwijl dat percentage in 
de “PTA eerst” groep 35,2% betrof.(4) Dit hoge percentage kan enerzijds worden verklaard 
door het bekende feit dat gedotterde trajecten opnieuw dichtslibben en anderzijds door 
het feit dat klachten van het andere been opnieuw voor een PTA in aanmerking zullen 
komen. De uitdaging is dan ook om in de komende jaren het percentage stepped care te 
verhogen tot idealiter 100%. Het is aan zorgverzekeraars, het zorginstituut Nederland, 
huisartsen en vaatchirurgen om dit te realiseren. 
Hoe?
Maar hoe kan dit percentage verhoogd worden? Het aantonen van de effectiviteit van 
GLT als primaire behandeling, de meerwaarde van een volledig ClaudicatioNet traject 
en de aangetoonde besparingen met de effectuering van het stepped care model bieden 
immers geen garantie dat invoering van deze behandeling vanzelf zal volgen. Een aantal 
obstakels moet overwonnen worden. Ten eerste dient zowel bij patiënt, huisarts, vaat-
chirurg en andere betrokken zorgverleners waar nodig het beeld van gesuperviseerde 
looptherapie als inferieure behandeling bijgesteld te worden. Dit is noodzakelijk om te 
komen tot de gewenste en noodzakelijke actieve participatie van de patiënt en past bij het 
leggen van verantwoordelijkheid bij die patiënt. De houding van de verwijzende arts zal 
daarin moeten veranderen.(13)
Marketingstrategieën van de medische industrie proberen artsen juist te overtuigen 
dat de nieuwste medische technologie effectiever en duurzamer is dan de vorige generatie 
dotter ballonnen en stents. Deze bedrijven hebben, in tegenstelling tot de ‘sponsor’ van 
GLT, een gigantisch budget en sluiten met hun marketing aan bij de intrinsieke wens tot 
handelen van vaatchirurgen en interventie-radiologen. Het is dan ook noodzakelijk om 
in de komende jaren meer aandacht te geven aan de behandeling van claudicatio in de 
eerste lijn. Substitutie van deze zorg naar deze eerste lijn zal vanzelf leiden tot implemen-
tatie van stepped care, eenvoudigweg omdat invasieve interventies geen optie zijn binnen 
de huisartsenpraktijk. 
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De vraag voor de komende jaren luidt dan ook; ‘hoe krijgen wij alle neuzen dezelfde 
kant op?’. Een belangrijke aanzet daartoe werd gedaan in 2011 met de oprichting van 
ClaudicatioNet.(14) De stichting ClaudicatioNet beoogd het creëren van een zorgmodel 
waarin evidence-based zorg geleverd wordt aan een goed geïnformeerde en actief parti-
ciperende, centraal-staande PAV patiënt. ClaudicatioNet faciliteert daarmee in feite een 
geïntegreerd zorgnetwerk dat patiënten en behandelaars (bijv. vaatchirurgen, huisartsen, 
fysiotherapeuten) met elkaar in contact brengt. De stepped care approach wordt hierdoor 
geïmplementeerd in het Nederlandse zorgsysteem. Transparantie en hoogwaardige con-
servatieve zorg voor alle patiënten met PAV is het doel. De stichting beschikt over een 
landelijk dekkend netwerk van geschoolde fysio- en oefentherapeuten die een driejarig 
specialisatietraject doorlopen.(3,14) Met eHealth- (en in de nabije toekomst ook mHealth) 
wordt inzicht verkregen in de kwaliteit van geleverde zorg. Niet alleen de patiënt krijgt 
op deze wijze feedback over zijn of haar vorderingen, maar ook de therapeut en verwijzer 
kunnen worden ‘gebenchmarkt’ met hun ‘peers’. In dit proefschrift worden enkele van 
deze processen en diensten uitgebreid beschreven.(3) 
Op weg naar nieuwe uitkomstmaten
Belangrijk onderdeel is het toepassen van betrouwbare en valide meetinstrumenten voor 
instelling en evaluatie van de geboden fysiotherapeutische behandeling. In het tweede 
deel van deze thesis (“towards new outcome measures”) wordt een wetenschappelijke ba-
sis gelegd voor een mogelijke nieuwe uitkomstmaat van claudicatio-behandeling.(15-18) De 
meeste gebruikte uitkomstmaat in onderzoek naar PAV is op dit moment de ‘maximale 
of pijnvrije loopafstand of –tijd’. Deze parameters geven echter alleen inzicht in de mate 
van fysieke capaciteit. Het verhogen van deze capaciteit betekend niet vanzelfsprekend 
dat de patiënt ook meer gaat bewegen (= activiteit). Of sterker nog dat de kwaliteit van 
leven wordt beïnvloedt.(16) Bovendien vertoont de loopcapaciteit een grote variabiliteit 
in de tijd. Deze beperkingen leiden tot een mindere betrouwbaarheid en validiteit van 
deze uitkomstmaat dan gewenst. Een alternatieve maat waarbij over langdurige tijd de 
activiteit van een claudicant gemeten kan worden zou uitkomst kunnen bieden. Zeker 
als deze wordt gecombineerd met de door de claudicatio-therapeut vastgelegde kwaliteit 
van leven en door de patiënt aangeleverde Patient Related Outcome Measures (PROMS). 
Op welke manier krijgt dit valorisatietraject vorm? 
Het percentage ‘stepped care’ bij claudicanten zal in de komende jaren verder moeten 
toenemen. Succesfactoren voor deze toename zijn terug te voeren op een toename van 
kosten in de eerste lijn, welke direct zullen leiden tot aanzienlijke besparingen in de 
tweede lijn. En daarmee komt meteen het probleem voor een groot deel aan het licht. 
De besparingen in de tweede lijn lijken welhaast als triviaal te worden ervaren, terwijl 
de eerste lijn niet weet waar ze de investeringen vandaan moet halen. Zorgverzekeraars, 
Zorginstituut-Nederland en uiteindelijk het Ministerie van Volksgezondheid spelen een 
belangrijke rol om deze impasse te doorbreken. Een verstandige eerste stap moet bestaan 
uit het opnemen van GLT in de basiszorg. 
Ook zal in de toekomst nog meer wetenschappelijk onderzoek nodig zijn. Allereerst 
moet een gedegen kosteneffectiviteitsstudie naar het ClaudicatioNet-concept worden 
verricht, aangezien nu alleen een kostenanalyse is verricht. Tevens kan men het effect van 
optimalisatie van inhoud van de trainingsprogramma’s bestuderen.(19) Bij het beschik-
baar komen van data uit de landelijke ClaudicatioNet database (per medio 2015) ontstaat 
de mogelijkheid om deze verschillende behandelingsstrategieën gerandomiseerd en met 
grote studiepopulaties te vergelijken. 
Betrokken partijen zullen de handen ineen moeten slaan om de zorg voor de patiënt 
met etalagebenen in de komende jaren te optimaliseren. Deze thesis kan dienen als op-
maat hiervoor en is een duidelijke handreiking naar betrokken stakeholders.
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Een keihard cliché, maar promoveren doe je niet alleen! Veel mensen hebben een 
steentje bijgedragen aan mijn promotie en ik wil dan ook iedereen hartelijk danken. Een 
aantal personen wil ik graag in het bijzonder noemen:
Hooggeleerde promotor prof. dr. J.A.W. Teijink, beste Joep. Waar moet ik beginnen? 
Jouw onuitputtelijke energie en doorzettingsvermogen zijn ongekend. Ik ken maar weinig 
mensen die zoveel balletjes tegelijkertijd in de lucht kunnen houden, maar toch weet je 
altijd tijd vrij te maken voor je promovendi. Het enthousiasme waarmee ideeën direct 
worden omarmd samen met jouw positiviteit werken aanstekelijk. Door jou ben ik het 
medisch wetenschappelijk onderzoek gaan waarderen. De steun om mijn carrière niet te 
vervolgen in de vaatchirurgie, maar in de orthopedie, is veelzeggend en waardeer ik zeer. 
Zonder jou geen manuscript. Joep enorm bedankt!  
Weledelzeergeleerde copromotor dr. M.R.M. Scheltinga, beste Marc, “wie schrijft 
die blijft!”. Een quote die jij zeer regelmatig ten gehore brengt en mij heeft aangezet om 
te starten met dit avontuur. Jouw enthousiasme voor onderzoek is ongekend. Welke 
perifeer werkzame vaatchirurg is nu tweemaal copromotor op één dag?  Zonder jouw 
daadkracht had menig artikel nog als word-document op mijn computer gestaan. De 
snelheid waarmee jij teksten reviseert is ongelofelijk. Uit het feit dat mijn teksten in de 
loop van de tijd minder rood gekleurd terugkwamen, blijkt dat ik veel van je geleerd heb. 
Fantastisch dan ook dat ik nu mijn klinische ervaring in het MMC mag opdoen. Marc 
onwijs bedankt!
Alle medeauteurs, dank voor jullie kritische blik op mijn werk. Van zowel de positieve 
als negatieve feedback heb ik veel opgestoken. In het bijzonder wil ik Saskia Houterman 
danken. De discussies over het weergeven van onze resultaten, het meedenken in studie-
designs en de hulp met statistische analyses, zijn van grote waarde geweest voor mijn 
artikelen.  
Leden van de manuscriptcommissie, hartelijk dank voor de beoordeling van mijn 
proefschrift.
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Dank ook aan alle patiënten, die direct of indirect hebben bijgedragen aan dit 
proefschrift. Uiteindelijk gaat het allemaal om het optimaliseren van de behandeling voor 
jullie.
Mijn medepromovendi Gert-Jan, Rutger, Pieter, Thijs, Lindy, Yannick en de nieuwste 
aanwinst David. Zonder jullie waren de uurtjes in “ons hok” waarschijnlijk een lange zit 
geworden. De eeuwige strijd tussen de aorta-boys, de strijd voor WiFi en goede koffie 
leidde tot een inspirerende werkomgeving. Creativiteit staat bij deze club hoog in het 
vaandel. CHAPSTICK!
Mijn ClaudicatioNet collega’s Danielle, Loes, Nicole, Regine en Yvonne. Bij 
fysiotherapeutisch Nederland staan deze namen inmiddels in het geheugen gegrift. Ons 
eigen jaarcongres, onze beursstand, de gadgets, de presentaties, de huisstijl, de humor, de 
talloze ritten naar informatiebijeenkomsten, etc etc. Bedankt voor alles. 
De Vaatclub. Marc, Philippe, Edith, Bianca, Jan, Marijn, Sjaak en de reeds hierboven 
genoemde personen. Bedankt voor het meedenken met menige studie, het meehelpen 
met presentaties, revisies en natuurlijk de jaarlijkse uitjes.  
De maatschap chirurgie en de assistenten van zowel het Catharina Ziekenhuis als het 
Maxima Medisch Centrum. Ik wil jullie graag hartelijk danken voor het opnemen van mij 
als arts-onderzoeker binnen jullie gelederen.
De dames van de polikliniek van beide ziekenhuizen. Bedankt voor jullie tomeloze 
inzet en enthousiasme bij de inclusie van patiënten voor mijn studies.
De leden van de Oud-leden Vereniging Bonobo. Niet zozeer voor de wetenschappelijke 
bijdrage, maar vooral voor de veelvuldige momenten van afleiding. Mannen, het gaat 
soms zeker om het feestje!
 
De Nijmeegse Fiets Combinatie. Ook al ben ik het anker, de vele uurtjes op het zadel 
gaven steeds weer de energie om de finish (dit proefschrift) te halen. Thnx!
Mijn ceremoniemeesters. Michiel Heevel en Sander Klieverik voor een dag die we niet 
snel zullen vergeten. 
Mijn paranimfen. Dr. T. van Assen! Fantastisch dat wij op één dag de spreekwoordelijke 
“s” zullen kwijt raken. Samen promoveren is een bekroning op onze vriendschap. We 
maken er een fantastisch feest van!
Steven, broer(tje). Ongelofelijk hoe jij altijd voor mij klaar staat. Het is eigenlijk met 
geen pen te beschrijven. Ik kan niet trotser zijn om jou als broer te hebben, oprecht 
bedankt. 
Mijn schoonfamilie, Joop, Annelies, Thea, Susan, Maxime. Altijd weer geïnteresseerd 
in mijn medische verhalen. Bedankt voor jullie interesse.
Mijn familie. Frans en Adri, Josine en natuurlijk oma Joke. Zonder jullie 
onvoorwaardelijke steun en vertrouwen had ik nooit zo ver kunnen komen. 
Mijn geliefde, Kelly. Ik kan zonder moeite een hele pagina volschrijven waarom ik 
dit manuscript aan jou zou moeten opdragen. We hebben zowel pieken als dalen gekend 
tijdens dit project, maar jij bent degene die altijd voor mij klaar staat. Onbeschrijfelijk 
hoe wij elkaar aanvullen. Jij bent voor mij een lot uit de loterij. Wij, als team, kunnen de 
wereld aan! Hunt, op naar de volgende uitdaging!
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